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The development of new therapeutic strategies for breast cancer is urgently needed. 
Exploitation of radioiodide uptake by the overexpressed sodium iodide symporter (NIS) 
has been widely proposed as a novel therapeutic strategy. However, radioiodide uptake 
is insufficient for tumour destruction. The proto-oncogene PBF binds NIS and inhibits its 
plasma membrane retention, thereby repressing critical radioiodide uptake in thyroid 
cancer. This thesis demonstrated that PBF, also upregulated in breast cancer, similarly 
repressed NIS in breast cancer cells, where phosphorylation of PBF at Y174 was key to NIS 
interaction and could be disrupted via treatment with the Src inhibitor dasatinib. 
Mutation of a predicted Src consensus sequence (EEN/AAA170-172AAA) abrogated 
pY174 PBF and radioiodide uptake repression. In the presence of dasatinib-resistant Src 
(T341I), dasatinib no longer rescued PBF repression of NIS, indicating that Src specifically 
mediates PBF phosphorylation. Inhibition of N-myristoylation also significantly increased 
radioiodide uptake. Combined Src and myristoylation inhibition induced a ~70% increase 
of radioiodide uptake in the absence of PBF overexpression. Thus, disrupting Src 
phosphorylation of PBF by targeted mutagenesis and Src kinase inhibition reveal 
radioiodide uptake into breast cancer cells can be significantly enhanced through 
therapeutic approaches focused on Src:PBF:NIS and myristoylation, making radioiodide 
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1.1 Breast cancer 
Breast cancer is the second most common cancer worldwide, and is the leading cause of 
cancer-related death in women. The global burden of breast cancer is greater than that of 
all other cancers and the rate of incidence is steadily increasing (Jemal et al., 2010). Based 
on current incidence projections, 3.2 million new cases of breast cancer will be diagnosed 
each year by 2050 (Hortobagyi et al., 2005). In the UK, around 55,000 people are diagnosed 
with breast cancer each year (Cancer Research UK, 2015). In order to understand the 
pathology and risk factors of this multi-faceted disease, it is important to first cover the 
biology and anatomy of the normal breast. 
1.1.1 The normal breast 
Breasts are comprised of glandular tissue and under hormonal control produce milk for the 
purpose of feeding infants. Along with the brain and lungs, breasts are one of the only 
organs that are not fully developed at birth and undergo multiple changes throughout life 
(Russo and Russo, 1987). The adult human breast sits atop the anterior chest wall and is 
composed of layers of different types of tissue, predominantly adipose and glandular tissue 
(Guinebretiere et al., 2005).  
 The glandular tissue is made up of a network of ducts that transport milk from 
lobules to the nipple (Figure 1-1). Lobules are functional units located at the end of ducts 
that synthesise milk. Each lobule consists of around 20 smaller structures known as acini. 
Acini have a layer of epithelial cells that line the lumen that synthesise and secrete milk into 
the terminal duct, surrounded by an external layer of myoepithelial cells. The duct network 
is composed of 15-20 larger ducts which divide into smaller ducts creating a ductal tree. Like 
acini, the ductal lumen is lined with a single layer of epithelial cells surrounded by an 
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external layer of myoepithelial cells. These myoepithelial cells have the ability to contract 
which narrows the ductal lumen facilitating the transport of milk. The ducts and lobules are 
surrounded by connective tissue composed of blood and lymphatic vessels, nerves, adipose 
and fibrous tissue (Guinebretiere et al., 2005).  
 
Figure 1-1. Anatomy of the breast. Each mammary gland contains 15–20 lobes, each lobe 
containing a series of branched ducts that drain into the nipple. Taken from Ali and 
Coombes, 2002. 
 
1.1.2 Pathology of breast cancer 
Breast cancer is a heterogeneous disease that can be divided into a number of subtypes 
dependent on pathology, location, receptor status and gene signatures. There are two 
major subdivisions of breast cancer based on pathology alone, carcinoma in situ and 
invasive carcinoma. 
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1.1.2.1 Carcinoma in situ  
There are two major forms of carcinoma in situ; ductal (DCIS) and lobular (LCIS) carcinoma in 
situ. Both involve the growth of abnormal cells that follow the existing regional architecture 
(Guinebretiere et al., 2005). 
 LCIS was first described in 1941 (Foote and Stewart, 1941) and accounts for 
approximately 15% of in situ breast cancers. It is difficult to detect, as it is not associated 
with calcification and often does not display any mammographic abnormalities (Sonnenfeld 
et al., 1991), so is usually discovered after coincidental surgery (Guinebretiere et al., 2005). 
It is often multifocal and bilateral with women commonly being diagnosed between the 
ages of 40 and 50, and fewer than 10% of patients being post-menopausal (Fulford et al., 
2004). A high frequency of LCIS diagnoses are characterised by the loss of heterozygosity on 
chromosome 16q at the site of the gene that encodes the cell adhesion molecule E-cadherin 
(Berx et al., 1995). 
 As DCIS is difficult to detect at the pre-symptomatic stage it was considered rare, 
and patients were generally diagnosed upon presenting with nipple discharge or a palpable 
tumour (Contesso and Petit, 1979). However due to the availability of advanced screening 
technologies, DCIS diagnoses now account for more than 15-25% of breast cancers (Van 
Cleef et al., 2014), the most common mammographic indicator being an isolated cluster of 
microcalcifications (Guinebretiere et al., 2005). The majority of DCIS are unilateral, with the 
tumour confined to one quadrant of the breast, but larger lesions may be multi-centred. 
Many clinicians consider DCIS to be pre-malignant, as over time the tumours can progress to 
invasive ductal carcinoma (Buerger et al., 1999; Giardina et al., 2003; Wellings and Jensen, 
1973). DCIS patients tend to be diagnosed later in life than those that develop LCIS, with 
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most DCIS patients being post-menopausal. In DCIS patients disease prognosis is relatively 
good, with an overall 10 year mortality rate of between 1-2% (Allegra et al., 2009; Van Cleef 
et al., 2014). 
1.1.2.2 Invasive carcinoma 
Similar to carcinomas in situ, there are two major forms of invasive carcinomas; invasive 
ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). 
 IDC (also referred to as invasive carcinoma of no special type (NST)) accounts for 
approximately 55% of all breast carcinomas (Eheman et al., 2009) and can occur in both pre- 
and post-menopausal women (Guinebretiere et al., 2005). IDC can arise from DCIS (Sinn and 
Kreipe, 2013) and the tumours are devoid of characteristics seen in other breast cancers 
(Eheman et al., 2009). 
 ILC is less common than IDC, accounting for only 10-15% of breast carcinomas 
(Guinebretiere et al., 2005) and as the nomenclature suggests the tumours originate from 
terminal areas of lobules within breasts (Ogbagabriel et al., 2005). The disease can occur in 
both pre- and post-menopausal women and is associated with a relatively poor prognosis 
(Guinebretiere et al., 2005). The tumours are often multifocal within the breast, presenting 
as singly dispersed cells which lack E-cadherin, a trait shared by LCIS tumours (Wahed et al., 
2002). 
1.1.3 Risk Factors for breast cancer 
1.1.3.1 Gender and Age 
In the UK, of the 55,000 people that are diagnosed each year with breast cancer, the vast 
majority are women, with only around 400 being male. As with many carcinomas, the 
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incidence of breast cancer increases with age, with the chance of developing the disease 
doubling approximately every ten years until menopause, at which point the rate of 
increase significantly slows (McPherson et al., 2000) (Figure 1-2). In the UK between 2010 
and 2012, 80% of breast cancer cases were diagnosed in females over the age of 50. The 
high number of cases diagnosed in women in their 50s may partly be explained by the age 
women are first offered a mammogram in the UK (Cancer Research UK, 2015).  
 Until the age of 50 there is a similar incidence of oestrogen receptor positive and 
negative carcinomas (discussed further in section 1.1.4.3). After 50, oestrogen negative 
tumour rates decrease while oestrogen receptor positive tumour diagnoses continue to 
slowly increase (Benson et al., 2009).  
 
Figure 1-2. Incidence of breast cancer in the UK by age. Average number of new breast 
cancer cases per year and age-specific incidence rates per 100,000 the UK female 
population. Taken from Cancer Research UK, http://www.cancerresearchuk.org/content/ 
breast-cancer-incidence-statistics#heading-One, Accessed Jan 2016. 
 
1.1.3.2 Age at menarche and menopause 
Women who experience menarche at an early age (< 12 years old) have a significantly 
higher chance of developing breast cancer, as this increases overall lifetime exposure to the 
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hormonal milieu associated with regular menstrual cycles. Breast cancer risk is reduced by 
about 10% for every two years there is a delay in the onset of menstruation (Kelsey et al., 
1993). 
 Women who have a late menopause also have a dramatically increased risk of 
developing breast cancer (Collaborative Group on Hormonal Factors in Breast, 2012; Kelsey 
et al., 1993) with those who have a natural menopause at the age of 45 having half the 
breast cancer risk of those who do not undergo menopause until the age of 55. A bilateral 
oophorectomy before the age of 35 decreases the risk of developing breast cancer by 60% 
compared with women who go through natural menopause (McPherson et al., 2000). 
1.1.3.3 Age at first full-term pregnancy 
In addition to early menarche and late menopause, nulliparity and late age at first birth have 
both been identified to increase the incidence of breast cancer in women. The risk of breast 
cancer in women who have their first child in their 20s is half that of women who have a 
baby over the age of 30, though only full-term pregnancies are linked with a reduced breast 
cancer risk (Choudhury et al., 2013; Kelsey et al., 1993). Interestingly, nulliparous women 
have a lower chance of developing breast cancer than women who have their first child over 
the age of 35, and having a second child at an early age can further reduce the risk of 
developing breast cancer (McPherson et al., 2000). 
1.1.3.4 Family History 
As many as 10% of breast cancer incidences in Western countries have been attributed to 
genetic predisposition to the disease. Breast cancer susceptibility is generally inherited in an 
autosomal manner with limited penetrance. The risk of developing breast cancer is 
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increased if a first degree female relative has developed breast cancer, up to as much as 
nine-fold if the disease was bilateral and pre-menopausal (McPherson et al., 2000).  
 The best characterised indicators of genetic predisposition are mutations within the 
genes BRCA1 and BRCA2, which are located on the long arms of chromosomes 17 and 13 
respectively. BRCA1/2 are tumour suppressors with roles in DNA repair mechanisms, the 
disruption of which can lead to genomic instability and therefore an increased risk of cancer. 
BRCA1/2 mutations account for approximately 75% of hereditary breast cancer cases 
(McPherson et al., 2000). Inherited mutations in other genes that have been associated with 
breast cancer include ATM, TP53, CHEK2, PTEN and STK11, although their contribution to 
disease incidence is minimal compared with that of BRCA1/2 (Benson et al., 2009). 
1.1.3.5 Lifestyle 
As well as factors beyond the control of the individual, diet, exercise and weight can 
influence the risk of developing breast cancer, as is indeed the case with many cancers. Both 
pre- and post-menopausal women who are physically active have a 30-40% lower risk of 
developing breast cancer compared with sedentary women (Thune and Furberg, 2001), with 
as little as 2-3 hours of moderate intensity exercise a week being associated with a 40-50% 
reduction in breast cancer risk (Holick et al., 2008; Holmes et al., 2005). 
 Associations have been identified between body mass index (BMI) and breast cancer 
risk in relation to menopausal status. In post-menopausal women, an association between 
being overweight (defined as a BMI of 25 to 29.9 kg/m2) or obese (BMI of 30 kg/m2 or 
greater) and increased breast cancer incidence has been found in many studies (Eliassen et 
al., 2006; Lahmann et al., 2004; Renehan et al., 2008). There have been conflicting reports 
regarding the effect of BMI on breast cancer risk in pre-menopausal women. One large 
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cohort study reported that increased BMI in pre-menopausal women actually decreases 
breast cancer risk (Reeves et al., 2007). Conversely, another study identified a positive 
correlation between BMI and breast cancer risk in the Asian population (Cheraghi et al., 
2012) and abdominal obesity has been linked with pre-menopausal cancer risk (Harvie et al., 
2003). Obesity has also been associated with increased tumour diameter, decreased survival 
and increased lymph node involvement (Berclaz et al., 2004; Cleveland et al., 2007). 
  Populations with high fat diets exhibit an increased incidence of breast cancer (Key 
et al., 2003) and it has been shown that a reduction of the proportion of dietary fat can 
decrease breast cancer risk by up to 8% (Prentice et al., 2006). Smoking and alcohol intake 
are also implicated as risk factors for breast cancer development (Ferrini et al., 2015; Key et 
al., 2003). 
1.1.3.6 Hormone Replacement Therapy (HRT) 
Long-term use of combined oestrogen-progestogen hormone replacement therapy (HRT) 
has been classified by the International Agency for Research on Cancer (IARC) as a cause of 
breast cancer (Ritte et al., 2012) and an estimated 3% of UK breast cancer cases have been 
linked to HRT use (Parkin, 2011). The risk of developing breast cancer decreases 5 years 
after cessation of HRT. Although there is no correlation between HRT use and breast cancer 
mortality, HRT can reduce the sensitivity and specificity of breast cancer screening by 
increasing breast density and thus reducing the chance of early detection (McPherson et al., 
2000). 
1.1.4 Hormones and Hormone Receptors 
 As evidenced by the major risk factors discussed above, there is substantial evidence of a link 
between breast cancer and female sex hormones. This association is further supported by HRT 
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being classified as a cause of breast cancer. Early menarche and late menopause result in the 
woman being exposed to a higher number of menstrual cycles, thus a prolonged exposure to 
cycles of oestrogen and progesterone. Oestrogen and progesterone cycles have a stimulatory 
effect on breast epithelium and can induce differentiation of immature ducts into terminal end 
buds (Cork et al., 2008)(the roles of prolactin and oxytocin are discussed in sections 1.2.3 and 
1.2.4.1). Pregnancy reduces the cumulative exposure to oestrogen and causes lobules to further 
differentiate. Undifferentiated epithelial lobular cells from nulliparous women have been 
observed to be more susceptible to transformation than differentiated cells in parous women 
(Russo et al., 2005). 
 Further to the role hormones play in the development of breast cancer, the disease is 
split into different subtypes based on the presence or absence of hormone receptors. The key 
hormone receptors in breast cancer classification are the oestrogen (ER), progesterone (PR) and 
epidermal growth factor 2 (ERBB2/HER2) receptors. 
1.1.4.1 Oestrogen 
 Oestrogens have an essential role in the development of the female sex organs and 
secondary sex characteristics such as the regulation of the menstrual cycle and reproduction 
(Travis and Key, 2003). There are 3 major forms of oestrogen; oestrone (E1), oestradiol (E2) 
and oestriol (E3). E2, also known as 17-β-estradiol, is the most biologically active and potent 
form of oestrogen. The biological effects of oestrogens are dictated by circulating 
concentrations and differential rates of intracellular conversion of the molecules to 
derivatives. In pre-menopausal women, oestradiol is the predominant form of circulating 
oestrogen, which is secreted by the ovaries in monthly cycles. Post-menopause, peripheral 
tissues such as adipose tissue become the major source of oestrogen, secreting oestrone 
produced from androgen precursors (Cleary and Grossmann, 2009). 
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  Much of the evidence for the link between oestrogen and breast cancer comes from 
retrospective observational studies that have found circulating and excreted levels to be 
associated with risk for the disease. Post-menopausal women who have a relatively high 
serum level of oestrogen have been reported to have a two-fold risk of breast cancer 
compared with women with lower serum levels (Key et al., 2002). Though there are 
conflicting reports, some associations have been made between breast cancer risk and 
polymorphisms in genes involved in oestrogen synthesis, such as CYP17, CYP19 and 
HSD17B1 (Dunning et al., 1999; Feigelson et al., 2001).  
1.1.4.2 Oestrogen Receptor 
Oestrogens mediate cellular effects by binding to the intracellular nuclear receptors 
oestrogen receptor (ER) alpha (ERα) and beta (ERβ). Of the two oestro en receptors, ERα 
was the first to be identified with ERβ remaining undiscovered until the late 90s (Kuiper et 
al., 1996). The ERα  ene is over 140kb and is located on chromosome 6q25.1, encoding a 
595 amino acid protein, whereas the human ERβ gene is ~61.2kb and located on 
chromosome 14q23.2, spanning 8 exons and producing a 530 amino acid protein. Both 
forms contain autonomous domains with specific roles including ligand-binding (E), a hinge 
region (D), DNA-binding (C) and transactivation domains (A/B)(Figure 1-3). The DNA-binding 
domain is highly conserved between the two isoforms, only differing by two amino acids 
(Ruff et al., 2000). 




Figure 1-3. Comparison of the structures of ERα and ERβ. Both human oestrogen receptors 
— ERα and ERβ — share structural domains (A–F). From a functional perspective, ERs can be 
divided into three parts — the amino-terminal or A/B domain, the DNA-binding or C domain, 
and the ligand-binding or E domain. The F domain is involved in distinguishing between 
oestrogen agonists and antagonists. Taken from Behl, 2002. 
 In the classical pathway, oestrogens bind to ligand-binding domains in region E 
inducing the migration of the receptor from the cytosol to the nucleus. Here the receptors 
form stable homo- (ERα/α or ERβ/β) or hetero- (ERα/β) dimers. The activated dimers then 
interact with the oestrogen response elements (ERE) of target genes. Interaction between 
the dimers and ERE induces dissociation of co-repressor proteins and the recruitment of 
coactivators leading to chromatin remodelling and target gene transcription (Chen et al., 
2008). Genes heavily regulated by the EREs include the progesterone receptor and 
vitellogenins. Other pathways include the interaction of ERs with transcription factors such 
as AP1 (Jakacka et al., 2001) and SP1 (Porter et al., 1997) rather than direct binding to DNA. 
Oestrogens also have non-genomic effects on cells and have been shown to induce an 
increase in intracellular calcium and nitric oxide leading to activation of pathways including 
mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) (Chen et al., 
2008). 
 In normal mammary tissue, ERβ is the predominant form of ER, with expression in 
both luminal and myoepithelial cells (Speirs et al., 2002). Though ERβ knockout mice 
Chapter 1  Introduction 
13 
 
undergo normal mammary gland development there are subtle differences associated with 
decreased differentiation and increased proliferation in the alveoli of lactating mammary 
glands dependent on age of the mice (Forster et al., 2002; Palmieri et al., 2002).  
1.1.4.3 Oestrogen in breast cancer  
The carcinogenic effect of oestrogen is said to be executed via three mechanisms. 
Oestrogen is capable of promoting cellular proliferation and survival via ER through the 
genomic and non-genomic mechanisms outlined in 1.1.4.2 (Figure 1-4). There are an ever 
increasing number of molecules being identified to be under the regulation of EREs. Two 
examples include LRP16 and WNT11. E2 stimulates LRP16 expression, a protein that can 
interfere with the transcription of E-cadherin, subsequently increasing the invasiveness of 
the breast cancer (Han et al., 2008). E2 also induces WNT11 expression via ER which 
increases the resistance of cells to apoptosis (Lin et al., 2007; Vendrell et al., 2007).  




Figure 1-4. Pathways for oestrogen-induced carcinogenesis. The complementary pathways 
contribute to the carcinogenicity of oestrogen and to the initiation, promotion, or 
progression of breast cancer. Adapted from Yager and Davidson, 2006. 
 
 Oestrogen can also promote cellular proliferation via ER-independent mechanisms 
as witnessed in ER-negative breast cancer cells. In ER-negative MDA-MB-231 cells, 
treatment with oestrogen induced the rapid phosphorylation of AKT at Ser473 leading to 
protein activation along with stimulation of protein kinase C (PKC), resulting in increased cell 
proliferation (Chen et al., 2008).  
In addition to these downstream effects, many oestrogen metabolites are thought to 
be carcinogenic and have been observed to have direct genotoxic effects (Figure 
1-4)(Cavalieri and Rogan, 2016; Yager and Davidson, 2006).  
E2
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1.1.4.4 Progesterone  
Progesterone is an endogenous steroid and progestogen sex hormone that is essential in 
the regulation of the menstrual cycle, pregnancy and embryogenesis. The hormone is also 
essential for normal breast development during puberty, lactation and breastfeeding. 
Progesterone is heavily prescribed, often alongside oestrogen, as contraception or HRT. It 
mediates its cellular effects through interaction with the progesterone receptors (PR) (Lange 
and Yee, 2008). 
1.1.4.5 Progesterone Receptor 
 The progesterone receptor (PR) is vital for female reproductive activities, as 
evidenced by knockout PR mice displaying pleiotropic reproductive abnormalities (Lydon et 
al., 1995). There are two major isoforms of the PR - PR-A and PR-B - both of which belong to 
the nuclear hormone receptor family. Both isoforms are expressed from a single gene, with 
transcription of each being regulated by different promoters and the initiation of translation 
at two different AUG codons (Kastner et al., 1990). PR-A and PR-B are comprised of 
autonomous domains including several transactivation domains (A/B), a DNA-binding 
domain (C), a hinge region (D) containing a nuclear localisation signal and a ligand-binding 
domain (E).  




Figure 1-5. Structure of PR variants. Domain organization of the human PR-A and -B 
isoforms. h, hinge region; LDB, ligand-binding domain; ID, inhibitory domain. The numbers 
denote the positions of amino acids for each isoform. AF-1, -2, and -3 are transcription 
activation domains. Taken from Li and O'Malley, 2003. 
 
 Upon progesterone binding to PR, the receptor undergoes a conformational change 
inducing nuclear translocation, dimerisation and interaction with progesterone response 
elements (PRE) in the promoter regions of target genes. As with ER, the binding of PR to PRE 
leads to the dissociation of co-repressors and the recruitment of co-activators to form a 
productive transcription initiation complex at the promoter of the target gene. PRs can also 
be activated in a ligand-independent manner by cell-permeable agents that increase 
intracellular kinase activity (Conneely and Lydon, 2000). Target genes of PR are involved in a 
wide array of cellular activities including cell signalling, proliferation, apoptosis and 
metabolism of lipids and steroids (Cork et al., 2008). 
1.1.4.6 Progesterone in breast cancer 
The cited effects of progesterone on breast cancer remain largely controversial. There have 
been some suggestions that progesterone combined with oestrogen in HRT increases the 
risk of breast cancer more so than therapies containing oestrogen alone (Cork et al., 2008). 
However, progesterone has also been reported to be protective against breast cancer risk as 
it can inhibit enzymes involved in E2 formation in breast cancer cells and stimulate the 
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activity of enzymes converting oestrogens to less biologically active forms, thus inhibiting 
promotion of breast cancer via oestrogen (Pasqualini, 2007). In rats, it was observed that a 
combination treatment of progesterone and tamoxifen could inhibit the oestrogen-induced 
tumour formation more effectively than single reagent therapies (Mohammed et al., 2015). 
As the different forms of progestogens also have different affinities for PR-A and -B, it may 
be the case that progesterone can have both synergistic and antagonistic effects on the 
oestrogen pathways (Kenemans and Bosman, 2003). 
1.1.4.7 HER2 
Human epidermal growth factor receptor 2 (HER2), also referred to as NEU or ERBB2, is an 
orphan receptor that is amplified in many breast cancers. It is a proto-oncogene located on 
chromosome 17q12 that encodes for a 1255 amino acid transmembrane glycoprotein 
(Rubin and Yarden, 2001). Like other members of the HER family it is comprised of a 
cysteine-rich extracellular ligand binding site, a transmembrane domain and an intracellular 
region that has tyrosine kinase catalytic activity. Although HER2 does not have a ligand, all 
other HER variants are activated by ligand binding, leading to dimerisation and 
transphosphorylation (Moasser, 2007). HER2 is often the dimerisation partner of choice for 
other HER family members, as it is always in an open conformation having its dimerisation 
domains exposed. To add to this, HER2 has the strongest catalytic kinase activity giving HER2 
heterodimers the strongest signalling activity (Graus-Porta et al., 1997). 
 In breast cancer, HER2 is the dominant tyrosine kinase receptor, being amplified in 
20% of cases (Slamon et al., 1987). A variant of HER2 lacking the extracellular p95 domain is 
present in up to 30% of human breast tumours with HER2 overexpression (Molina et al., 
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2002). This mutated form is constitutively active and resistant to drugs targeted at HER2 
(Scaltriti et al., 2007). 
1.1.4.8 Receptor Status 
Breast cancer can be further subdivided into categories based on the expression of ER, PR 
and HER2 within the tumour. The table below describes the subcategories of breast cancer 
dependent on receptor status and their prevalence (Table 1-1). The differential expression 
of these receptors can determine the treatment a patient receives for their specific form of 
the disease. 
Subtype ER Status HER2 Status PR Status Prevalence 
Basal-like 
 (Triple Negative) 
- - - 15-20% 
Luminal A + - + 40% 
Luminal B + +  + 20% 
HER2 amplified - + - 10-15% 
 
Table 1-1. Breast cancer subtypes. The subdivisions of breast cancer dependent on receptor 
status and their prevalence. Adapted from Carey et al., 2006. 
 
1.1.5 Treatments 
There are four major strategies for the treatment and management of patients with breast 
cancer - surgery, chemotherapy, radiotherapy and hormone treatment. A combined 
approach using several of these methods is usually employed. After diagnosis of the disease, 
it is important to gauge disease stage and receptor status as these factors can dictate 
treatment plans. Disease staging is determined based on the tumour size, lymph node 
involvement and presence of metastases (Moulder and Hortobagyi, 2008).  




Surgical resection of the disease involves removing the primary tumour and any involved 
lymph nodes. Traditionally, even localised breast cancer was treated with a radical 
mastectomy and axillary lymph node dissection. However more recently it has been 
reported that lumpectomy followed by radiation therapy (breast-conserving surgery) is 
equally effective with similar rates of local recurrence and overall survival (Clarke et al., 
2005). A double mastectomy may be performed if a young patient presents with a known 
BRCA mutation, with the aim of removing the primary cancer and reducing the risk of a 
second cancer incidence.  
1.1.5.2 Chemotherapy 
Chemotherapy is frequently used in patients with breast cancer to palliate symptoms and 
reduce the risk of recurrence. Chemotherapy may be used prior to surgery with the hope of 
shrinking the tumour but is more commonly used after surgery to kill residual cancer cells. 
Adjuvant chemotherapy reduces the risk of death by 25% and the risk of distant metastasis 
by 18% (Rossi et al., 2015). Drugs are usually administered in a combination of two or three, 
with the most common class of drugs for breast cancer treatment being anthracyclines 
including doxorubin and epirubin. These compounds inhibit DNA synthesis by intercalating 
between base pairs and topoisomerase II which blocks transcription and replication 
(Pommier et al., 2010). Though chemotherapy can be an effective treatment, patients often 
experience a plethora of side effects and resistance to therapy can arise. 
1.1.5.3 Radiotherapy 
The role of radiotherapy in the treatment of breast cancer has a long and controversial 
history with the first clinical trial into its use as a treatment for breast cancer beginning in 
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1949 (Paterson and Russel, 1959). Although radiotherapy decreases risk of a local relapse by 
70%, the reduction in relapse rates does not translate into a reduction in mortality (Cuzick, 
2005). This disparity may be due to the detrimental effect radiotherapy has on the immune 
system (Stjernsward, 1974). More recent data have suggested that radiotherapy used 
following breast-conserving surgery has a positive effect on overall survival (Vinh-Hung and 
Verschraegen, 2004). 
1.1.5.4 Hormone Therapy 
There are a variety of hormone treatments available to patients dependent on their 
receptor status. For the 70% of breast cancer patients that have ER-positive tumours, 
selective oestrogen response modulators (SERM) can be used. These are a group of 
compounds that have a similar chemical structure to oestrogens and are capable of binding 
to the ER (Moulder and Hortobagyi, 2008). Tamoxifen is the most publicised SERM, and is 
recommended for the treatment of both pre- and post-menopausal women (Jordan, 1993). 
In the US it has also been approved by the FDA for the prevention of breast cancer in 
women at high risk of developing the disease. Tamoxifen competitively inhibits the action of 
oestrogen by binding to the ER itself. In the same manner as oestrogen, tamoxifen causes 
dimerisation of the receptors which then bind to discrete EREs in target genes. However 
when oestrogen binds to the ER, both activation function (AF) domains, AF-1 and AF-2, are 
activated, yet when tamoxifen binds only AF-1 is activated (Figure 1-6). The inactivity of AF-2 
attenuates transcription and coactivator binding, resulting in inhibition of the G1 phase of 
the cell cycle and slower cell proliferation (Figure 1-6) (Howell et al., 2000). Though 
tamoxifen is generally well tolerated, there are side effects and patients can develop 
resistance, particularly those with amplified HER2 (Clemons et al., 2002). 




Figure 1-6. Mode of action of oestrogen and tamoxifen. The top panel illustrates the 
mechanism by which oestradiol can activate transcription of target genes. The bottom panel 
demonstrates the effect tamoxifen has on binding to ER. Taken from Clemons et al., 2002. 
  
 Trastuzumab (Herceptin) is a recombinant monoclonal antibody targeted to the 
extracellular domain of HER2 for patients that have amplified HER2. Trastuzumab decreases 
signalling via several mechanisms including prevention of HER2 dimerisation, inhibition of 
extracellular domain shedding, immune activation and increased degradation of HER2 
(Valabrega et al., 2007). The addition of trastuzamab to chemotherapy reduced recurrence 
by half and mortality by a third in women with HER2 positive breast cancer (Romond et al., 
2005). 
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1.1.6 New Treatments Required 
Although there are a variety of treatments available for breast cancer patients, it is still the 
leading cause of cancer-related death in women and thus still remains a formidable issue. 
The heterogeneity of the disease observed at both intra- and inter-tumoural level continues 
to make the disease challenging to treat. This is particularly true for patients with metastatic 
triple negative disease, where there are reduced treatment options. Resistance to 
chemotherapy and hormone therapies can also arise, rendering the drugs ineffective. Side 
effects can also cause patients discomfort and reduce their quality of life, as well as 
increasing the risk of chronic illnesses such as chemo-induced acute myeloid leukaemia 
(AML). 
 Currently used in the management and diagnostic imaging of thyroid disorders, the 
inherent ability of breast cells to take up iodide opens the possibility for a potential 
alternative treatment for breast cancer via radioiodide therapy. Although utilisation of 
radioiodide treatment for breast cancer has been proposed previously, further 
understanding into the regulation and post-translational modifications are required before 
it can be translated from bench to bedside. 
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1.2 Sodium Iodide Symporter (NIS) 
1.2.1 Identification and Structure 
The sodium iodide symporter (NIS) is a large integral plasma membrane glycoprotein (Figure 
1-7), the primary role of which is transporting iodide (I-) into cells. NIS is primarily expressed 
in the thyroid but has also been described to have roles in the salivary glands, gastric 
mucosa and lactating mammary glands (discussed in section 1.2.3). The ability of the thyroid 
to accumulate iodide was reported as early as 1896 (Baumann, 1896), although molecular 
information on NIS was not available until the rat gene was cloned in 1996 (Dai et al., 1996). 
Human NIS, also referred to as solute carrier family 5 member 5 (SLC5A5), was cloned a year 
later and was found to share 84% homology and 92% similarity to rat NIS (Smanik et al., 
1997). Located on chromosome 19p13.11, the human NIS gene comprises 15 exons 
interrupted by 14 introns and encodes a 643 amino acid protein (Smanik et al., 1997). The 
protein consists of thirteen transmembrane domains, an extracellular N-terminal and a 
cytosolic C-terminal tail (Figure 1-7). Several phosphorylation sites have been identified in 
vivo along with three N-linked glycosylation sites at positions 225, 485 and 497 (Levy et al., 
1998; Vadysirisack et al., 2007) (Figure 1-7). Mutation of all three glycosylation sites reduced 
NIS function by approximately 50%, suggesting that although important for maximum NIS 
function, glycosylation is not essential (Levy et al., 1998).  




Figure 1-7. Secondary structure of hNIS. The secondary structure of human NIS with 13 
transmembrane domains as predicted by UniProt  
(http://www.uniprot.org/uniprot/Q92911). NIS is glycosylated at Asn225, Asn485 and 
Asn497, all found on hydrophilic extracellular loops. Red amino acids are conserved residues 
that have been observed to be phosphorylated in rat NIS, while amino acids in yellow are 
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1.2.2 NIS in the thyroid 
1.2.2.1 Function 
The primary function of the thyroid is to produce the iodine-containing hormones 
triiodothyronine (T3) and thyroxine (T4). The concentration of iodide within thyroid 
follicular cells is 20-50 times greater than the extracellular concentration, so iodide 
cannot passively diffuse into cells. NIS takes advantage of the inverse sodium ion (Na+) 
electrochemical gradient, maintained by the Na+/K+-ATPase, to couple the transport of 
one I- anion and two Na+ cations across the basolateral membrane into thyroid follicular 
epithelial cells. The NIS-mediated transport of I- into thyroid follicular cells is the rate-
limiting step of T3 and T4 biosynthesis (Spitzweg et al., 2001).  
Once within cells, I- is transported across the apical membrane of cells into the 
follicular lumen where it is organified by thyroid peroxidase. Organification involves the 
oxidation and subsequent incorporation of iodine into tyrosine residues in thyroglobulin 
molecules. Iodide can be incorporated into tyrosine residues producing either 
monoiodotyrosine (MIT) or diiodotyrosine (DIT). Thyroglobulin is later digested in 
lysosomes releasing MIT and DIT with the hormone being produced dependent on the 
coupling reaction - T4 is formed from the coupling of two DIT molecules whereas T3 is a 
combination of DIT and MIT. 
1.2.2.2 Regulation 
The main proximal promoter region of human NIS is located between -478 and -389 
relative to the translation start codon, and contains both a TATA box (AATAAAT) and a GC 
box (CCCGCCCC) (Ryu et al., 1998). A putative ERE (5' CG-GGTCA-CCG-CCGACT-CC 3') was 
also identified 9bp upstream of the TATA box element (Alotaibi et al., 2006). Along with 
an important enhancer region at -2504 to -2260, a NIS upstream enhancer (NUE) was 
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identified between -9348 and -9054 (Ohno et al., 1999). The activity of the NUE has been 
observed to be specific to thyroid cells whereas the proximal promoter is functional in a 
variety of cell-lines (Schmitt et al., 2002; Taki et al., 2002).  
In the thyroid, NIS expression is primarily regulated by thyroid stimulating 
hormone (TSH) (Kogai et al., 1997). When TSH binds to its receptor (TSHR), a G protein-
coupled receptor adenylate cyclase becomes activated (Kogai et al., 2006) generating 
intracellular cyclic adenosine monophosphate (cAMP). This increase in cAMP activates 
transcription factors including the cAMP response element-binding protein (CREB) and 
Pax8 (Poleev et al., 1997). NIS transcription is subsequently induced by the binding of 
Pax8 and CREB to the NUE (Ohno et al., 1999). 
TSH not only regulates transcription of NIS in the thyroid, but also plays a key role 
in the post-translational regulation of NIS. Withdrawal of TSH for 5 days in FRTL-5 cells 
abolished radioiodide uptake and decreased membrane vesicle expression of NIS by 50% 
(Riedel et al., 2001). The presence of TSH in thyroid cells can modulate NIS stability, 
increasing the half-life of NIS by up to 40%. TSH also regulates the subcellular distribution 
of NIS (Riedel et al., 2001). In the presence of TSH, NIS is primarily located at the 
basolateral membrane. However, NIS expression at the plasma membrane was observed 
to decrease over time following TSH withdrawal from cells. Phosphorylation of NIS has 
been observed in vivo, and phosphopeptide mapping revealed a marked change in NIS 
phosphorylation in the presence and absence of TSH. There were five phosphopeptides 
detected in the presence of TSH which reduced to three after TSH withdrawal. However, 
the precise sites, mechanism and importance of NIS phosphorylation remain unknown 
(Riedel et al., 2001). 
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The concentration of iodide within thyroid follicles also plays a role in NIS 
regulation. In response to critically high levels of iodide, the organification process is 
inhibited by an autoregulatory phenomenon known as the acute Wolf-Chaikoff effect. 
This mechanism protects the thyroid from high doses of iodide whilst maintaining an 
adequate supply for thyroid hormone synthesis (Wolff et al., 1949). Although the 
mechanism for the acute Wolff-Chaikoff effect is still not fully understood, there is 
evidence to suggest that the generation of thyroid peroxidase inhibitors such as 
intrathyroidal iodolactones, iodoaldehydes and iodolipids contribute to the decreased 
synthesis of thyroid hormones (Leung and Braverman, 2014). The Wolf-Chaikoff effect 
has been observed to be transient lasting approximately 24 hours and thyroid hormone 
production resumes after adaptation (Wolff et al., 1949). This adaptation has been 
associated with decreased expression of NIS in thyroid follicular cells (Eng et al., 1999). 
It has been demonstrated that high levels of I- can downregulate NIS mRNA in 
both dog (Uyttersprot et al., 1997) and rat thyroid (Eng et al., 1999). However a later 
study in FRTL-5 cells observed no change in NIS mRNA but did identify a reduction in NIS 
protein at high I- concentrations, suggesting a post-transcriptional effect (Eng et al., 
2001). In the PCCI3 rat thyroid follicular cell line, excess iodide resulted in increased Akt 
phosphorylation and PI3K activity. Additionally, use of specific PI3K and Akt inhibitors 
abolished the I- inhibitory effect on NIS function (Serrano-Nascimento et al., 2014). 
Increased iodide has also been observed to increase cellular reactive oxygen species 
(ROS) inhibiting NIS function at the cell surface through post-translational mechanisms 
(Arriagada et al., 2015). 
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1.2.2.3 NIS in thyroid disease 
The natural ability of the thyroid to take up iodide is central to the diagnosis and 
treatment of th roid diseases such as h perth roidism, Graves’  isease and thyroid 
cancer. This mechanism has been exploited for the treatment of thyroid disease for over 
70 years with radioiodide being used to treat thyroid carcinoma as early as the 1940s 
(Hertz and Roberts, 1942; Seidlin et al., 1946). A large proportion (68-80%) of thyroid 
cancers and their metastases retain the ability to accumulate iodide with functional NIS 
expression (Castro et al., 2001). This uptake has allowed ablation of malignant tissue 
using the β-emitting radioiodide-131 (131I) and nuclear imaging of the disease using 
radioiodide 123, 124 and 125 (123I, 124I and 125I)(Spitzweg et al., 2001).  
Although 131I has a place as a therapeutic treatment for thyroid cancer it also 
represents a significant public health hazard. It has been widely implicated in many of the 
detrimental effects associated with open-air atomic bomb testing in the 1950s, the 
Chernobyl disaster in 1986, and the Fukushima explosion of 2011. One of the major 
products from the nuclear fission of both uranium and plutonium is 131I. This isotope of 
iodide decays through beta decay and is notable for causing mutation and death in cells 
that it penetrates and other cells up to several millimetres away (the ‘B stander Effect’). 
In nuclear fallout, the doses of radioiodide received from nuclear contamination are 
much lower than the high doses used therapeutically to kill diseased cells. These lower 
doses are not sufficient to induce cell death but are capable of initiating mutations that 
may then drive cell transformation and tumourigenesis.  
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1.2.3 NIS expression in the lactating breast 
While iodide accumulation in the thyroid is important for the production of thyroid 
hormones, it is also vital that breastfeeding mothers accumulate iodide in their milk. 
Iodide is an essential constituent of breast milk as infants that receive deficient levels of 
iodide are at an increased risk of mortality and impaired neurological development (Cao 
et al., 1994; DeLong et al., 1997).  
 The ability of mothers to accumulate iodide in their milk was observed as early as 
1952 (Honour et al., 1952) but NIS was not identified as the transporter responsible until 
nearly 50 years later (Cho et al., 2000; Tazebay et al., 2000). Alveolar cells display distinct 
functional NIS expression in the basolateral plasma membrane (Cho et al., 2000). Rat 
lactating mammary gland NIS is only ~75kDa in size which is smaller than the 100kDa 
form observed in rat thyroid. However the difference in size can be attributed to 
differences in glycosylation as both the rat mammary gland and thyroidal NIS have an 
unglycosylated form of NIS of ~50kDa (Tazebay et al., 2000). Although unglycosylated 
forms of NIS are still functional, they are observed to have a reduced activity compared to 
fully glycosylated mature NIS (Levy et al., 1998). 
 NIS expression in mammary glands is under different regulation to that in the 
thyroid, with expression solely being induced towards the end of gestation and 
throughout suckling. However within 24 hours of weaning, NIS expression is significantly 
reduced (Tazebay et al., 2000). Investigation into regulation of mammary gland NIS has 
focused on the potential roles of hormones heavily involved in lactation such as oxytocin 
and prolactin (discussed in 1.2.4.1). 
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 Treatment of mice with oxytocin increased both the expression of NIS in 
mammary tissue and accumulation of radioiodide within milk (Tazebay et al., 2000). This 
was also confirmed in rats, where an antagonist of oxytocin decreased radioiodide uptake 
compared with control treated animals (Cho et al., 2000). The role of prolactin in NIS 
expression is not as clear cut and has produced varying results in different studies. Mice 
treated with prolactin alone and in combination with oxytocin did not display altered 
iodide accumulation in their milk, nor was NIS expression induced. However, rats treated 
with prolactin displayed increased NIS mRNA levels and use of bromocriptine, a potent 
inhibitor of prolactin release from the pituitary gland, decreased radioiodide uptake in rat 
mammary glands (Cho et al., 2000). Despite this, it is clear that oxytocin and prolactin do 
not act synergistically. Prolactin is documented to have an inhibitory effect on 
steroidogenesis (Dorrington and Gore-Langton, 1981), which has been suggested to 
decrease oestrogen levels below a threshold level, subsequently preventing NIS induction 
by concomitantly administered oxytocin. The combination of oestrogen, prolactin and 
oxytocin (in the absence of progesterone) led to the highest levels of mammary gland NIS 
expression in ovariectomised mice. This combination of hormones closely resembles 
relative hormonal levels in mice and rats during lactation (Tazebay, 2000). 
1.2.4  NIS in breast cancer 
Breast carcinomas have been documented to possess the ability to take up radioiodide 
for over 40 years. Initial studies established that breast tumour biopsies were capable of 
taking up more radioiodide than their normal counterparts (Eskin et al., 1974) with 
subsequent murine experiments replicating these findings (Thorpe, 1976). However it 
was not until the new millennium that expression of NIS was identified in breast cancer 
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with NIS mRNA being detected in 6 out of 7 human tumours (Kilbane et al., 2000) and the 
presence of NIS protein confirmed by immunohistochemistry (IHC) (Tazebay et al., 2000). 
Although none of the of the normal breast samples showed any IHC staining for NIS, 87% 
of the breast carcinoma samples were reported positive for NIS expression (Tazebay et 
al., 2000). Expression of NIS did not differentiate between tumour type with tumours 
such as invasive carcinoma and ductal carcinoma in situ having similar NIS levels (Tazebay 
et al., 2000; Wapnir et al., 2003). Initial studies did not indicate any correlation between 
NIS expression and the expression of TSHR, ER or PR in breast cancer (Oh et al., 2005), 
however a more recent study has identified an association between ER and NIS 
expression (Chatterjee et al., 2013). 
 Despite many tumours having NIS expression, only those with the highest NIS 
levels have measurable functional NIS, with only 17% of NIS positive tumours being 
capable of 99mTc-pertechnetate uptake (Moon et al., 2001). A subsequent study found 2/8 
(25%) NIS expressing tumours had detectable 123I uptake (Wapnir et al., 2004). The 
disparity between radioiodide uptake and NIS expression levels has resulted in the 
hypothesis that NIS may be aberrantly localised within breast cancer cells. In the lactating 
breast, NIS was primarily located along the basolateral membrane of epithelial cells 
whereas in breast cancer cells a mixture of cell surface and intracellular staining has been 
reported (Tazebay et al., 2000). This was confirmed by a later study where only 27% of 
NIS expressing breast cancers had staining for NIS at the plasma membrane (Beyer et al., 
2009). 
 To establish if NIS expression correlated with any genes heavily associated with 
breast cancer, 14 different genetically engineered mouse models of breast cancer were 
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investigated. Those that stained strongly for NIS expression included mice expressing the 
oncogene PyMT, HER2, the hCG subunit and Cox-2 within murine mammary glands. hCG 
and Cox-2 can induce cAMP whilst PyMT, HER2 and Cox-2 are capable of activating the 
PI3K pathway (Knostman et al., 2004). Increased levels of cAMP have previously been 
described to induce NIS expression in the thyroid (Section 1.2.2.2) (Ohno et al., 1999) and 
PI3K levels have been observed to positively correlate with NIS expression in breast 
tumours (Knostman et al., 2007). Investigation into the individual pathways in MCF-7 cells 
showed elevated cAMP levels increased NIS promoter activity and mRNA levels but did 
not alter radioiodide uptake, whereas PI3K activation increased both expression of NIS 
protein and radioiodide uptake (Knostman et al., 2004). Further studies revealed that 
although PI3K activation increases NIS expression, it leads to expression of an 
underglycosylated form of NIS with disrupted cell surface trafficking (Knostman et al., 
2007). 
 Along with primary breast tumours, the use of radioiodide has been proposed for 
locating, monitoring and treating metastases. Whilst metastases may not retain NIS 
expression, with only 33% of metastases having detectable expression in one study 
(Wapnir et al., 2004), a study of 28 brain metastases from primary breast tumours 
reported that 75% of the tumours were NIS positive and only 24% of these tumours had 
plasma membrane staining for NIS (Renier et al., 2010). Of the 21 metastases that had 
NIS expression, all were ER and PR negative with a mixture of positive and negative HER2 
staining. Currently patients with brain metastases have to rely solely on surgery and/or 
external radiation due to the impermeability of the blood brain barrier to chemotherapy 
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reagents, so the potential for just under 20% of brain metastases to be treated with 
radioiodide therapy would be revolutionary (Renier et al., 2010). 
1.2.4.1 NIS regulation in breast cancer 
As discussed in section 1.2.2.2, NIS expression in the thyroid is under the regulation of 
TSH; however, TSH has no effect on NIS expression in breast cancer. To be able to exploit 
NIS for therapeutic use it is important to understand its regulation in breast cells.  
 As oxytocin and prolactin regulate NIS expression in the lactating breast it was 
logical to investigate their role in breast cancer. In 3D histocultures of breast tumours, 
treatment with oxytocin and prolactin individually induced NIS mRNA expression in a 
dose-dependent manner. However, as within the lactating breast a combination of the 
two hormones was not capable of further inducing NIS expression (Cho et al., 2000). The 
majority of breast cancers (50-90%) express the oxytocin receptor (Bussolati et al., 1996; 
Ito et al., 1996; Sapino et al., 1998) and it is hypothesised that induction of NIS via 
oxytocin acts in a similar manner to TSH stimulation in thyrocytes. The oxytocin receptor 
is a G protein-coupled receptor which activates the Gs-cAMP-protein kinase A (PKA) 
pathway (Olins and Bremel, 1984)(Figure 1-8). Prolactin is known to increase the 
expression of genes containing γ-interferon activation sequences (GAS) in their promoter 
regions, through the activation of the Jak2/STAT5 cascade in breast cells (Burdon et al., 
1994) (Figure 1-8). A GAS sequence was subsequently identified within the NIS proximal 
promoter (Cho et al., 2000). Further studies have produced conflicting results in MCF-7 
cells, with one failing to identify any induction of NIS expression after prolactin treatment 
(Kogai et al., 2005), whereas another observed increased NIS mRNA and iodide-trapping 
post-prolactin treatment (Arturi et al., 2005). 




Figure 1-8. NIS transcriptional regulation in breast cancer. A schematic displaying the 
different mechanisms by which NIS expression can be induced in breast cancer. Akt - 
Protein kinase B, cAMP - Cyclic adenosine monophosphate, CRB - cAMP response element-
binding,GAS - γ-interferon activation sequence, IGF - Insulin-like growth factor, IRS1 - 
Insulin receptor substrate, JAK - Janus Kinase, MAPKK3B - Mitogen-activated protein 
kinase Kinase 3B, PI3K - phosphoinositide 3-kinase, PKA - Protein kinase A, RAR - Retinoic 
acid receptor, RXR - Retinoid X receptor, STAT5 - Signal transducer and activator of 
transcription 5. Taken from Poole and McCabe, 2015. 
 
 Insulin and insulin-like growth factors (IGF) 1/2 have also been implicated in 
regulating NIS expression in breast cancer. Treatment with insulin and IGF1/2 stimulated 
both NIS mRNA and protein expression in MCF-7 cells and increased 125I uptake (Arturi et 
al., 2005). Ligand-activated IGF-1 receptor is known to act on the insulin receptor 
substrate-1 (IRS-1), which leads to activation of the PI3K pathway (Dupont and Le Roith, 
2001) and has previously been associated with NIS expression in breast cancer cells 
(Section 1.2.4) (Figure 1-8). 
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 Retinoids are well documented to be useful for the treatment of a variety of 
neoplasms (reviewed in (Connolly et al., 2013)) with the use of systemic retinoids being 
approved by the FDA for the treatment of cutaneous T cell lymphoma (Duvic et al., 2001) 
and acute promyelocytic leukaemia (APL) (Tallman et al., 1997). Treatment of MCF-7 cells 
with all trans-retinoic acid (ATRA) increased 125I uptake in a dose-dependent manner that 
could be inhibited by the potent NIS inhibitor potassium perchlorate, indicating specific 
NIS-mediated uptake (Kogai et al., 2000). Treatment with ATRA not only increased NIS 
mRNA and protein expression in MCF-7 cells, it also reduced colony formation in the 
presence of 131I suggesting radioiodide in combination with ATRA may be a viable breast 
cancer treatment. MCF-12A cells (derived from normal breast tissue) and ER-negative 
MDA-MB-231 cells did not display such a marked response to ATRA, with MDA-MB-231 
cells only having slight induction of NIS protein expression and neither cell-line displaying 
altered radioiodide uptake (Kogai et al., 2000). A major disparity between the two cancer 
cell-lines is that MCF-7 cells are known to express both the retinoic acid receptor (RAR) 
and retinoid X receptor (RXR) whereas MDA-MB-231 are considered RA 'resistant' due to 
decreased expression of RARα and RARβ compared with MCF-7 cells (Liu et al., 1996). 
Further to this, responsiveness to ATRA was later positively correlated with expression of 
ERα in breast cancer cells, with both ERα and RARα bein  required for NI  induction 
(Alotaibi et al., 2006).  
 To establish whether systemic retinoids would be useful in vivo, mice bearing 
MCF-7 xenograft tumours were assessed for NIS expression and activity. Mice that were 
treated with an ATRA slow-release pellet for five days prior to treatment with 125I 
displayed increased NIS expression and accumulated almost 15 times more radioiodide 
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than control treated mice. In a murine model of breast cancer (murine mammary tumor 
virus-polyoma virus middle T antigen (MMTV-PyVT)-transgenic mice), treatment with 
ATRA doubled radioiodide accumulation (Kogai et al., 2004). 
 Dexamethasone (Dex) has been identified to synergistically increase both NIS 
expression and radioiodide uptake when used in conjunction with ATRA in MCF-7 cells. 
Dex treatment alone only slightly induced NIS mRNA levels, but when used in 
combination with ATRA there was a ~70-fold increase in NIS mRNA. Additionally, Dex was 
observed to increase the stability of NIS mRNA (Kogai et al., 2005). Further studies 
confirmed the synergistic effect of ATRA and Dex with MCF-7 cells treated with the 
combination displaying reduced cell survival compared with cells treated with ATRA alone 
after treatment with 131I (Unterholzner et al., 2006).  
In cells, ATRA and other retinoids bind to RAR which leads to homodimerisation or 
heterodimerisation with RXR. These heterodimers then go on to bind to retinoic acid 
response elements (RAREs) on target genes stimulating transcription (Figure 1-8). 
Although the NIS promoter in MCF-7 cells does not contain any putative full RAREs, it 
does contain several DR-2 element sequences with typical half-sites between the first and 
thirteenth intron. Initial studies identified these DR-2 sites to be unresponsive to ATRA 
(Kogai et al., 2008), although a subsequent stud  reported bindin  of RARα to the intronic 
DR-2 elements 30 minutes after MCF-7 cells were treated with ATRA (Alotaibi et al., 
2010), suggesting a potential role in NIS induction (Kogai and Brent, 2012). A DR-5 
element located within in promoter region of NIS was discovered to be responsive to 
ATRA in MCF-7 cells (Kogai et al., 2008) (Figure 1-8). Although these half-sites have been 
reported to be active in human cells in vitro, introns of murine NIS do not contain DR-2 or 
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DR-5 elements yet ATRA is still capable of inducing NIS expression in transgenic mice 
models (Kogai et al., 2004), suggesting non-traditional mechanisms of transduction may 
be apparent. 
Following treatment with ATRA, a homeobox protein, Nkx-2.5 is induced in MCF-7 
cells (Figure 1-8) (Dentice et al., 2004). It has been suggested that Nkx-2.5 is crucial for 
the induction of NIS with ATRA since mutations in Nkx-2.5 significantly reduce radioiodide 
uptake (Dentice et al., 2004). To further identify proteins involved in ATRA's induction of 
NIS expression, a range of inhibitors were utilised to identify critical pathways. Among the 
proteins identified to be important were the IGF receptor, PI3K, AKT and p38 mitogen-
activated protein kinase (MAPK) (Kogai et al., 2008). It is well documented that natural 
retinoids can stimulate IGF receptors (Kang et al., 1997) and that activated RAR/RXR 
heterodimers can interact with IRS-1 (del Rincon et al., 2003). It is also hypothesised that 
activated heterodimers interact with IRS-1, which leads to activation of the PI3K pathway 
inducing NIS expression (Kogai et al., 2008) (Figure 1-8). A subunit of PI3K, p85, has also 
been observed to directly interact with activated RAR/RXR heterodimers with inhibition 
and silencing of the p85 subunit resulting in reduced NIS expression after ATRA treatment 
(Ohashi et al., 2009).  
The MAPK signalling pathway has also been associated with ATRA's induction of 
NIS with activated RAR/RXR heterodimers being observed to stimulate the p38-Rac1 
pathway (Alsayed et al., 2001) (Figure 1-8). Inhibition of p38 reduced both basal NIS 
expression and induction after ATRA treatment in MCF-7 cells (Kogai et al., 2008). 
Silencing and inhibition of Rac1, MAPK kinase 3B (MAPKK3B) and p38β revealed all three 
were critical for full induction of NIS by ATRA in MCF-7 cells. It has been hypothesised 
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that in breast cancer cells, ATRA activated RAR/RXR heterodimers interact with the small 
GTPase Rac-1 resulting in MAPKK3B phosphorylation of p38. The phosphorylation of p38 
leads to the induction of NIS transcription through unknown factors (Kogai et al., 2012) 
(Figure 1-8). 
Although prolactin, oxytocin and ATRA can be utilised to boost endogenous NIS 
expression within breast cancer cells, their mechanisms of action are not fully elucidated 
and the complications of systemic treatment, such as toxicity, still exist. Thus, there have 
been multiple efforts to increase NIS levels and radioiodide uptake using exogenous NIS. 
1.2.4.2 NIS gene therapy in breast cancer 
There have been several methods utilised in attempts to exogenously boost NIS 
expression, including retro-, adeno- and oncolytic-viral expression. The first technique 
employed to exogenously express NIS was retroviral delivery with 131I uptake being 
sufficient to kill murine and human tumour cells in xenograft models (Mandell et al., 
1999). To establish whether pre-existing tumours could benefit from exogenous 
expression of NIS, murine xenograft MCF-7 and SiHa (cells originating from a cervical 
carcinoma) tumours were directly injected with NIS adenovirus. Directly injected tumours 
were capable of accumulating 25 times more radioiodide than their control counterparts. 
However, there was no difference in tumour size between control and NIS transduced 
cells after treatment with 131I. It was hypothesised that this disparity between uptake and 
cell death was due to the length of time that cells retain radioiodide being too short to 
sufficiently inhibit cell growth and ablate tumour cells (Boland et al., 2000). In 
adenovirally-transduced MCF-7 cells with NIS under the expression of the CMV promoter, 
retinoic acid was capable of further increasing radioiodide uptake in a similar manner to 
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cells endogenously expressing NIS (Lim et al., 2007). The CMV promoter is known to 
contain RAREs within its sequence (Angulo et al., 1996) which can be bound by activated 
endogenous RAR/RXRs (Titcomb et al., 1994). 
 Another approach to increasing NIS expression is to exogenously express NIS 
within cells under the control of cell-type specific promoters. In a prostate cancer study, 
LNCaP prostate cancer cells were stably transfected with NIS under the regulation of the 
prostate-specific antigen (PSA) promoter and used to generate xenograft models. After 
an intraperitoneal (IP) injection of 3 mCi 131I, there was a significant reduction in tumour 
size compared with control tumours (Spitzweg et al., 2000). Similar to PSA, in breast 
cancer cells the MUC1 promoter has also been investigated. MUC1, a glycoprotein usually 
found in haematopoietic cells, is expressed in approximately 90% of breast cancers and is 
associated with poor survival and increased metastasis (Gendler, 2001). In MUC1-positive 
breast cancer T47D cells, adenoviral transduction of NIS led to a 58-fold increase in 
radioiodide uptake. In comparison, MDA-MB-231 cells that are MUC1-negative displayed 
no increase in radioiodide uptake after transduction. Studies in vivo using T47D murine 
xenograft tumours that were injected at multiple sites with adenoviral NIS under the 
MUC1 promoter displayed an 83% reduction in tumour size after IP treatment with 131I, 
while tumours injected with control adenovirus continued to increase in size (Dwyer et 
al., 2005). The oestrogen receptor promoter and the human telomerase reverse 
transcriptase promoter have also been successfully used in breast cancer cells resulting in 
increased 131I uptake and inhibited tumour growth after adenoviral transduction of NIS 
(Riesco-Eizaguirre et al., 2011). 
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  Oncolytic viruses have also been employed as a method to deliver NIS to tumour 
cells. Murine xenograft tumours that were injected with GLV-h153, an oncolytic vaccinia 
virus carrying human NIS, had increased visualisation with 124I compared with control 
tumours. Further to this, virally injected tumours displayed a significant reduction in 
tumour growth after treatment with 131I (Gholami et al., 2014).  
 Although NIS gene therapy appears effective, an efficient and optimal method of 
delivery of the gene to the tumour site has not yet been established. Superparamagnetic 
iron oxide (SPIO)-labelled AC133+ progenitor cells (APCs) that had been adenovirally-
transduced with human NIS increased 99mTc uptake in mice with MDA-MB-231 xenograft 
tumours. MRI and single photon emission computer tomography (SPECT) showed that 
although the labelled APCs had been injected intravenously, there was a large 
accumulation of the cells at the site of the tumour (Rad et al., 2009). Due to the fact that 
mesenchymal stem cells (MSCs) have been well-documented to migrate to tumour sites 
in vivo, they have been hypothesised to be an efficient delivery mechanism for gene 
therapy (Dwyer et al., 2010; Spaeth et al., 2008). Intravenous injection of MSCs 
adenovirally-transduced with NIS increased the levels of 99mTc detected at the site of the 
MDA-MB-231 murine xenograft tumours using SPECT. Not only did this form of delivery 
increase the levels of 99mTc detected, there was also an increase in retention with 99mTc 
remaining detectable at the tumour site after 14 days. Expression of NIS was confirmed 
within tumour cells and compared with control mice there was a significant reduction in 
tumour size after treatment with 131I (Dwyer et al., 2011). 
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1.2.5 Binding partners of NIS 
Only three putative binding partners of NIS have been reported; pituitary tumor-
transforming gene (PTTG)-binding factor (PBF) (Smith et al., 2009) (discussed in 1.4), 
heat-shock protein 90 (HSP90) (Marsee et al., 2004) and leukemia-associated RhoA 
guanine exchange factor (LARG) (Lacoste et al., 2012).  
HSP90 was initially identified as a novel RET/PTC1-interacting protein, a 
rearranged form of the RET tyrosine kinase seen in 10-20% of papillary thyroid cancers. It 
has been observed to indirectly associate with NIS, with inhibition of hsp90 resulting in an 
increase in radioiodide uptake with NIS expression levels remaining unchanged. It has 
been hypothesised that hsp90 may function as a chaperone protein for NIS (Marsee et 
al., 2004). 
LARG is a guanine nucleotide exchange factor for the RhoA GTPase that has been 
implicated in many cellular roles including cell adhesion and reorganisation of the 
cytoskeleton. LARG is capable of binding NIS directly through its N-terminal PDZ domain 
in multiple cancer cell-lines, including breast. The interaction between LARG and NIS 
leads to the activation of RhoA, which facilitates cell migration and invasion. The 
interaction between NIS and LARG was found to occur intracellularly, suggesting that the 
aberrant localisation of NIS within cancer cells may increase migration of these cells. This 
correlates with the observation that NIS is localised at the leading edge of metastatic 
breast cancer cells (Lacoste et al., 2012).  
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1.3 Pituitary Tumor-Transforming Gene-Binding 
Factor (PBF) 
1.3.1 Structure 
The pituitary tumor-transforming gene-binding factor, hereafter referred to as PBF (also 
known as PTTG1IP) gene is located on chromosome 21 at 21q22.3. The human PBF gene 
consists of 6 exons spanning 24kb and encodes a 180 amino acid protein with a predicted 
molecular mass of 22kDa (Chien and Pei, 2000). Although PBF shares no significant 
homology with other human proteins, it is highly conserved among a range of species 
(73% homology to mouse, 60% to chicken and 52% to zebrafish) (Yaspo et al., 1998) 
implying it has evolutionary importance.  
 Initial protein prediction studies suggested that PBF was a cell surface 
glycoprotein due to the presence of a potential N-terminal signal peptide, a 
transmembrane domain and an endocytosis motif (Yaspo et al., 1998). The presence of a 
plexin-semaphorin-integrin (PSI) domain between residues 40 - 95 supports the theory 
that PBF is a cell surface protein as PSI domains are usually located extracellularly, being 
involved in cellular signalling and protein-protein interaction (Bork et al., 1999). However 
the presence of a bipartite nuclear localisation signal (Chien and Pei, 2000) and the 
detection of a nucleolus signal and nuclear export signal using appropriate prediction 
software (La Cour et al., 2004; Scott et al., 2010) suggest that PBF may also have a role in 
the nucleus/nucleolus. 
 PBF is a poorly studied protein but is predicted to contain sites for post-
translational modifications such as phosphorylation, SUMOylation and N- and O-
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glycosylation (Chien and Pei, 2000). Phosphorylation prediction software identified Y174 
as a phosphotyrosine site (discussed in 1.4.3) with S85, S126, S132 and T10 as potential 
phosphoserine/threonine sites (Figure 1-9). Small Ubiquitin-Like Modifier (SUMO) 
proteins covalently bind to many proteins altering their cellular function; prediction 
software (Zhao et al., 2014) has located the presence of a potential SUMOylation site at 
lysine 169 (Figure 1-9). PBF contains five potential glycosylation sites for N-linked and O-
linked oligosaccharides (Chien and Pei, 2000) with asparagine residues 45 and 54 both 
fulfilling criteria for N-terminal glycosylation (Rao and Bernd, 2010) (Figure 1-9). 




Figure 1-9. A schematic diagram of the structure of PBF. PBF contains a putative N-
terminal signal peptide, a PSI domain, a transmembrane domain and an intracellular C-
terminal region. The PSI domain is cysteine rich containing multiple disulphide bonds 
represented by red lines. The C-terminal region contains a nuclear localisation signal (NLS) 
and a tyrosine based sorting signal. P represents a phosphorylation site and G a 
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1.3.2 PBF Expression 
PBF is ubiquitously expressed in normal tissues, with Northern blot analysis revealing PBF 
mRNA expression in tissues such as the stomach, spleen, testis, colon and thyroid (Chien 
and Pei, 2000; Stratford et al., 2005; Yaspo et al., 1998). PBF was first implicated in 
tumourigenesis when it was found to be overexpressed in pituitary tumours compared 
with normal pituitary tissue (McCabe et al., 2003). Subsequently the upregulation of PBF 
mRNA and protein was detected in well-differentiated thyroid carcinomas, including 
papillary thyroid cancer (PTC) and follicular thyroid carcinoma (FTC), with a significant 
association with early tumour recurrence (Stratford et al., 2005). Further investigations 
have observed PBF upregulation in a wide array of cancers including colon (Read et al., 
2014b) and breast (Watkins et al., 2010).  
 
1.3.3 PBF Identification and Interaction with PTTG 
PBF was first identified through its interaction with pituitary tumor-transforming gene 
(PTTG)(Chien and Pei, 2000). PTTG is a multifunctional human securin that has roles in 
cell transformation (Pei and Melmed, 1997), control of mitosis (Zou et al., 1999), DNA 
repair (Romero et al., 2001), gene regulation (Zhang et al., 1999b) and foetal 
development (Boelaert et al., 2003). First identified due to its high expression in pituitary 
tumours compared with normal pituitary tissue (Pei and Melmed, 1997), PTTG has since 
been reported to be overexpressed in a variety of tumours, such as thyroid (Heaney et 
al., 2001), breast (Solbach et al., 2004) and colorectal (Heaney et al., 2000) cancer, where 
high expression correlates with poor prognosis (Heaney et al., 2000; McCabe et al., 2003; 
Zhang et al., 1999a). The PTTG protein is comprised of 202 amino acids and has been 
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demonstrated to have potent transforming ability both in vitro and in vivo (Pei and 
Melmed, 1997).  
 The interaction between PBF and PTTG was identified through a yeast two-hybrid 
screen with binding confirmed using GST-pulldown (Chien and Pei, 2000). Deletion 
studies have shown that the 30 C-terminal amino acids of PBF interact with PTTG within a 
domain located between amino acids 123 and 154. PBF facilitates the translocation of 
PTTG into the nucleus and is required for PTTG activation of fibroblast growth factor 2 
(FGF-2) (Chien and Pei, 2000). Subsequently levels of PTTG and PBF were found to 
correlate in pituitary adenomas (McCabe et al., 2003) and thyroid carcinomas (Stratford 
et al., 2005). Overexpression of PTTG was observed to increase PBF mRNA expression in 
vitro (Stratford et al., 2005) although neither EGFR nor TGF-α affected PBF expression 
despite causing an increase in PTTG levels (Vlotides et al., 2006).  
 Recently a bitransgenic mouse model has been created with thyroid-specific 
expression of PTTG and PBF (Bi-Tg). Phenotypically Bi-Tg mice displayed enlarged thyroids 
and an increased number of hyperplastic lesions compared with wild-type (WT), PBF-Tg 
and PTTG-Tg mice. The expression of both PBF and PTTG led to genetic instability and the 
induction of the tumour suppressor protein p53. Approximately 30 genes involved with 
DNA damage repair were also downregulated compared with WT mice. These findings 
suggest that both PBF and PTTG may accelerate cancer initiation and progression with 
fundamental roles in interrupting DNA damage pathways and increasing genetic 
instability (Read et al., 2016). 
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1.3.4 PBF in thyroid cancer 
Thus far, PBF has primarily been studied within the context of thyroid cancer, with PBF 
mRNA expression being 3.3-fold higher in a cohort of differentiated thyroid cancers 
compared with normal thyroid tissue. Within this disease PBF upregulation has been 
correlated with unfavourable clinical parameters such as age, early recurrence, distant 
metastases at diagnosis, tumour multicentricity, tumour, node, and metastasis (TNM) 
stage and disease-specific mortality (Figure 1-10)(Hsueh et al., 2013; Stratford et al., 
2005).  
  
Figure 1-10. PBF overexpression is associated with disease-specific mortality. There is a 
significant association between high PBF expression and decreased disease specific 
survival rates by Kaplan–Meier analysis (P=0.0835). Taken from Hsueh et al. 2013. 
 
 Though PBF upregulation is associated with thyroid cancer, no mutations in PBF 
have so far been identified within thyroid cancers. The entire coding region of PBF was 
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initially sequenced in 24 thyroid tumours and no mutations were detected (Stratford et 
al., 2005). Subsequently, no PBF mutations were reported in the 507 papillary thyroid 
tumours that were sequenced as part of The Cancer Genome Atlas (TCGA) study (TCGA, 
2016). Similar large-scale sequencing studies have identified 27 PBF mutations in a variety 
of other human cancers, with 18 missense substitutions, 5 synonymous substitutions, 2 
in-frame deletions and 2 in-frame insertions. However, the detection of PBF mutations in 
only 27 out of the 29,052 tumour samples sequenced to date suggests that it is a very 
rare event (COSMIC Database, 2016a).  
 PBF has been observed to have transforming ability both in vitro and in vivo. In a 
fibroblast cell line (NIH3T3) stably transfected with PBF, there was a 12-fold increase in 
colony formation compared with vector-only transfected cells. These stably expressing 
cell lines were subsequently injected into nude mice. Mice injected with the PBF over-
expressing cells developed aggressive high grade invasive carcinomas (Stratford et al., 
2005).  
 To further investigate the specific role of PBF in thyroid disease, a transgenic 
mouse model was generated. These mice overexpressed hemagglutinin (HA) tagged PBF 
(PBF-HA) specifically in the thyroid gland (PBF-Tg mice). To ensure that PBF expression 
was achieved only within the thyroid, PBF was inserted under the control of the 
thyroglobulin promoter. Although there was no tumour induction in mice aged up to 18 
months, all PBF-Tg mice had significantly enlarged thyroids compared with their WT 
counterparts. PBF-Tg thyroid glands were 1.7 times heavier by 7 weeks and 3.2 times 
heavier by 52 weeks compared with WT littermates. The enlarged thyroids had 
significantly increased numbers of macrofollicular and hyperplastic lesions suggesting PBF 
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upregulation affects the structural development of the thyroid. PBF-Tg mice also 
displayed altered thyroid hormone secretion with increased intra-thyroidal T3 and T4 
levels compared with WT mice (Smith et al., 2012). Within PBF-Tg thyroids, there was 
increased expression of phosphorylated AKT (p-AKT), cyclin D1 and thyroid-stimulating 
hormone receptor (TSHR) (Read et al., 2011). 
  PBF has recently been discovered to have roles in DNA damage repair and genetic 
instability, and has been identified to be a negative regulator of the tumour suppressor 
protein p53 in both thyroid (Read et al., 2014a) and colorectal cancer (Read et al., 2014b). 
PBF has also been observed to interact with the DNA repair enzyme ATR, suggesting PBF 
may have an impact on p53-independent DNA damage repair mechanisms (unpublished 
observations from the McCabe Group, Birmingham, UK).  
 
1.3.5 PBF in breast cancer 
Though PBF has mainly been studied in the context of thyroid disease, there is an interest 
in PBF within the breast cancer field. Whereas PBF is minimally expressed within normal 
breast tissue it has been found to be strongly expressed in breast tumours. In a study of 6 
normal breast specimens and 20 TMA specimens, PBF mRNA was not detected in any of 
the normal samples whereas in 18 breast cancer specimens PBF was detected with a 
mean ΔCt of ~8 to 10 (Watkins et al., 2010) (Figure 1-11A). Immunohistochemistry 
confirmed that normal breast samples had absent or low expression of PBF protein in 
contrast to strong expression in epithelial cells of all tumour types and grades of breast 
cancer assessed (Watkins et al., 2010) (Figure 1-11B). Though PBF expression was strong 
in all tumour t pes, there was a particularl  si nificant correlation between ERα and PBF 
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expression (Watkins et al., 2010). An independent study with a larger cohort later 
confirmed the correlation between PBF and ER expression (Xiang et al., 2012). 
 This correlation between PBF and ERα sparked further investi ation into their 
relationship. PBF was observed to be regulated by oestrogen with PBF mRNA and protein 
expression bein  induced in ERα-positive MCF-7 breast cancer cells after 48 hour 
treatment with diethylstilbestrol and 17β-estradiol (Watkins et al., 2010). Analysis of the 
human PBF promoter revealed that the region from -399 to -292 relative to the start 
codon was replete with putative ERE. This polymorphic region contains a variable number 
of tandem repeats of an 18-nucleotide sequence housing an ERE half-site 
(gcccctcGGTCAcgcctc). A greater number of repeats in the promoter correlated with 
higher levels of PBF mRNA in breast specimens. Of three normal tissues successfully 
analysed all were homozygous for three repeats whereas the 27 tumour samples 
successfully analysed were either homozygous for three repeats or heterozygous for 
three and five repeats. These EREs were found to be oestrogen-responsive with ERα 
directly binding to the promoter region of PBF (Watkins et al., 2010). 




Figure 1-11. Expression of PBF in normal and cancerous breast tissue. (A) Expression of 
PBF mRNA relative to 18s mRNA (ΔCt values) in 20 TMA samples of breast tumours 
compared with normal breast. ND, not detected after 40 cycles of PCR. (B) Representative 
immunohistochemical examination of PBF staining in one normal breast sample and 
seven tumour samples from TMA sections. Columns 1 to 4 represent the different staining 
intensities observed from 0 (absent) to +3 (intense). Values in the bottom right-hand 
corners indicate the percentage of PBF expression observed in the whole section, with 
original magnifications annotated next to tumour type. (C) Representative 
immunohistochemical examination of PBF staining in three normal breast samples (N1–
N3; US BioMax; ×40 original magnification) and three tumour samples from TMA sections. 
T1, Grade I; T2, Grade II; T3, Grade III; all ×40 original magnification. Taken from Watkins 
et al.2010. 
  
 The exact function of PBF within cell transformation and breast cancer is yet to be 
elucidated, although it has been observed to increase cell invasion in MCF-7 cells. MCF-7 
cells transfected with PBF displayed a 2.5-fold increase in cell invasion compared with 
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empty vector transfected cells in vitro (Watkins et al., 2010). Though treatment with 
oestrogen is well-documented to induce invasion in MCF-7 cells (Thompson et al., 1988), 
it was unable to do so in cells lacking PBF expression suggesting that PBF plays a role in 
mediating the induction of invasion by oestrogen (Watkins et al., 2010). PBF was 
subsequently found to be a secreted protein, with mutational studies confirming the 
need for PBF to be secreted to induce cell invasion (Watkins et al., 2010).  
 
1.3.6 PBF and Cell Motility 
Tandem mass spectrometry identified cortactin as a putative binding partner of PBF 
(Watkins et al., 2016). Cortactin is a scaffold protein that is essential to the assembly of 
individual actin filaments into branched structures, thus having a major influence on the 
ability of cells to migrate and invade. Overexpression of cortactin has been associated 
with increased cellular motility and invasion (Kirkbride et al., 2011).  
 PBF and cortactin were confirmed to bind in vitro with PBF further increasing the 
ability of cortactin-expressing cells to migrate and invade. PBF and cortactin were shown 
to co-localise within invading cells in both invadopodia actin puncta and surrounding 
podosome-like adhesion rings. Knockdown of PBF decreased the ability of cortactin to 
induce cell invasion and migration. Further to this, abrogation of PBF phosphorylation at 
Y174 also decreased cell migration and disrupted the binding affinity of PBF and cortactin 
(Watkins et al., 2016). With PBF and cortactin both being dysregulated in multiple tumour 
types, PBF may be a potential target for decreasing tumour metastasis through inhibition 
of its interaction with cortactin. 
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1.4 PBF and NIS  
As briefly mentioned earlier, PBF and NIS can interact within thyroid carcinoma cells with 
PBF being shown to potently repress iodide uptake. Primary cells originating from the 
thyroids of PBF-Tg mice (discussed in 1.3.4) were assessed for their ability to take up 
radioiodide compared with cells from WT mice. Thyroid cells from PBF-Tg were capable 
of approximately 70% less radioiodide uptake compared with their WT mice 
counterparts. Use of siRNAs targeting PBF rescued radioiodide uptake in cells from PBF-
Tg mice. These findings were subsequently confirmed in human primary thyrocytes 
where endogenous PBF knockdown increased radioiodide uptake (Read et al., 2011). 
There are two known mechanisms for PBF's repression of NIS: transcriptional and post-
translational. 
 
1.4.1 PBF repression of NIS transcription 
In vitro overexpression of PBF in primary human thyrocytes decreased NIS mRNA 
expression by 95% (Boelaert et al., 2007). PBF was observed to repress NIS mRNA 
expression through interactions with both the NIS proximal promoter and the NUE in 
FRTL-5 cells. Further investigation in primary human thyrocytes confirmed PBF repression 
of NIS through the NUE, although proximal promoter activity was unaffected by the 
presence of PBF. Mutational studies revealed that PBF's repression of the NUE relies on 
the presence of an upstream stimulating factor 1 (USF1)-binding site (Boelaert et al., 
2007) located within the PAX8 consensus sequence in the NUE (Lin et al., 2004). Specific 
deletion of the PAX8 site while maintaining the USF1 site also prevented PBF repression 
of NIS and even resulted in a 28% increase in NUE activity (Boelaert et al., 2007). 
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Knockdown of PBF also increased NIS mRNA expression in the human primary thyrocytes 
(Read et al., 2011).  
 
1.4.2 Effect of PBF on NIS subcellular localisation  
Along with influencing NIS expression, PBF can modulate the subcellular localisation of 
NIS. PBF and NIS have been shown to co-localise in FRTL-5 and COS-7 cells, particularly 
within intracellular vesicles (Smith et al., 2009). GST-pulldown and 
coimmunoprecipitation experiments confirmed that NIS and PBF bind in vitro (Figure 
1-12A). Immunofluorescence studies revealed that not only did PBF and NIS co-localise, 
PBF overexpression was able to alter the subcellular localisation of NIS (Figure 1-12B). 
Exogenous NIS localised predominantly at the plasma membrane with partial staining in 
intracellular vesicles (Figure 1-12B(i)). However when PBF was co-transfected into cells 
alongside NIS, there was increased NIS staining within vesicles and a reduction in plasma 
membrane staining (Figure 1-12B(ii)). Cell surface biotinylation studies confirmed a 
reduction of plasma membrane NIS in the presence of PBF overexpression. Within 
intracellular vesicles PBF and NIS both co-localised with CD63 (Smith et al., 2009), a 
tetraspanin with known links to clathrin-dependent trafficking (Berditchevski and 
Odintsova, 2007), having a similar staining pattern to late endosomes. This reduction in 
plasma membrane NIS correlated with a reduction in radioiodide uptake in vitro. 
Mutational studies revealed the 30 C-terminal amino acids of PBF were important for its 
interaction with NIS and localisation within clathrin-coated vesicles (Smith et al., 2009). In 
a similar manner, PBF modulates the subcellular localisation of monocarboxylate 
transporter 8 (MCT8) impacting on thyroid hormone transport (Smith et al., 2012). 




Figure 1-12. PBF binds to and alters the subcellular localisation of NIS. (A) 
Coimmunoprecipitation assays in COS-7 cells transfected with NIS-MYC and empty vector 
(VO), PBF-HA and empty vector (VO), or NIS-MYC and PBF-HA. A band corresponding to 
PBF (arrowed) was observed at approximately 30 kDa when NIS-MYC and PBF-HA were 
cotransfected. Total cell lysate was assessed for expression of NIS-MYC, PBF-HA and β-
actin in each sample. (B) (i) Immunofluorescent detection of NIS-HA and endogenous PBF 
in cells transfected with NIS-HA and empty vector (VO) control. (ii) Immunofluorescent 
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1.4.3 Discovery and Importance of pY174 PBF  
PBF contains a tyrosine-based sorting signal between Y174-F177 (Smith et al., 2013), with 
the amino acid sequence obe in  the YXXФ motif (Y for tyrosine, X for any residue and Ф 
for a large hydrophobic residue) witnessed in many endocytosed proteins (Bonifacino and 
Dell'Angelica, 1999). The lead tyrosine in PBF's motif (Y174) was predicted to be 
phosphorylated, thus it was proposed that phosphorylation of this residue may regulate 
PBF localisation. The use of an antibody specific to pY174 PBF confirmed that the residue 
was phosphorylated, with a Y174A mutant form of PBF not being detected by the 
antibody (Smith et al., 2013). pY174 PBF was observed to co-localise with NIS in a variety 
of cell-lines, primarily at the plasma membrane with some intracellular staining. The 
Y174A PBF mutant was retained in the plasma membrane of cells and did not colocalise 
intracellularly with NIS. Co-immunopreciptation assays confirmed reduced binding 
between NIS and Y174A PBF. 
 Tandem mass spectrometry was used in multiple cell-lines to elucidate tyrosine 
kinases that might be responsible for phosphorylating PBF. Several members of the Src 
Family Kinase (SFK) family including Lyn (data not published) and Src were identified 
(Smith et al., 2013). Binding between PBF and Src was confirmed in HeLa cells with 
exogenous expression of Src increasing pY174 PBF levels without altering total PBF levels 
in several thyroid cell-lines. Treatment with PP1, a potent SFK inhibitor (discussed in 
5.1.2.1), decreased pY174 PBF levels in vitro in both transformed thyroid cell-lines and 
primary human thyrocytes (Figure 1-13A). PP1 treatment decreased the interaction 
between PBF and NIS as determined by proximity ligation assays (PLA) and restored PBF's 
repression of radioiodide uptake in TPC-1 cells and primary thyrocytes (Figure 1-13B). 
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These findings are significant as they suggest that the interaction between NIS and PBF in 
thyroid cancer is reliant on the phosphorylation of PBF at Y174 (Smith et al., 2013). 
 
Figure 1-13. PP1 inhibits PBF phosphorylation and restores radioiodide uptake in primary 
thyrocytes. (A) Endogenous pY174 PBF in human primary thyroid cultures treated with 2 
μM PP1 for 30 minutes. (B) Human primary thyroid cells were transfected with empty 
vector (VO) or PBF-HA and treated with vehicle (Veh = DMSO) or PP1 (2 μM) for 24 hours 
prior to the measurement of 125I uptake. ns = not significant.***=p <0 .001. **= p <0 .01. 
*=p <0.05.Taken from Smith et al., 2013. 
 
1.5 Hypothesis and Aims 
Radioiodide therapy is a central treatment for patients diagnosed with thyroid cancer. 
However, many differentiated tumours are challenging to treat due to their decreased 
NIS expression and functionality. Patients affected by this reduction often have poorer 
outcomes than patients for whom the treatment is effective. PBF is overexpressed in 
many thyroid cancers repressing radioiodide uptake via transcriptional and post-
translational mechanisms. PBF is capable of binding to and altering the subcellular 
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localisation of NIS, rendering the transporter inactive due to its aberrant localisation. The 
phosphorylation of PBF at Y174 is critical for this interaction between NIS and PBF with 
abrogation of phosphorylation restoring radioiodide uptake in thyroid cancer cells. 
 With NIS expression being upregulated in around 80% of breast cancers, it has 
widely been hypothesised that radioiodide therapy may be an effective treatment for 
many breast cancer patients. However, in a similar manner to thyroid cancer, NIS is 
aberrantly localised intracellularly rather than at the plasma membrane. With PBF also 
known to be upregulated in breast cancer, the hypothesis of this thesis is that PBF 
represses radioiodide uptake in breast cancer by altering the subcellular localisation of 
NIS in a similar manner to that observed in thyroid cancer. Further to this, it is proposed 
that Src-mediated phosphorylation of PBF at Y174 is integral to the interaction with NIS 
and that the utilisation of drugs to inhibit PBF phosphorylation will significantly enhance 
radioiodide uptake in breast cancer cells. If the interaction can be overcome in the 
manner hypothesised it may enable the use of 131I as a therapeutic option for breast 
cancer. 
The main aims of this thesis are to:- 
1. determine whether NIS expression and function are repressed by PBF in breast 
cancer. 
2. assess the phosphorylation of PBF at Y174 and its effect on NIS repression in 
breast cancer 
3. determine whether the inhibition of PBF phosphorylation can restore plasma 
membrane localisation of NIS and radioiodide uptake in breast cancer cells. 
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4. identify drugs that most potently inhibit PBF phosphorylation and maximise 
radioiodide uptake in breast cancer cells.  




CHAPTER 2 – MATERIALS AND METHODS 
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Unless otherwise stated, all reagents described were obtained from Sigma-Aldrich (Poole, 
Dorset, UK) 
Additional materials and methods can be located within each chapter. 
2.1  Cell Culture 
2.1.1 Cell lines 
MCF-7 (Michigan Cancer Foundation-7) cells were obtained from the European Collection 
of Cell Cultures (supplied by Sigma). MCF-7 cells originated from a pleural effusion in a 69 
year-old Caucasian female with a primary invasive breast ductal carcinoma in 1973 (Soule 
et al., 1973). They can be classified into the luminal A subcategory, as the cells are 
positive for both ER and PR (Levenson and Jordan, 1997) but do not have HER2 
amplification (Benz et al., 1992).  
 MDA-MB-231 cells were obtained from the American Type Culture Collection 
(Virginia, USA). MDA-MB-231 cells are derived from a pleural effusion metastasis of an 
adenocarcinoma in a 51 year-old Caucasian female in the 1970s. The cells fall into the 
triple negative subcategory of breast cancer having no amplification of HER2 nor 
expression of ER and PR.  
 Both cell lines were purchased fresh from cell culture collections at the beginning 
of this project and underwent ploidy and STR cell line authentication profiling every 18 
months to confirm cell line identity (electropherograms not shown)(DDC Medical).  
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2.1.2 Cell culture 
Both cell lines were routinely cultured in RPMI 1640 medium (Life Technologies Ltd, 
Paisley, UK) supplemented with 10% (v/v) heat-inactivated foetal bovine serum (FBS), 
penicillin (105 U/l) and streptomycin (100 mg/l) (Invitrogen, Paisley, UK). Cells were 
passa ed biweekl  and incubated at 37⁰C and 5% CO2 in humidified conditions.  
2.1.3 Cell splitting and seeding 
Cells were briefly washed in phosphate-buffered saline (PBS) before incubation at 37°C 
for 5 minutes in 0.125% trypsin-EDTA (Life Technologies). Trypsin was neutralised using 
complete media, with 20% of the suspension being transferred to a new T75 with fresh 
medium to maintain the cell line. Remaining cells were counted using a FastRead 
Counting Slide (Immune Systems Ltd) before being seeded at a density appropriate for 
the experiment. 
 
2.2 Transfection and transduction 
2.2.1  Plasmids 
Overexpression of protein was achieved through transfection with mammalian 
expression vectors containing the complete coding sequence for the gene of interest. For 
transient transfection the pcDNA3.1 (+) vector (Invitrogen) was utilised whereas for 
stable transfection the vector pCI-neo (Promega, Madison, WI, USA) was used. Both 
plasmids contained full-length cDNA under the cytomegalovirus (CMV) promoter and 
sites for antibiotic resistance. 




Figure 2-1. Schematics of pcDNA3.1 (+) and pCI-neo vectors. pcDNA3.1 (+) schematic 
taken from Invitrogen website and the pCI-neo schematic taken from the Promega 
website. Both vectors contain CMV promoters, ampicillin bacterial resistance gene and a 
neomycin resistance gene. 
 
2.2.2 Plasmid Preparation 
2.2.2.1 Bacterial Transformation 
Transformation was carried out usin   ubclonin  Efficienc ™  H5α™ Competent E.Coli 
cells (Invitrogen) according to the manufacturer's instructions. Plasmid DNA (10ng) was 
combined with 50µl of  H5α Cells and incubated for 30 minutes on ice. The bacterial cells 
were then heat shocked at 42°C for 20 seconds to increase the permeability of the cell 
membranes. The cells were incubated on ice for a further 2 minutes before 950µl of Luria 
Broth (LB) was added and the suspension incubated for 1 hour at 37°C with shaking. 
Bacterial cells were pelleted by centrifugation at 13,000rpm and the supernatant 
discarded. The cells were resuspended in remaining supernatant ( ~50µl) and was plated 
on LB-Agar (1% Agar) plates containing carbenicillin (100µg/ml) and incubated at 37°C for 
16 hours. 
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Bacterial colonies that grew on LB-carbenicillin (100µg/ml) plates were deemed to have 
been transformed and single colonies were to inoculate 5ml of LB broth containing 
carbenicillin (100µg/ml) and incubated at 37°C for 8 hours with shaking at 200rpm.  
2.2.2.2 DNA Amplification 
Amplification of the plasmid was performed usin  the GenElute™ HP Plasmid Maxiprep 
kit (Sigma) according to the manufacturer's instructions. The DH5-α bacterial suspension 
from 2.2.2.1 was added to 150ml LB broth containing carbenicillin (100µg/ml) cultured 
overnight at 37°C in an orbital shaker. After incubation, 270µl of glycerol was combined 
with 1.53ml of the bacterial suspension in LB broth to create a glycerol stock which can 
be stored long-term at -80°C and used to re-amplify DNA as required. The remaining 
suspension was centrifuged at 5000 x g for 10 minutes and the supernatant was 
discarded. The bacterial pellet was thoroughly re-suspended in 12ml Resuspension 
Solution, followed by the addition of 12ml Lysis Solution. The mixture was inverted eight 
times and left to stand for 5 minutes. The lysis was terminated by the addition of chilled 
12ml Neutralisation Solution. 9ml of Binding Solution was added to the suspension which 
after mixing was immediately transferred to the barrel of a filter syringe and incubated at 
room temperature for 5 minutes. During this time, a spin column was prepared by 
centrifuging 12ml Column Preparation through it at 3000 x g for 2 minutes. The eluate 
was discarded and the DNA suspension filtered through the syringe into the spin column 
before being centrifuged at 3000 x g for 2 minutes. The column was then washed in two 
stages, initially with 12ml of Column Wash Solution 1 with centrifuging at 3000 x g for 1 
minute followed by 12ml of Column Wash Solution 2 with centrifugation for 5 minutes at 
3000 x g. The DNA was then eluted from the column using 3ml nuclease free water and 
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centrifuging at 1000 x g for 5 minutes. Plasmid DNA was quantified using the NanoDrop© 
ND-1000 Spectrophotometer (NanoDrop) and sequenced as detailed in 4.2.5. 
2.2.2.3 Sequencing 
To sequence the plasmid DNA, 300ng of DNA was combined with 3.2pmol of the forward 
(T7 short or T7) or reverse (BGH reverse primer or T3) primer and made up to 10µl with 
nuclease free water (Table 2-2). Plasmid to profile sequencing was performed by the 
functional genomics department at the University of Birmingham. 
 
Table 2-1. Primers used for sequencing cDNA within pcDNA3.1 (+) and pCI-neo plasmids. 
 
2.2.3 Transient plasmid transfection 
Transfection was performed using TransIT®-LT1 Transfection Reagent (Geneflow, 
Staffordshire, UK) at a 3:1 ratio with the DNA plasmid. Cells were seeded 18 hours prior 
to transfection. Plasmid DNA was combined with OPTI-MEM medium and incubated for 5 
minutes before the addition of TransIT®-LT1. The mixture was further incubated for 25-30 
minutes before the appropriate volume (shown in Table 2-2) was added to cells. 
 
Plasmid Sequencing Primer Sequence 
pcDNA3.1 (+) 
T7 Short 5' AATACGACTCACTATAG 3' 
BGH Reverse 5' TAGAAGGCACAGTCGAGG 3' 
pCI-neo 
T7 5' TAATACGACTCACTATAGG 3' 
T3 5' AATTAACCCTCACTAAAGG 3' 




Number of cells 
seeded per flask/well 
Plasmid DNA 
(µg/condition) 
Volume of transfection 
solution added 
(µl) 
T75 1,000,000 15 1500 
T25 350,000 5 500 
6 well plate 150,000 2 200 
12 well plate 75,000 1 100 
24 well plate 32,500 0.5 50 
 
Table 2-2. Amount of plasmid DNA used in transient transfection dependent on cell 
number. 
 
2.2.4 Stable plasmid transfection 
Prior to stable transfection, a kill curve was performed to determine the concentration of 
Geneticin (G418) (Sigma-Aldrich) required to kill all untransfected cells that do not have 
any endogenous resistance to G418. A range of doses from 0.5 to 5mg/ml in complete 
medium was utilised and both MCF-7 and MDA-MB-231 cells required 1mg/ml G418 for 
100% cell death within 10-14 days. 
Cells were transfected as described in 2.2.3 but pCI-neo vectors were utilised in 
place of the pcDNA3.1 (+) vectors. After transfection, both transfected and untransfected 
control cells were subjected to 14 days in medium containing a pre-determined 
concentration of 1mg/ml G418. Once the control untransfected cells had died, the stable 
transfected cells were maintained as described in 2.1 with the addition of 1mg/ml G418 
in the cell media.  
Stability of stable cell-lines was checked on a monthly basis by performing qRT-
PCR to ensure the stables cell-lines maintained increased expression of their transfected 
vectors. 
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2.2.5 Lentiviral stable transduction 
To stably express NIS within cell lines lentiviral particles containing the NIS gene 
(precision LentiORF SLC5A5 (w/o Stop Codon) particles) were purchased (Dharmacon, GE 
Healthcare, Buckinghamshire, UK) along with Precision LentiORF RFP Positive Control 
particles (Dharmacon). The viral particles contain plasmid DNA containing ampicillin and 
blasticidin resistance genes, a CMV promoter, an IRES element and a multiple cloning 
site. The NIS particles contained the complete coding sequence for full-length human NIS 
within the multiple cloning site whereas the control particles contained red fluorescent 
protein (RFP) gene within this site (Figure 2-2). Prior to lentiviral transduction, a 
blasticidin kill curve was performed to determine the concentration of blasticidin 
required to kill all cells without resistance genes.  
 Relative lentiviral transduction efficiency was determined using Precision 
LentiORF RFP Positive Control particles (Dharmacon). Cells were seeded in 96 well plates 
(1000 per well) for 24 hours prior to transduction. Cell medium was removed and 
replaced with 45µl Opti-MEM serum free medium (SFM) before 5µl viral mixture was 
added to each well. The viral mixture contained 80µg/ml polybrene (8µg/ml final 
concentration) (Sigma) and viral particles at varying concentrations from 4.45x107   
5.69x102 transducing units (TU)/ml in SFM. Cells expressing GFP were counted and 
relative transduction efficiency calculated. For MCF-7 cells 6.5x105 TU/ml was the 
optimum concentration of particles whereas MDA-MB-231 cells only required 2.2x105 
TU/ml for efficient transduction.  
 
  




Figure 2-2. Schematic of the plasmid DNA within RFP-control particles. This schematic 
shows the plasmid that is contained within Precision LentiORF RFP Positive Control 
particles. Precision LentiORF SLC5A5 (w/o Stop Codon) particles contain human NIS cDNA 




Once transduction efficiency had been calculated, cells were transduced for long-term 
culture. Cells were seeded into 96 well plates (1000 cells per well) and incubated for 24 
hours before medium was replaced with 45µl SFM. Viral mixtures containing polybrene 
and either RFP-control particles or NIS particles at the pre-determined concentrations in 
SFM were prepared and 5µl was added into each well. Cells were then incubated for 6 
hours before 50µl complete medium was added. Medium was replaced after 24 hours 
and then again 48 hours later with the addition of blasticidin. Cells were maintained in 
medium supplemented with blasticidin for all future cultures.  
 Following successful transduction the cells were kindly single-cell sorted by Dr 
Matt MacKenzie (University of Birmingham, UK) using Summit (v6.2.3.15613) on a 
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Beckman Coulter Moflo Astrios EQ™. Control RFP cells were  ated for stron  expression 
of RFP and GFP whereas cells transduced with NIS lentiviral particles were sorted on GFP 
expression alone (Figure 2-3). Single cell colonies with strong and medium expression of 
sorting genes were selected and grown from a single cell in a 96 well plate. Cells were 
maintained in medium containing blasticidin throughout. Colonies utilised for the 
majority of experiments were clone 1 and 2, selected on the basis of consistent cell 
growth, cell survival, NIS and PBF expression and high levels of radioiodide uptake. 
Radioiodide uptake experiments were performed on a fortnightly basis to ensure the NIS 
transduced cell-lines maintained functional NIS overexpression, with qRT-PCR being 
performed bimonthly to ensure increased NIS mRNA expression. 




Figure 2-3. Gating for lentiviral single cell sorting. (A) The gating for the RFP control 
lentiviral MDA-MB-231 cells with GFP expression on the x axis and RFP expression on the y 
axis. Cells were then selected for high expression or intermediate expression of both as 
shown in the right-hand panel. (B) The gating for NIS lentiviral MDA-MB-231 cells with 
GFP expression on the x axis. Cells were then selected for high expression or intermediate 
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2.3 Western blotting 
2.3.1 Protein extraction and quantification 
Forty-eight hours post-transfection, cells were washed with PBS and then lysed in 
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% 
v/v Igepal CA-630, 6 mM sodium deoxycholate, 1mM EDTA) containing 60 µl/ml protease 
inhibitor cocktail (Sigma) and phosphatase inhibitor cocktails 2 and 3 (1% v/v)(Sigma). To 
aid lysis, cells were subjected to a freeze-thaw cycle at -20°C for a minimum of 20 
minutes before cell plates were scraped and lysate suspension transferred into 
microcentrifuge tubes. Lysates were then sonicated for 3x30 seconds on medium setting 
(200W) (Bioruptor Standard, Diagenode, Liège, Belgium) and centrifuged for 10 minutes 
at 13,000rpm to pellet cell debris. 
 A bicinchoninic acid (BCA) colourimetric assay (Thermo scientific, Pittsburgh, PA) 
was utilised to determine protein concentration. Protein standards comprised of bovine 
serum albumin (BSA) in RIPA buffer were prepared at concentrations ranging from 0-5 
mg/ml. Both lysates and standards were measured in duplicate with 4 µl being combined 
with 80µl of BCA reagent (78.4µl Reagent A and 1.6µl Reagent B). After a 30 minute 
incubation at 37°C, the absorbance was measured at 560nm using a Victor3 1420 
Multilabel Counter (Perkin Elmer, Waltham, MA, USA). A standard curve was then 
produced which could be used to determine lysate protein concentration.  
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2.3.2 Western blotting 
Protein lysates (10-60 µg) were denatured at 37°C for 30 minutes in 5x Laemmli buffer 
(250mM Tris-HCl pH 6.8, 10% SDS, 0.02% bromophenol blue, 50% glycerol, 12.5% β-
mercaptoethanol). Resolving gels (375mM Tris (from 1.5M pH 8.8 stock), 12% acrylamide 
(from 30% (w/v) acrylamide:0.8% (w/v) bis-acrylamide stock (Geneflow)), 3.5mM SDS, 
0.1% (v/v) tetramethylethylenediamine (TEMED) (Sigma), 4.4mM ammonium persulphate 
(APS)) were made and any loose acrylamide cleared from wells. Denatured protein 
samples were loaded onto the gel along with a well of 4μl of protein ladder (BLUeye pre 
stained protein ladder, Geneflow). Proteins were then separated by SDS-Polyacrylamide 
gel electrophoresis (SDS-PAGE) in running buffer (24.8mM Tris, 192mM glycine, 3.47 mM 
SDS) initially at 70 V but later increased to 140 V.  
 Proteins were transferred to activated polyvinylidene fluoride membranes (PVDF) 
(Fisher) at 360mA for 1 hour 20 minutes in transfer buffer (25mM Tris, 192mM glycine, 
20% methanol). Following transfer the membranes were blocked in 5% non-fat milk 
(Marvel dried milk powder, Premier Foods Group Ltd, London) in Tris-Buffered Saline with 
Tween (TBST)(20mM Tris, 137mM NaCl, 0.025% v/v Tween 80) for 1 hour at room 
temperature. The membranes were then incubated with primary antibodies (Table 2-3) in 
5% non-fat milk in TBST overnight at 4°C. After three washes in TBST, blots were 
incubated for 1 hour at room temperature, with the appropriate horseradish peroxidise-
conjugated secondary antibody (Dako, Denmark). After three further washes, SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific) or Pierce ECL 2 (Thermo 
Scientific) chemiluminescence detection systems were used to visualise the bands on 
Kodak film for 5 seconds to 60 minutes. Scanning densitometry was carried out to 
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determine quantifiable differences in protein expression (ImageJ software, 
http://imagej.nih.gov/ij/). 
 
2.4 Fluorescence immunocytochemistry 
Glass coverslips were washed in ethanol and sterile PBS and placed into 6 well plates 
before cells were seeded on top of them. Forty-eight hours after transfection, cells were 
washed briefly in PBS before being fixed using 800μl of fixing solution (0.1 M phosphate 
buffer (pH 7.4) containing 2% paraformaldehyde, 2% glucose and 0.2% sodium azide) for 
20 minutes at room temperature. Three subsequent washes in PBS were performed 
before cells were permeabilised in chilled methanol for 10 minutes. Cells were further 
washed in PBS, before blocking in 10% newborn calf serum (NCS) diluted in PBS at room 
temperature for 30 minutes. Primary antibodies (Table 2-3) were diluted to the desired 
concentrations in 1% BSA in PBS and added to cells for 1 hour at room temperature. 
Further washes in PBS were carried out before cells were incubated for an hour at room 
temperature with secondary antibodies in 1% BSA, 1% NCS in PBS. Secondary antibodies 
were as follows: Alexa-Fluor 488-conjugated goat anti-mouse IgG and Alexa-Fluor-594-
conjugated goat anti-rabbit IgG (Invitrogen), both used at 1:250 along with Hoechst 
33342 stain (Sigma-Aldrich) for nuclei (1:1000). After rinsing in PBS, the coverslips were 
mounted onto slides using Fluorescent Mounting Solution (Dako) and stored at 4°C. Cells 
were visualised on Zeiss Axioplan fluorescent microscope (Zeiss, Oberkochen, Germany) 
using 10x, 20x 40x or 100x objectives. 
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2.5 RNA extraction and Reverse Transcription 
2.5.1 RNA extraction  
Total RNA was extracted from cells using TRI Reagent® RNA Isolation Reagent (Sigma-
Aldrich) to perform a single step acid guanidinium phenol-chloroform extraction. Cells in 
6 well plates were harvested with 500μl TRI Rea ent/well. Following the manufacturer’s 
protocol, the samples were then thoroughly mixed with chloroform (200µl/ml TRI 
reagent) (Sigma-Aldrich) and incubated for 15 minutes at room temperature. To separate 
the samples into three phases they were centrifuged for 15 minutes at 12,000 g at 4°C. 
The top aqueous layer, containing the RNA, was transferred to fresh microcentrifuge 
tubes and incubated with isopropanol (500µl/ml TRI reagent) (Sigma-Aldrich) for 10 
minutes at room temperature before further centrifugation for 10 minutes at 12,000 g at 
4°C. The supernatant was then discarded and the pellet washed with 75% ethanol 
(1ml/ml Tri-reagent). The samples were vortexed and centrifuged for a further 5 minutes 
at 7,500 g at 4°C. The supernatant was again discarded and the pellet left to air-dry at 
room temperature for 10 minutes. Once dry, the pellet was re-suspended in 30μl of 
nuclease free water and stored at -80°C. RNA concentration was determined by 
measuring absorbance at a wavelength of 260nm on a NanoDrop ND-1000 
Spectrophotometer (NanoDrop Products, Wilmington, DE, USA). 
2.5.2 Reverse Transcription 
RNA (500ng) was diluted in nuclease free water to a volume of 5µl and incubated at 70°C 
for 10 minutes. The RNA was then combined with reagents from the Reverse 
Transcription System (Promega) to give a 10µl total volume. Each reaction consisted of 
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2l 25mM MgCl2, 1l RT 10X Reaction buffer (10mM Tris-HCl pH 9.0 at 25°C, 50mM KCl, 
0.1% Triton® X-100), 1l 10mM dNTPs, 0.25l RNasin (ribonuclease inhibitor), 0.3125l 
Avian Myeloblastosis virus (AMV) reverse transcriptase and 0.5l random primers. 
Samples were incubated at room temperature for 10 minutes before undergoing reverse 
transcription as follows (1) 42°C for 1 hour, (2) 95°C for 5 minutes and (3) 4°C for 5 
minutes. Samples were then diluted with the addition of 10µl nuclease free water before 
being stored at -20°C. 
 
2.6 Quantitive real-time PCR (qRT-PCR) 
Relative expression of specific mRNAs were determined using qRT-PCR in relation to the 
abundant internal control 18S. qRT-PCR was performed either using custom-made 
primers (Alta Biosciences, Birmingham, UK) and probes (Eurogentec, Liège, Belgium) or 
with TaqMan® Gene Expression Assays (Life Technologies). The probes consisted of 
oli onucleotides containin  a 5’ fluorophore, FAM (6-carboxy-fluorescein) for all target 
genes and VIC for 18S controls, and a 3’ quencher, TAMRA (6-carboxy-tetramethyl-
rhodamine). The fluorophore is excited by the light source in the PCR machine, however 
without gene amplification the quencher is in close proximity to the fluorophore and can 
suppress any fluorescence due to fluorescence resonance energy transfer (FRET). FRET 
involves the transfer of energy from the excited high energy fluorophore to the low 
energy quencher. As the Taq polymerase extends the primer, the probe is broken down 
by exonuclease activity releasing the fluorophore thus disrupting the close proximity of 
the quencher and fluorophore. As a result of this distancing, the quencher can no longer 
suppress the fluorescence allowing fluorescence emission and detection of this excitation 
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by an ABI 7500 halogen light and charge-coupled device (CCD) camera. Hence the 
fluorescence detected is directly proportional to the level of cDNA template available for 
primer amplification.  
 Duplicates of 1µl cDNA were loaded into 96 well plates and 24µl 'PCR mastermix' 
added to each well. For custom-made primers and probe, the 'PCR mastermix' contained 
4.5l Forward Primer (5pmol/l), 4.5l Reverse Primer (5pmol/l), 0.75l Probe 
(5pmol/l) (Alta Biosciences), 12.5l 2x qPCR MasterMix Plus QGS (Eurogentec), 1.25µl 
Eukaryotic 18S (Applied Biosystems, Life Technologies) and 0.5l nuclease-free water. All 
custom-made primers and probes were validated for multiplexing with 18S. When using 
TaqMan® Gene Expression Assays, the 'PCR mastermix' contained 1µl TaqMan® Gene 
Expression Assay (Life Technologies) for a specific gene, 12.5µl 2x qPCR MasterMix Plus 
QGS (Eurogentec) and 10.5µl nuclease-free water. TaqMan® Gene Expression Assays had 
not been independently validated for multiplex with 18S so it was necessary to singleplex 
when using these assays. 18S was set up with separate 1µl cDNA, 1µl Eukaryotic 18S 
(Applied Biosystems), 12.5µl 2x qPCR MasterMix Plus QGS (Eurogentec) and 10.5µl 
nuclease-free water. 
 qRT-PCR was performed on the ABI Prism 7500 real-time PCR system (Applied 
Biosystems). The steps were as follows: 50°C for 2 minutes; 95°C for 10 minutes; 40 cycles 
of 95°C for 15 seconds and 60°C for 1 minute. For each gene and 18s control, a threshold 
line was set in the exponential phase and the cycle threshold (CT) calculated from the 
cycle number at which each logarithmic PCR plot crossed the threshold line. These values 
were then used to calculate ΔCT values (ΔCT = CT target gene   CT 18S) and fold change (2
-
(ΔCT of experimental samples – ΔCT control samples)). 
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2.7 Radioiodide Uptake 
Radioiodide uptake assays were performed to assess functional NIS levels in cells. Cells 
were seeded in 24 well plates and assays were performed typically 48 hours after 
transfection. Control cells were incubated for one hour with 100µM sodium perchlorate 
(Sigma-Aldrich) prior to the addition of radioiodide. Sodium perchlorate inhibits NIS 
function allowing any changes in uptake to be attributed to NIS functionality by removing 
any inherent background uptake. Cells were incubated with 10-6M NaI containing 0.05µCi 
125I (Hartmann Analytic) for an hour at 37°C. Cell medium was removed and any 
unincorporated radioiodide removed by rapidly washing the cells with Hank’s balanced 
salt solution (HBSS). The cells were lysed with 100µl 2% SDS and radioactivity counted for 
one minute using a gamma counter (1260 Multigamma II, Wallac). A BCA assay (as 
described in 2.3.1) was then undertaken to calculate protein concentration of the lysates 
which were used to standardise the observed counts. 
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2.8 Table of antibodies used 






















Anti-NIS Rabbit polyclonal 
Abcam 
(ab 0   0   
discontinued) 
1:1000 1:500 
































































Table 2-3. Antibodies used in this study. 
 




Data were analysed using SigmaPlot (SPSS Science Software UK Ltd). The Shapiro-Wilk 
test was performed on each data set to ensure the data followed a Gaussian distribution 
before it was further analysed using a Student's t-test or one-way ANOVA. For data that 
did not possess a normal distribution a Mann-Whitney U test was used for analysis. 
Significance was taken as p < 0.05. For qRT-PCR, statistics were performed on ΔCt to 
avoid potential bias through transformation of data using 2-ΔΔCt. 




CHAPTER 3 - PBF ALTERS NIS LOCALISATION 
AND REPRESSES RADIOIODIDE UPTAKE IN 
BREAST CANCER CELLS   




As discussed in 1.4 there is substantial evidence for an association between PBF and NIS in 
thyroid cancer (Boelaert et al., 2007; Smith et al., 2009; Smith et al., 2013). The PBF protein 
has been observed to bind directly to the NIS protein in thyroid cancer cells (Smith et al., 
2009). Upon binding of the two proteins, PBF alters the subcellular localisation of NIS, 
translocating it away from the plasma membrane into intracellular vesicles. This 
mislocalisation of NIS impairs its functionality and reduces the ability of the cells to take up 
radioiodide (Smith et al., 2009).  
 In thyroid cells, PBF exerts an effect not only on the NIS protein but also on the NIS 
gene (Boelaert et al., 2007). Overexpression of PBF decreased NIS mRNA expression by 
95% in primary thyrocytes, and PBF was observed to repress NIS transcription through 
interactions with both the proximal NIS promoter and the NUE in FRTL-5 cells. However in 
primary thyrocytes PBF had no effect on the proximal promoter and was only capable of 
repressing NIS expression via the NUE (Boelaert et al., 2007), which has previously been 
described to be a thyroid-specific enhancer of NIS (Schmitt et al., 2002; Taki et al., 2002). 
 The aim of the work described in this chapter was to establish whether the two 
proteins have the same relationship in the context of breast cancer. NIS and PBF have both 
been observed to be minimally expressed in normal breast tissue but are upregulated in 
the majority of breast tumours (Tazebay et al., 2000; Watkins et al., 2010). However, it is 
not known if PBF can interact with or regulate the expression of NIS in the breast cancer 
disease state. The effect of PBF on NIS expression and function was determined in MCF-7 
and MDA-MB-231 breast cancer cells.  
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3.2 Materials and Methods 
3.2.1 Breast Cancer Samples 
Four matched normal and breast cancer samples were kindly donated by the Breast Cancer 
Campaign. Samples were first homogenised on ice in RIPA buffer containing sodium 
orthovanadate and phosphatase and protease inhibitor cocktails using a conventional 
rotor-stator homogeniser. Samples were then further homogenised using a dounce 
homogeniser followed by use of a micro pestle. Homogenates were centrifuged at 
13000rpm for 20 minutes at 4°C, the upper fat layer was removed and the supernatant 
transferred to a new tube. Lysates were then quantified and PBF and NIS protein 
expression analysed by Western blotting as described in sections 2.3.1 and 2.3.2 
respectively. 
 
3.2.2 Cell Culture 
MCF-7 and MDA-MB-231 cells were maintained as described in 2.1.2 with stably 
transfected MCF-7 cells being cultured in medium containing G418 (1 mg/ml) and 
lentivirally-transduced MDA-MB-231 cells being cultured in medium containing blasticidin 
(15 µg/ml). All cell lines were seeded at 30,000 cells per well in a 24 well plate for 
radioiodide uptake and at 150,000 and 200,000 cells per well in a 6 well plate for 
immunofluorecent microscopy and protein extraction respectively. 
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3.2.3 ATRA and Dexamethasone Treatment 
MCF-7 and MDA-MB-231 cells were treated with varying concentrations of all trans-
retinoic acid (ATRA) and dexamethasone. ATRA (Sigma) was dissolved in dimethyl sulfoxide 
(DMSO) to create a stock solution of 10mM and stored at -80°C. Dexamethasone (Sigma) 
was dissolved in ethanol as per manufacturer's instructions to create a stock solution at 
1mM and stored at -20°C. Further dilutions of both ATRA and dexamethasone were 
performed in cell medium to minimise the toxicity of DMSO and ethanol to the cells. In all 
combination treatments, an equal volume of ethanol and DMSO in cell media was used as 
a control. 
 
3.2.4 Development of Stable and Lentiviral Cell lines 
3.2.4.1 NIS Lentiviral Cells 
Lentivirally-transduced MDA-MB-231 cells were generated as described in 2.2.5. The MDA-
MB-231 cells utilised in this chapter were control clone 1 and NIS clones 1 and 2, selected 
due to their consistent cell growth, cell survival, NIS and PBF expression and high levels of 
radioiodide uptake.  
3.2.4.2 PBF Knockdown Lentiviral Cells 
To stably knockdown PBF within cell lines, lentiviral particles containing shRNA targeted to 
PBF mRNA (SMARTvector Human Lentiviral PTTG1IP - VSH6063/SH-011820) were used 
(Dharmacon, GE Healthcare, Buckinghamshire, UK) along with SMARTvector Non-targeting 
hCMV-TurboGFP Control Particles (S-005000-01; Dharmacon). The viral particles contained 
a puromycin resistance gene and a CMV promoter. The viral vectors express PBF shRNA 
modelled on precursor microRNA (pre-miRNA) that are transcribed under the control of 
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RNA Polymerase III (Pol III) promoters. shRNAs are produced as single-stranded molecules 
consisting of 50-70 nucleotides. They form a stem-loop structure with a 19-29 base-pair 
region of double-stranded RNA (the stem) bridged by a region of single-stranded RNA (the 
loop) and a short 3’ overhan . Once transcribed, the shRNAs translocate from the nucleus 
to the cytoplasm where they are cleaved at the loop by the nuclease Dicer. Following 
cleavage they enter the RNA-induced silencing complex (RISC) to direct cleavage and 
subsequent degradation of complementary mRNA.  
 Prior to lentiviral transduction, a puromycin kill curve was performed to determine 
the concentration of puromycin required to kill 100% of cells without the resistance gene. 
MDA-MB-231 and MCF-7 cells both required 4 µg/ml puromycin for 100% death after 7-10 
days. For transduction, cells were seeded into 96 well plates (1000 cells per well) and 
incubated for 24 hours before medium was replaced with 45µl serum free medium (SFM). 
Viral mixtures (30 µl) containing polybrene (1 µl) and either control or PBF shRNA particles 
(5 µl) in SFM were prepared and 5µl was added into each well. Cells were then incubated 
for 6 hours before 50µl complete medium was added. Medium was replaced after 24 hours 
and then again 48 hours later with the addition of puromycin. For lentiviral PBF 
knockdown, MCF-7 cells were utilised along with MDA-MB-231 cells that had previously 
been lentivirally-transduced with control-RFP (clone A) and NIS (clone 1 and 2) particles. 
Cells were assessed for PBF knockdown using qRT-PCR (described in section 3.2.9) and 
were maintained in medium supplemented with puromycin for all future cultures. 
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3.2.4.3 Stable Transfection 
MCF-7 and MDA-MB-231 cells were stably transfected with empty vector and PBF in pCI-
neo vectors as described in section 2.2.4 (plasmids kindly gifted by Dr Vicki Smith) (Smith et 
al., 2009). Stable transfection was confirmed using qRT-PCR. 
 
3.2.5  Transient Transfection 
Transfection efficiency experiments were performed to determine optimal cell numbers 
and transfection reagents. TransIT®-LT1 Transfection Reagent produced the highest levels 
of transfection efficiency using a Green fluorescent protein (GFP) plasmid in MCF-7 (75% 
efficiency) andMDA-MB-231 (80% efficiency) cells with the least amount of cytotoxicity 
compared to Fugene 6 (Promega) and Lipofectamine (Thermo Fisher Scientific) (data not 
shown). The cell numbers described in Table 2-2 provided the optimal number of cells with 
for transfection without cell crowding after 48 hours for both MCF-7 and MDA-MB-231 
cells. 
  Transfection was performed as described in section 2.2.3 using an empty vector, 
PBF, PBF-HA, and NIS-MYC in pcDNA3.1 (+) vectors (Smith et al., 2009).  
 
3.2.6 Radioiodide uptake 
Radioiodide uptake was performed as described in 2.7. Transient transfection or treatment 
with ATRA and dexamethasone was performed 48 hours prior to the addition of 125I to 
cells. 
 
Chapter 3  PBF and NIS in breast cancer 
86 
 
3.2.7  Western Blotting 
Protein extraction and Western blotting were performed as described in sections 2.3.1 and 
2.3.2 respectively. In order to preserve protein phosphorylation and allow the detection of 
pY174 PBF prior to harvesting, cells were treated for 20 minutes with the irreversible 
tyrosine phosphatase inhibitor pervanadate (100 µM from a 30mM stock of 951.1 µL PBS, 
6 µL hydrogen peroxide, 42.9 µL sodium orthovanadate (Na3VO4) that had been incubated 
in the dark for 15 minutes). Cells were harvested as normal in RIPA buffer with the addition 
of 1 mM Na3VO4along with normal protease and phosphatase inhibitors. Antibodies used 
were anti-pY174 PBF antibody (Covalab) (Smith et al., 2013), anti-PBF (Smith et al., 2009), 
anti-phospho-Src (Y418) (Abcam), anti-Src (Cell Signalling) and β-actin (Sigma-Aldrich) 
(refer to section 2.8). Appropriate secondary antibodies were used. 
 
3.2.8 Fluorescence immunocytochemistry 
Fluorescence immunocytochemistry was performed as described in 2.4. Cells were treated 
with pervanadate (as in Section 1.2.7) prior to fixation to allow the detection of pY174 PBF. 
Antibodies used included anti-pY174 PBF antibody (1:50) (Covalab) (Smith et al., 2013), 
anti-HA tag (mouse) (1:200) (Covance), anti-HA tag (rabbit) (1:100) (Santa Cruz) and anti-
Myc tag (1:750) (Cell Signalling).  
 
3.2.9 RNA extraction and qRT-PCR 
RNA extraction, reverse transcription and qRT-PCR were performed as described in 2.5 and 
2.6. Expression of PBF was assessed using the PBF TaqMan® Gene Expression Assay 
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(Hs01036322_m1 )(Life Technologies). Expression of NIS was assessed using custom-made 
primers and probe (Table 3-1). 
 Sequence 
Forward Primer 5' CCCCAGCTCAGGAATGGA 3' 
Reverse Primer 5' CGTAATAAGATAGGAGATGGCATAGAA 3' 
FAM-labelled Probe 5' CCAGCCGGCCCGCCTTAGC 3' 
Table 3-1. Sequence of custom-made primers and probe for NIS qRT-PCR. 
 
3.2.10 Statistics 
Data were analysed using Sigma Plot (SPSS Science Software UK Ltd). The student's t-test 
was utilised to compare data between two groups whereas the one-way ANOVA was used 
to compare more than two groups of parametric data with significance taken at p < 0.05 
for both.  




3.3.1 PBF and NIS are expressed in breast cancer 
PBF has previously been observed to be upregulated in breast tumours compared to 
normal breast tissue (Watkins et al., 2010). NIS has been demonstrated to be upregulated 
in 70-80% of breast tumours (Kilbane et al., 2000; Tazebay et al., 2000). The breast cancer 
campaign kindly donated four matched normal and tumour samples for preliminary 
investigation into NIS and PBF expression in breast cancer tumours. The four matched 
normal and tumour breast samples displayed increased PBF expression compared with 
their normal counterparts. On average the tumours displayed a 9-fold increase in PBF 
levels compared with the normal tissue (Figure 3-1). PBF can be detected by Western 
blotting at multiple different sizes due to post-translational modifications and 
oligomerisation (unpublished observations); monomeric PBF protein is detected at around 
28kDa with a fully glycosylated form being detected around 37kDa (Smith et al., 2009). NIS 
is primarily detected by Western blotting at approximately 75kDa as a fully glycosylated 
form; other prominent bands include the unglycosylated 55kDa form and the 100kDa 
dimer of the unglycosylated form (Tazebay et al., 2000). Only 3 of the 4 tumours had 
increased expression of glycosylated NIS, with tumours displaying on average a 4-fold 
increase in NIS levels (Figure 3-1). Though the sample size was low, there did appear to be 
a correlation between NIS and PBF expression within tumour samples. 




Figure 3-1. PBF and NIS expression in breast tumour samples. Western blot of protein from 
matched normal/tumour patient samples. Total PBF and NIS were detected with β-actin 
used a loading control. n=1 
 
3.3.2 Endogenous NIS expression and function in MCF-7 and MDA-MB-231 
cells 
Both MCF-7 and MDA-MB-231 cells have endogenous levels of PBF and NIS expression. To 
allow further investigation of the two proteins in breast cancer cells, it is important to 
assess these endogenous expression levels. Both cell-lines display approximately equal 
levels of PBF mRNA expression (MCF-7 ΔCT=12.8 and MDA-MB-231 ΔCT=12.3) (Figure 
3-2A). MDA-MB-231 cells have higher endogenous levels of NIS mRNA (ΔCT=17.6) than 
MCF-7 cells (ΔCT=20.5) (Figure 3-2A). 
 To establish whether the higher levels of NIS mRNA in MDA-MB-231 cells resulted 
in increased functional NIS levels compared to MCF-7 cells, endogenous radioiodide uptake 
in the two cell-lines was assessed. The cell-lines were left untreated or treated with sodium 
perchlorate (NaClO4) for one hour prior to the addition of 
125I. Sodium perchlorate is a NIS 
specific inhibitor that was utilised to assess background radioiodide uptake, allowing for 
differences in NIS specific uptake to be quantified between conditions. TPC-1 cells, a cell-
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MDA-MB-231 cells were capable of 0.18 and 0.19 pmol 125I/µg protein NIS-specific uptake 
(Figure 3-2B). Both breast cancer cell-lines displayed similar levels of NIS-specific uptake to 
the thyroid cancer cell-line, with TPC-1 cells displaying 0.18 pmol 125I/µg protein of NIS- 
specific. uptake (Figure 3-2B). This data suggests that although MDA-MB-231 cells have 
increased NIS mRNA levels compared to MCF-7 cells, this increased expression does not 
translate to increased function.  
 
 
Figure 3-2- Endogenous expression and radioiodide uptake of MCF-7and MDA-MB-231. (A) 
The expression of 18s, PBF and NIS in untreated MCF-7 cells and MDA-MB-231 cells. Data 
displayed as ΔCT values with smaller bars indicating higher expression. n=3 (B) MCF-7, 
MDA-MB-231 and TPC-1 cells were left untreated or treated with sodium perchlorate 
(NaClO4) 1 hour prior to the addition of 
125 I to establish baseline NIS-specific radioiodide 
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3.3.3 Creation of Stable Cell lines  
3.3.3.1 Characterisation of PBF Stables 
To enable the study of PBF in breast cancer cells, MCF-7 and MDA-MB-231 cells with 
stably-transfected with an empty vector and PBF were generated. Transfection of MCF-7 
cells with PBF significantly boosted PBF expression with a 3.8-fold increase compared to 
cells transfected with the empty pCI-neo vector (Figure 3-3). MDA-MB-231 showed a 
significant 9.3-fold increase in PBF expression (Figure 3-3). 
 
 
Figure 3-3. Stable expression of PBF in MCF-7 and MDA-MB-231 cells. MCF-7s and MDA-
MB-231 cells were stably-transfected with empty pCI-neo vector (VO) and PBF. RNA was 
extracted from cells and qRT-PCR used to assess PBF mRNA expression using 18s as the 
internal housekeeping gene. Graph displays fold change compared with empty vector 
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3.3.3.2 Creation of NIS Lentiviral Stables 
To maximise the radioiodide uptake of breast cancer cells, MDA-MB-231 cells were 
transduced with control or NIS lentiviral particles. Three clones of control and five clones of 
NIS lentiviral cells were selected and assessed for their PBF expression, NIS expression and 
radioiodide uptake. The five NIS clones displayed dramatically increased levels of 
radioiodide uptake as expected (Figure 3-5) whereas the control transduced cells had 
minimal radioiodide uptake that were similar to background radioiodide levels (Figure 3-5). 
Increased NIS expression in the NIS lentiviral cells compared with the controls was 
confirmed (Figure 3-5A). Both the NIS and control lentiviral transduced cells had similar 
levels of PBF expression (Figure 3-5B). 
 
Figure 3-4. Functionality of NIS lentiviral clones. Radioiodide uptake in the control and NIS 
lentiviral transduced MDA-MB-231 cell clones normalised to sodium perchlorate (NaClO4) 
controls to display NIS-specific activity. n=2 with 3 replicates in each n. * = p<0.05 
compared to all three control clones (A,B, & C). 










































Figure 3-5. Expression NIS lentiviral clones. The expression of NIS (A) and PBF (B) mRNA in 
the individual clones of control and NIS lentiviral transduced MDA-MB-231 cells grown from 
a single cell colony. Displayed as ΔCT values with smaller bars indicating the higher 
expression. n=2 with 3 replicates in each n. 
 
3.3.3.3 Creation of PBF Knockdown Lentiviral Stables 
To enable the investigation of breast cancer cells lacking PBF expression, PBF was knocked 
down in breast cancer cells using PBF shRNA lentiviral particles. PBF was successfully 
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knocked down in MCF-7 cells with a 60% reduction in PBF expression compared with 
scrambled control MCF-7 cells (Figure 3-6).  
 
 
Figure 3-6. Lentiviral knockdown of PBF in MCF-7 cells. MCF-7 cells were lentivirally 
transduced with scrambled or PBF shRNA. PBF was efficiently knocked down as determined 
by qRT-PCR. Statistics were performed on ΔCT values. n=3 with 4 replicates in each n. 
*=p<0.05 
 
PBF was also knocked down in MDA-MB-231 cells that had been transduced previously 
with control particles or NIS lentiviral particles, resulting in efficient knockdown of over 




























Figure 3-7. Lentiviral PBF knockdown in MDA-MB-231 NIS Lentiviral Cells. MDA-MB-231 
cells that had previously been lentivirally-transduced with either control or NIS particles 
were further transduced with Scrambled shRNA or PBF shRNA. PBF was efficiently knocked 
down in all cell lines. n=2 with 4 replicates in each n. *=p<0.05 
 
3.3.4 Treatment with ATRA and Dex increases NIS expression but does not 
affect PBF expression 
Treatment of MCF-7 cells with ATRA and dexamethasone has been previously observed to 
increase NIS mRNA and protein levels (Kogai et al., 2005). To confirm the MCF-7 cells used 
in this project were comparable to those used in previous studies, they were treated with 
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mRNA were quantified using qRT-PCR. Treatment with 100nM ATRA and 1µM 
dexamethasone provided the largest increase in NIS (192-fold, p=0.004) compared with 
vehicle-only treated cells (Figure 3-8). This is comparable to published data where the 
same concentration induced a 150-fold increase (Kogai et al., 2005).  
  
Figure 3-8. Treatment with ATRA/Dex increases NIS mRNA expression in MCF-7 cells. MCF-7 
cells treated with varying doses of ATRA and dexamethasone for 48 hours were analysed by 
qRT-PCR for NIS mRNA expression using 18s as the internal housekeeping gene. Graph 
displays fold change compared with vehicle-only treated cells. Statistics were performed on 
ΔCT values. n=3 with 4 replicates in each n.* = p<0.05. **=p<0.01. 
 
 Though the effect of ATRA and dexamethasone on NIS levels in MCF-7 cells has 
been widely reported and exploited, the effect of these drugs on PBF levels has not been 
studied. Treatment of MCF-7 cells with varying concentrations of ATRA and 
dexamethasone had no significant effect on PBF mRNA levels (Figure 3-9).  
ATRA (M) 10-8 10-7 10-6 0 0 0 10-6 10-6 10-7
Dex (M) 0 0 0 10-8 10-7 10-6 10-6 10-7 10-6




Figure 3-9. Treatment with ATRA/Dex does not significantly alter PBF mRNA expression. 
MCF-7 cells treated with varying doses of ATRA and dexamethasone for 48 hours were 
analysed by qRT-PCR for PBF mRNA expression using 18s as the internal housekeeping 
gene. Graph displays fold change compared with vehicle-only treated cells. Statistics were 
performed on ΔCT values. n=3 with 4 replicates in each n. 
 
   
 
  
ATRA (M) 10-8 10-7 10-6 0 0 0 10-6 10-6 10-7
Dex (M) 0 0 0 10-8 10-7 10-6 10-6 10-7 10-6
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3.3.5 PBF expression increases NIS expression levels in breast cells 
To assess whether exogenous expression of PBF had any effect on levels of NIS expression, 
qRT-PCR was performed on RNA extracted from MCF-7 cells stably-expressing PBF. Here, 
exogenous expression of PBF increased NIS expression by over 12-fold compared with 
vector-only expressing cells (p=0.001) (Figure 3-10).  
 
Figure 3-10. Exogenous PBF increases NIS mRNA expression. MCF-7 cells stably transfected 
with an empty vector (VO) and PBF were analysed by qRT-PCR for NIS mRNA expression 
using 18s as the internal housekeeping gene. Statistics were performed on ΔCT values. n=2 
with 4 replicates in each n. **=p<0.01.  
 
Transient transfection of PBF suggested a trend of increasing NIS expression levels in MCF-
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expression in ATRA/Dex treated cells with a 1.8-fold increase compared with empty vector 
transfected ATRA/Dex treated cells (p=0.025)(Figure 3-11). 
 
Figure 3-11. Transient transfection of PBF increases NIS mRNA expression. MCF-7 cells that 
had been transiently transfected with an empty vector (VO) or PBF and treated with 
ethanol and DMSO (vehicle only) or 100nM ATRA and 1µM dexamethasone were analysed 
by qRT-PCR for NIS mRNA expression. Statistics performed on ΔCT values. n=2 with 4 
replicates in each n.. *=p<0.01. 
 
3.3.6 PBF Knockdown decreases NIS expression 
Following induction of NIS mRNA with PBF overexpression, it was important to assess if 
knockdown of PBF could have the converse effect. PBF was efficiently lentivirally knocked 
down in MCF-7 (Figure 3-6) and MDA-MB-231 cells (Figure 3-7). Knockdown of PBF in all 
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with NIS, PBF knockdown reduced NIS mRNA levels by 88% (p=0.002). PBF knockdown in 
MCF-7 cells decreased NIS by 44% (p=0.04).  
 
Figure 3-12. PBF knockdown decreases NIS mRNA. MCF-7 cells and MDA-MB-231 cells 
lentivirally-transduced with NIS were lentivirally-transduced with scrambled or PBF shRNA. 
Expression levels of NIS mRNA were quantified using qRT-PCR. Statistics performed on ΔCT 
values. n=2 with 4 replicates in each n.. *=p<0.05. **=p<0.01. 
 
3.3.7 PBF reduces radioiodide uptake 
To establish the effect that PBF has on NIS function, radioiodide uptake studies were 
performed. MCF-7 cells treated with ATRA and dexamethasone displayed increased 
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in a similar manner to that observed in Kogai et al (2005)(Figure 3-13). Stable transfection 
of PBF within these treated cells reduced radioiodide uptake by a 28% (p=0.023) (Figure 
3-13). Figure 3-13 demonstrates the levels of radioiodide uptake witnessed when cells are 
treated with the NIS specific inhibitor, sodium perchlorate. All future radioiodide uptake 
graphs have been normalised to the sodium perchlorate controls and only show specific 
NIS activity. 
 
Figure 3-13. PBF decreases the radioiodide uptake of ATRA/Dex treated MCF-7 cells. MCF-7 
cells stably transfected with either a control empty vector (VO) or PBF were treated with 
ethanol and DMSO (vehicle) or 100nM ATRA and 1µM dexamethasone for 48 hours prior to 
the addition of 125I. Sodium perchlorate (NaClO4) controls plotted to show NIS-specific 
activity. n=3 with 4 replicates in each n. * = p<0.05. ** = p<0.01. 
 
 Initial optimisation experiments were performed by varying the cell number and 
transfection time prior to radioiodide addition (24 hour, 48 hour and 72 hour) to allow for 
maximum radioiodide uptake. MDA-MB-231 cells that had been transiently transfected 
with NIS-MYC had a three-fold increase in radioiodide compared to control empty vector 
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transfected cells (Figure 3-14). Co-transfection of NIS-MYC with PBF decreased radioiodide 




Figure 3-14. Overexpression of PBF decreases radioiodide uptake in MDA-MB-231 cells 
expressing NIS. MDA-MB-231 cells were transiently transfected with an empty vector (VO), 
PBF and NIS-MYC for 48 hours prior to the addition of 125I. Normalised to sodium 
perchlorate (NaClO4) controls to display only NIS-specific activity. n=3 with 4 replicates in 
each n. ** = p<0.01. *** = p<0.001. 
 
3.3.8 Knockdown of PBF does not have a significant effect on radioiodide 
uptake 
Having demonstrated that PBF overexpression reduces radioiodide uptake, it was then 
important to establish whether silencing PBF expression could increase radioiodide uptake. 
PBF was effectively silenced in MCF-7 (Figure 3-6) and MDA-MB-231 (Figure 3-7) cells using 
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lentiviral particles. In MCF-7 cells treated with ATRA and dexamethasone, a trend towards 
increased radioiodide uptake was seen with PBF knockdown (43% increase) but the data 
were not statistically significant (Figure 3-15A). MDA-MB-231 cells that had been 
transduced with NIS displayed a more modest effect with radioiodide uptake marginally 
increasing with PBF knockdown (19.8% and 7% for clone 1 and 2 respectively) (Figure 
3-15B).  
 




Figure 3-15. PBF knockdown effect on radioiodide uptake. (A) MCF-7 cells lentivirally-
transduced with control and PBF shRNA were assessed for radioiodide uptake. n=3. (B) 
MDA-MB-231 cells that had been lentivirally-transduced with RFP-control (clone A) and NIS 
(clones 1 and 2) particles were further transduced with control and PBF shRNA particles and 
assessed for their ability to take up radioiodide. Normalised to sodium perchlorate (NaClO4) 
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3.3.9 PBF alters the subcellular localisation of NIS in breast cancer cells 
Transient transfection of NIS-MYC into MCF-7 cells resulted in expression of NIS 
throughout the cell with some evidence of plasma membrane and cytoplasmic vesicle 
staining (Figure 3-16A). However when PBF-HA was co-transfected into MCF-7 cells 
alongside NIS-MYC there was increased cytoplasmic vesicle staining of NIS-MYC (Figure 
3-16B+C) and high vesicular colocalisation between the two proteins (represented by 
yellow staining). Figure 3-16C in particular displays a high number of vesicles (depicted by 
localised yellow spots) containing NIS and PBF, compared to Figure 3-16A which has very 
little NIS in these locations.  
 
3.3.10 NIS and pY174 PBF colocalise 
As PBF and NIS have been observed to colocalise in breast cancer cells (3.3.9), it was 
important to establish whether NIS and pY174 PBF (phosphorylated PBF) were capable of 
colocalising in breast cancer cells. Immunofluorescence studies revealed clear 
colocalisation between pY174 PBF and NIS-MYC in MCF-7 cells at both the plasma 
membrane and in intracellular vesicles (Figure 3-17). 






Figure 3-16. PBF alters the subcellular localisation of NIS. MCF-7 cells were co-transfected 
with empty pcDNA(3.1+) vector (VO) and NIS-MYC or PBF-HA + NIS-MYC. In A, NIS-MYC is 
visualised using a mouse anti-MYC antibody in green and a rabbit anti-PBF antibody in red. 
In B + C, PBF-HA is visualised using a rabbit anti-HA antibody in red and NIS-MYC visualised 
using a mouse anti-MYC tag antibody in green. In all images nuclei are visualised in blue 
using Hoechst stain. 100x magnification. n=3. 




Figure 3-17. pY174 PBF and NIS colocalise within MCF-7 cells. Immunofluorescent 
detection of pY174 PBF (red) and NIS-MYC (green) in MCF-7 cells transfected with PBF and 
NIS-MYC. Yellow staining is indicative of colocalisation between pY174 PBF and NIS. Nuclei 















The main aim of this chapter was to establish whether PBF and NIS were associated in 
breast cancer, and from the results detailed above it is clear the two proteins have a 
relationship in breast cancer cells. 
 
3.4.1 PBF and NIS are both expressed in breast cancer 
Though PBF and NIS expression have both independently been observed in breast cancer 
(Tazebay et al., 2000; Watkins et al., 2010), their expression has not previously been 
correlated in breast cancer. Data in this chapter showed that in 3/4 of matched normal 
and tumour samples both PBF and NIS are upregulated at the protein level in breast 
cancer tumours. Although this suggests a potential correlation between the two proteins 
it is important to note that this is a particularly small sample size and a large number of 
samples would be needed to verify this association. Unfortunately no further samples 
were made available to us during this PhD.  
 Both MCF-7 and MDA-MB-231 cells expressed endogenous levels of PBF and NIS 
mRNA. Although both cell-lines displayed similar levels of PBF mRNA, there was a marked 
difference in their NIS mRNA levels. Despite MDA-MB-231 cells having increased NIS 
mRNA levels compared to MCF-7 cells, there was little difference between the 
endogenous radioiodide uptake between the two cell-lines. This may suggest that 
increased levels of NIS mRNA may not necessarily lead to increased protein translation 
within MDA-MB-231 cells. Alternatively, the protein product may be non-functional or be 
aberrantly localised away from the plasma membrane. Western blotting would be 
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required to assess if increased NIS mRNA results in increased NIS protein in MDA-MB-231 
cells compared to MCF-7 cells. 
3.4.2 PBF enhances NIS mRNA expression 
In thyroid cancer cell lines, PBF overexpression downregulates NIS mRNA expression 
through repression of both the proximal NIS promoter and the NUE, though the 
repression of NIS by PBF at the proximal promoter is controversial and was not witnessed 
in primary thyrocytes (Boelaert et al., 2007). Here we did not observe any repression of 
NIS mRNA or protein expression by PBF; instead overexpression of PBF appeared to 
enhance NIS expression. PBF was capable of increasing NIS mRNA levels in both the 
presence of endogenous NIS, ATRA/Dex-induced NIS and exogenous NIS. Conversely, the 
knockdown of PBF in breast cancer cells decreased NIS expression, further suggesting a 
positive correlation between PBF and NIS expression. 
 These data directly contradict the relationship observed between PBF and NIS in 
thyroid cancer. However as the repression of NIS by PBF has been reported to occur 
primarily by interaction with the NUE, an enhancer that has been identified to be thyroid-
specific, the lack of repression is unsurprising. The novel finding is that NIS is upregulated 
by PBF. One potential hypothesis for this induction could be due to Akt, a known 
downstream target of the PI3K pathway which has been heavily associated with NIS 
regulation in breast cancer cells (Kogai et al., 2008). In transgenic mice with thyroid-
specific overexpression of PBF, significantly increased levels of the phosphorylated forms 
of p-Akt have been reported compared to WT mice, with no change to total Akt levels 
(Read et al., 2011). If PBF overexpression influences Akt phosphorylation and activity, it 
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may constitute a mechanism for the upregulation of NIS witnessed in the presence of PBF 
overexpression. 
 Western blotting would be required to establish that the effects observed with 
NIS mRNA translate to protein expression. However due to limitations with the PBF 
antibody this could unfortunately not be performed as part of this work. There were few 
commercial PBF antibodies available each with limited functionalities so for throughout 
this project a custom made PBF antibody was utilised which was not fully optimised 
during this initial phase of the thesis. 
 
3.4.3 PBF represses NIS function 
As previously observed in thyroid cancer, PBF overexpression reduced radioiodide uptake 
in breast cells. Here we have shown that PBF affects NIS functionality in a similar manner 
in breast cells. The reduction in radioiodide uptake in breast cancer cells is consistently 
above 25% in the presence of PBF whether NIS is exogenously expressed or endogenously 
enhanced. However, the knock-down of PBF was incapable of increasing radioiodide 
uptake in several experimental scenarios. It is possible that this conflicting data may be 
due to the fact that NIS expression is greatly reduced in cells that have PBF silenced and 
with the overall reduction in NIS levels it may be difficult to observe the effect PBF 
knockdown has on the protein function alone.  
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3.4.4 PBF alters the subcellular localisation of NIS in breast cancer  
As in thyroid cancer, PBF was observed to colocalise with NIS and alter its subcellular 
localisation. Overexpression of both proteins in breast cancer cells increased NIS staining 
in intracellular vesicles where a high level of colocalisation with PBF was apparent. Not 
only did NIS colocalise with total PBF, there was also a high level of colocalisation with 
pY174 PBF within both the plasma membrane and intracellular vesicles in breast cancer 
cells. These data agree with the previous findings in thyroid cancer (Smith et al., 2011; 
Smith et al., 2009; Smith et al., 2013). NIS has previously been described to be located 
intracellularly within breast cancer cells (Beyer et al., 2009; Tazebay et al., 2000) and as 
hypothesised this may be due to its interaction with upregulated PBF in breast cancer. 
 
Overall, it is clear from these data that PBF and NIS have a functional relationship in 
breast cancer. PBF can alter the subcellular localisation of NIS and repress NIS function 
within breast cancer cells. This is similar to the relationship observed in thyroid cancer 
cells between PBF and NIS. This is potentially therapeutically important as it supports the 
hypothesis that PBF represses radioiodide uptake in breast cancer cells and that 
inhibition of PBF and NIS interaction may increase radioiodide uptake. Therefore it was of 
great interest to establish whether phosphorylation of Y174 in PBF is critical for the 
interaction between NIS and PBF in breast cancer cells as observed in thyroid cancer.
 
  




CHAPTER 4 - PHOSPHORYLATION MUTANTS OF 
PBF DO NOT BIND TO NIS OR DECREASE 
RADIOIODIDE UPTAKE 




PBF has been described as a membrane glycoprotein with expression primarily at the 
plasma membrane and in cellular vesicles (Smith et al., 2009). The presence of a tyrosine-
based sorting signal within the C-terminal region of PBF has been observed to be critical 
for the correct trafficking of PBF in cells (Smith et al., 2013). Tyrosine-based sorting 
signals have a prominent role in endocytosis (Collawn et al., 1990) and sorting to 
lysosomes (Guarnieri et al., 1993) with the motif sequence bein  YXXφ (where Y is 
tyrosine, X is an  amino acid and φ is an amino acid with a bulk  h drophobic side chain) 
(Canfield et al., 1991). The YXXφ si nals are reco nised b  homolo ous µ , µ , µ3 and µ  
subunits of the corresponding heterotetrameric adaptor protein (AP) complexes AP-1, 
AP-2, AP-3 and AP-4 that function as cargo adaptors (Mardones et al., 2013). PBF 
conforms to the YXXφ motif between amino acids 174-177 where the sequence is YARF 
and mutation of either Y174 or F177 to alanine leads to accumulation of PBF at the 
plasma membrane (Smith et al., 2013).  
 Residue Y174 of PBF appears to be critical for multiple roles within the protein, 
being both the lead tyrosine of the sorting signal as well as being strongly predicted to be 
phosphorylated. Phosphorylation at this residue has been confirmed in many cell-lines 
including both COS-7 (monkey kidney epithelial) and K1 (human thyroid cancer) cell-lines 
(Smith et al., 2013). PBF phosphorylated at Y174 was demonstrated to colocalise with NIS 
in a variety of cell lines including T47D breast cancer cells. An interaction between Y174A 
PBF and NIS was assessed and mutation of the tyrosine to alanine almost completely 
abrogated PBF binding to NIS (Smith et al., 2013). 
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 The evidence thus far suggested that Y174 is critical for PBF localisation and for 
interaction with NIS. However it was not obvious whether differences in interaction with 
NIS are due to differences in PBF phosphorylation or localisation. To assess whether 
phosphorylation alone is critical for the interaction, a mutant that retains normal PBF 
localisation but is unable to be phosphorylated was required. In this chapter the 
consensus sequence for kinase recognition of PBF was identified and mutated. It was 
proposed that mutating this consensus sequence would abrogate phosphorylation of PBF 
but retain PBF's native cellular trafficking as the sorting signal would remain intact. Here, 
a mutant retaining normal PBF localisation yet lacking phosphorylation was identified, 
described and assessed in comparison to WT and Y174A PBF. 
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4.2 Material and Methods 
4.2.1 Prediction Tools 
To aid with the generation of a phospho-Y174 (pY174)-null mutant form of PBF, 
phosphorylation prediction software was utilised. The primary software employed was 
the online tool NetPhos 2.0 (Blom et al., 1999). The PBF peptide sequence was obtained 
from NCBI (accession number - AAH31097), altered to have mutations in the amino acid 
sequence surrounding Y174 and inputted to NetPhos 2.0 in FASTA format. To confirm 
predictions additional phosphorylation tools were utilised:- PhosphoMotif Finder 
(Amanchy et al., 2007), GPS3.0 (Xue et al., 2008) and KinasePhos2.0 (Wong et al., 2007). 
 
4.2.2 Cell Culture 
MCF-7 and MDA-MB-231 cells were maintained as described in 2.1.2 with stably-
transfected MCF-7 cells cultured in medium containing G418 (1 mg/ml) and lentivirally-
transduced MDA-MB-231 cells cultured in medium containing blasticidin (15 µg/ml). All 
cell lines were seeded at 3x104cells per well in a 24 well plate for radioiodide uptake and 
at 1.5x105 and 2x105 cells per well in a 6 well plate for fluorescence 
immunocytochemistry and protein extraction respectively. 
 
4.2.3 ATRA and Dexamethasone Treatment 
MCF-7 cells were treated with 100 nM ATRA and 1 µM dexamethasone as described in 
section 3.2.3. An equal volume of ethanol and DMSO in cell media was used as a control. 




The pcDNA3.1 (+)_PBF and pcDNA3.1 (+)_PBF-HA plasmids were mutated using the 
QuikChange II XL Site-Directed Mutagenesis kit (Agilent, California, USA). Forward and 
reverse primers for mutagenesis were designed and produced (Sigma) in accordance with 
the kit protocol to ensure maximum efficiency. 10 ng plasmid DNA was combined with 
125ng mutagenic forward and reverse primers (Table 4-1), 5 µl 10x reaction buffer, 1 µl 
dNTP mix, 3 µl Quiksolution, 2.5 U PfuUltra HF DNA polymerase and made up to a total 
volume of 50 µl with nuclease free water. Following an initial denaturation step at 95°C 
for 1 minute, 18 cycles of PCR were performed including denaturation (95°C for 50 
seconds), primer annealing (60°C for 50 seconds) and primer extension (68°C for 6 
minute). After an additional 7 minutes at 68°C, the reaction was cooled to 37°C. 10U Dpn, 
a restriction enzyme which specifically cleaves methylated and hemi-methylated DNA, 
was added to each reaction and incubated for 1 hour at 37°C to digest parental 
supercoiled dsDNA. XL10-Gold® Ultracompetent bacterial cells were transformed by the 
addition of 2 µl of the reaction mixture, incubated on ice for 30 minutes, followed by heat 
shock at 42°C for 30 seconds and returned to ice for a further 2 minutes. The cells were 










Table 4-1. Mutagenesis primers for EEN170-172AAA PBF. The red letters signify changes 
to the PBF sequence that result in amino acid substitutions. 
 
4.2.5 Plasmid Purification and Sequencing  
Carbenicillin-resistant bacterial colonies were used to inoculate 5ml LB containing 
carbenicillin (100 µg/ml) and incubated at 37°C for 16 hours with shaking at 200 rpm. 
Purification was performed using the Wizard® Plus SV Miniprep DNA Purification System 
(Promega) according to manufacturer’s instructions. 1.5 ml of the bacterial suspension 
was centrifuged at 10,000 x g for 5 minutes and the supernatant discarded. Cells were re-
suspended in 250 μl Cell Resuspension Solution and lysed using 250 μl Cell Lysis Solution 
and incubation at room temperature until the suspension had cleared. The lysate was 
incubated for 10 minutes with 10 μl alkaline protease to inactivate any endonucleases 
released during cell lysis. To terminate lysis, 350 μl Neutralisation Solution was added and 
the suspension inverted 4 times before centrifuging for 10 minutes at 14,000 x g. The 
cleared lysate was transferred to a spin column and further centrifuged at 14,000 x g for 1 
minute, discarding the eluate. Plasmid DNA was washed twice by centrifugation with 
Column Wash Solution (750 μl wash  ,  50 μl wash 2). Finally, the DNA was eluted with 
100 μl nuclease free water. DNA quantification was carried out using a NanoDrop© ND-
1000 Spectrophotometer (NanoDrop) and accompanying ND-1000 v3.3 software on the 




5' GA AAA AAA TAT GGC CTG TTT AAA GCA GCA GCC CCG TAT GCT 
AGA TTT G 3' 
EEN170-172AAA 
Reverse 
5' C AAA TCT AGC ATA CGG GGC TGC TGC TTT AAA CAG GCC ATA 
TTT TTT TC 3' 
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 To further amplify the mutated plasmid, purified plasmid DNA was used to 
transform DH5-α bacterial cells as described in 2.2.2.1 and the DNA then amplified using 
the  i ma GenElute™ HP Plasmid Maxiprep kit as described in 2.2.2.2. 
 
4.2.6 Development of Stable and Lentiviral Cell lines 
4.2.6.1 Stable Transfection 
MCF-7 and MDA-MB-231 cells were stably transfected with an empty pCI-neo vector, PBF 
(kindly gifted by Dr Vicki Smith), Y174A (kindly gifted by Waraporn 
Imruetaicharoenchoke) and EEN170-172AAA in the pCI-neo vector as described in 2.2.4. 
Stable transfection was confirmed using qRT-PCR. 
 
4.2.7 Transient Transfection 
Transfection was performed as described in 2.2.3. WT PBF-HA, EEN/AAA PBF-HA, Y174 
PBF-HA, NIS-MYC (kindly gifted by Dr Vicki Smith) and EEN170-172AAA in the pcDNA3.1 
(+) vector were transfected into MCF-7 cells in 6 well plates for use in fluorescence 
immunocytochemistry and Western blotting. For radioiodide uptake, cells were seeded in 
24 well plates and transfected with untagged forms of WT, EEN170-172AAA and Y174A 
PBF alongside NIS-MYC. 
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4.2.8 Radioiodide uptake 
Radioiodide uptake was performed as described in 2.7. Transfection and drug treatments 
were performed 48 and 24 hours respectively before the addition of 125I to cells. 
 
4.2.9  Western Blotting 
Protein extraction and Western blotting were performed as described in 2.3.1 and 2.3.2 
respectively. Cells were treated with 100µM sodium pervanadate for 20 minutes prior to 
harvesting to allow the detection of pY174 PBF. Antibodies used were anti-pY174 PBF 
antibody (Smith et al., 2013), anti-PBF (Smith et al., 2009), anti-phospho-Src (Y418) 
(Abcam), anti-Src (Cell Signalling) and β-actin (Sigma-Aldrich) (refer to section 2.8). 
Appropriate secondary antibodies were used. 
 
4.2.10 Fluorescence immunocytochemistry 
Fluorescence immunocytochemistry was performed as described in 2.4. Cells were 
treated with 100µM sodium pervanadate for 20 minutes prior to fixing to allow the 
detection of pY174 PBF. Antibodies used included anti-pY174 PBF antibody (1:50) 
(Covalab) (Smith et al., 2013), anti-HA tag (mouse) (1:200) (Covance), anti-HA tag (rabbit) 
(1:100) (Santa Cruz) and anti-Myc tag (1:750) (Cell Signalling).  
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4.2.11 BrdU proliferation 
Proliferation was assessed using a cell proliferation ELISA BrdU (5-bromo-2'-deoxyuridine) 
(colorimetric) assay (Roche). BrdU is a synthetic pyrimidine analogue, which is 
incorporated in place of thymidine into DNA during replication. This analogue can be 
detected by a peroxidase-conjugated BrdU antibody, which cleaves tetramethylbenzidine 
(TMB) substrate producing a blue colouring, therefore providing a method to quantify 
proliferation.  
 The BrdU assays were performed according to the manufacturer's instructions. 
Cells were seeded at 2,500 per well in a 96 well plate for 24 hours prior to the assay being 
performed. Cells were incubated with 10 µM BrdU labelling solution at 37°C for 4 hours. 
After removal of the labelling solution, cells were incubated at room temperature for 30 
minutes with 200 μl Fix enat Solution. Once removed, 50 μl anti-BrdU-POD (Monoclonal 
antibody from mouse-mouse hybrid cells (clone BMG 6H8, Fab fragments) conjugated 
with peroxidase (POD)) (10 µM) were added to each well and left for 90 minutes. 
Antibody solution was then removed and the wells washed 3 times with 200 μl BrdU 
wash solution before 100 μl BrdU-POD substrate (tetrametyl-benzidine) solution was 
added to each well. After brief shaking, the absorbance was then read at 405nm using the 
Wallac Victor plate reader. 
 
4.2.12 Co-immunoprecipitation Assay (Co-IP) 
Cells were cultured in T75 flasks and transfected as described in 2.2.3 for 48 hours. Prior 
to harvesting cells were treated for 20 minutes with 100 µM sodium pervanadate. Cells 
were then washed in PBS and harvested in 1 ml RIPA containing 60 µl/ml protease 
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inhibitor cocktail (Sigma) and phosphatase inhibitor cocktails 2 and 3 (1% v/v) (Sigma). 
Lysates were subjected to end-over-end rotation for 10 minutes at 4°C before being 
sonicated for 30 seconds (medium setting, Bioruptor Standard, Diagenode, Liège, 
Belgium) and undergoing an additional 10 minutes end-over-end rotation. Cell debris was 
then pelleted and lysate transferred to a fresh micro-centrifuge tube. 100 µl of lysate 
were removed and stored at -20°C for use as the whole cell lysate. The remaining lysate 
was incubated with primary anti-Myc antibody (7.5 µl) overnight at 4°C with end-over-
end rotation. Protein G sepharose beads (GE Lifesciences, Little Chalfont, 
Buckinghamshire, UK) were washed in RIPA buffer before a 1:1 (v:v) bead slurry was 
prepared in RIPA. The bead slurry (50 µl) was then added to each sample and incubated 
for 3 hours at 4°C with end-over-end rotation. The samples were briefly centrifuged, the 
supernatant discarded and the pelleted beads washed in 500 µl RIPA three times. Bound 
proteins were eluted from the beads in 50 µl 2x Laemmli buffer (Bio-Rad) containing 1:20 
β-mercaptoethanol (Sigma) by heating for 30 minutes at 37°C. The samples were pelleted 
and the supernatants transferred to fresh tubes and stored at -20°C ready for Western 
blotting as described in 2.3.2. The whole cell lysates retained earlier were denatured in 5x 
Laemmli buffer (250 mM Tris-HCl pH6.8, 10% SDS, 0.02% bromophenol blue, 50% glycerol 
and 12.5% β-mercaptoethanol) prior to Western blotting.  
 
4.2.13 RNA extraction and qRT-PCR 
RNA extraction, reverse transcription and qRT-PCR were performed as described in 2.5 
and 2.6. Expression of PBF was assessed using the PBF TaqMan® Gene Expression Assay 
(Hs01036322_m1 ) (Life Technologies). Expression of NIS was assessed using custom-
made primers and probe (Table 3-1). 





Data were analysed using Sigma Plot (SPSS Science Software UK Ltd). The student's t-test 
was utilised to compare data between two groups whereas the one-way ANOVA was 
used to compare more than two groups of parametric data with significance taken at p < 
0.05 for both.  




4.3.1 Prediction of non-phosphorylated forms of PBF 
NetPhos 2.0 (Blom et al., 1999) was initially utilised to predict the effect of mutating 
amino acids upstream of Y174 on the phosphorylation of this tyrosine residue. Figure 4-1 
shows that WT PBF is predicted to be phosphorylated at Y174 and mutation of this 
tyrosine to alanine removes all phosphorylation potential. Single amino acid substitutions 
were subsequently made to residues upstream of Y174, however individual mutations 
were not capable of reducing phosphorylation potential below the threshold (data not 
shown). Multiple substitutions were then run through the prediction tool (data not 
shown) and EEN170-172AAA (EEN/AAA) was found to reduce the phosphorylation 
potential to below the predicted threshold at Y174 (Figure 4-1). Mutating these residues 
to similarly charged amino acids could not reduce phosphorylation potential (data not 
shown). The sequence of the prospective EEN/AAA mutant was further tested for 
phosphorylation potential using different phosphorylation prediction tools that 
confirmed this mutant was not likely to be phosphorylated.  




Figure 4-1. Phosphorylation potential of WT PBF and mutant forms. NetPhos 2.0 (Blom et 
al., 1999) was utilised as a phosphorylation prediction tool. The charts show the 
phosphorylation potential of proteins at serine (green), threonine (blue) and tyrosine 
(pink) residues. Peaks crossing the red threshold line are considered to be phosphorylated 
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4.3.2 Creation of EEN/AAA 
Wild-type PBF was successfully mutated to EEN170-172AAA (EEN/AAA) using site-
directed mutagenesis. The new plasmid was sequenced and NCBI tools nucleotide BLAST 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&LIN 
K_LOC=blasthome) and BLAST x (http://blast.ncbi.nlm.nih.gov/Blast.cgi? 
PROGRAM=blastx&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome) were used to 
compare the sequences. BLAST confirmed the correct mutation of the PBF plasmid, with 
both the nucleotide sequence (Figure 4-2) and translated amino acid sequence revealing 
the correct mutation.  




Figure 4-2. Successful mutation of PBF at residues 170-172. Sequencing of the pcDNA 3.1 
plasmid containing human PBF confirmed successful mutagenesis of GAA GAA AAC 
(EEN/AAA) to GCA GCA GCC (AAA). 
 
4.3.3 Predicted Structure of WT and EEN/AAA PBF 
The sequence of PBF and the two mutants, Y174A and EEN/AAA, were entered into the 
Protein Homology/analogY Recognition Engine V 2.0 (Phyre2) online tool (Kelley et al., 
2015) which predicts protein structure based on homology and analogy to proteins that 
have had their structure determined. WT PBF is primaril  made up of α-helix and 
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unstructured regions (Figure 4-3). The C-terminal end of WT PBF, which contains the 
residue of interest Y174, is predicted to be largely unstructured. When this tyrosine 
residue at position 174 is mutated to alanine, the C-terminal end encompassing this 
residue chan es structure and is predicted to be an α-helix. However, the C-terminal 
structure of EEN/AAA PBF is very similar to WT with the region being largely unstructured 
(Figure 4-3). 
 
Figure 4-3. Structure of WT, Y174A and EEN/AAA PBF. The sequences of the 3 forms of 
PBF were entered into the Protein Homology/analogY Recognition Engine V 2.0 (Phyre2) 
online tool (Kelley et al., 2015) creating a model which could be manipulated within Swiss 
Pdb viewer. Red ribbon represents α-helices with yellow ribbon representing β-sheets. N-
terminal residues are lime green and located to the left of the image whereas C-terminal 
residues are displayed in violet to the right of the image. The baby blue labelled residue 
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4.3.4 EEN/AAA PBF is not phosphorylated at Y174 
To determine the phosphorylation status of the EEN/AAA PBF mutant, WT, EEN/AAA and 
Y174A PBF were transiently transfected into MCF-7 cells. Western blotting using the 
pY174-specific antibody demonstrated strong pY174 PBF expression with WT PBF 
transfection but pY174 PBF was not detected in either the EEN/AAA or Y174A PBF 
transfected cells (Figure 4-4). Both total PBF and β-actin showed equal expression in all 
three cell lysates (Figure 4-4), suggesting that the prediction tools were correct and 
EEN/AAA PBF is incapable of being phosphorylated at Y174. 
 
Figure 4-4. EEN/AAA PBF is not phosphorylated at Y174. MCF-7 cells were transfected 
with WT, EEN/AAA and Y174A PBF for 48 hours prior to harvesting. pY174 PBF and total 
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4.3.5 Generation of Stable Cell lines 
To enable the study of PBF in breast cancer cells, MCF-7 and MDA-MB-231 cells were 
stably transfected with WT, EEN/AAA and Y174A PBF. Stable transfection in MDA-MB-231 
cells significantly increased PBF mRNA expression with a 9.3, 3.3 and 29.4-fold increase 
retrospectively compared to empty vector transfected cells (Figure 4-5). This increased 
expression of PBF was confirmed by Western blotting, where although limited pY174 PBF 
was detected in cells transfected with EEN/AAA and Y174 PBF, there was a distinct 
increase in total PBF levels compared to empty vector transfected cells. Endogenous 
pY174 PBF was also detected in both cell-lines as observed in the pCI-neo empty vector 
stably transfected cells. MCF-7 cells also had significantly increased PBF expression after 
transfection with WT, EEN/AAA and Y174A PBF with an increase of 3.8, 5.5 and 4.6 -fold 
respectively (Figure 4-6). 
  







Figure 4-5. Expression of pY174 PBF, total PBF and NIS in stably transfected MDA-MB-231 
cells. (A) Relative expression of PBF as determined by qRT-PCR in MDA-MB-231 cells stably 
transfected with pCI-neo empty vector (VO), WT, EEN/AAA and Y174A PBF normalised to 
the empty vector control. Statistics were performed on ΔCT values. n=3 with 4 replicates 
in each n. *=p<0.05 compared to the empty vector control. (B) Western blotting of MDA-
MB-231 cells stably transfected with pCI-neo empty vector (VO), WT, EEN/AAA and Y174A 










VO 11.762 0.144 - -
PBF 8.595 0.504 9.266 0.026
EEN 10.089 0.302 3.343 0.038
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Figure 4-6. Expression of pY174 PBF, total PBF and NIS in stably transfected MCF-7 cells. 
(A) Relative expression of PBF as determined by qRT-PCR in MCF-7 cells stably transfected 
with pCI-neo empty vector (VO), WT, EEN/AAA and Y174A PBF normalised to the empty 
vector control transfected cells. Statistics were performed on ΔCT values. n=3 with 4 
replicates in each n.*=p<0.05 compared to the empty vector control. (B) Western blotting 
of MCF-7 cells stably transfected with pCI-neo empty vector (VO), WT, EEN/AAA and 
Y174A PBF. pY174 and total PBF were detected with β-actin used a loading control. n=2. 
 
4.3.6 Proliferation is not affected by the phosphorylation status of PBF 
PBF has previously been observed to be mildly pro-proliferative in transgenic mouse 








VO 15.702 0.145 - -
PBF 13.769 0.002 3.840 0.048
EEN 13.260 0.274 5.456 0.033
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any effect on proliferation, BrdU assays were employed in cells stably transfected with 
WT PBF and the phosphorylation mutants. In MCF-7 and MDA-MB-231 cells proliferation 
following PBF overexpression was not significantly different from the empty vector 
control but there was a slight trend towards being mildly proliferative (Figure 4-7). There 
was no significant difference in proliferation between WT PBF and the two 
phosphorylation mutants in either cell-line (Figure 4-7).  
  
Figure 4-7. Phosphorylation status of PBF does not affect proliferation. BrdU assays were 
performed on MCF-7 (A) and MDA-MB-231 (B) cells stably-transfected with empty vector 
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4.3.7 EEN/AAA PBF is not retained in the plasma membrane 
Fluorescence immunocytochemistry was utilised to assess the localisation of EEN/AAA 
PBF within MCF-7 cells. WT PBF was localised ubiquitously throughout the cells, with 
some plasma membrane expression but the majority located within the cytoplasm 
(Figure 4-8). As demonstrated previously (Smith et al., 2013), Y174A PBF was retained in 
the plasma membrane and was apparent within cell ruffles and lamellipodia (Figure 4-8). 
In contrast, EEN/AAA PBF localised in a similar manner to WT PBF, primarily being located 
within the cytoplasm but with some staining in the plasma membrane and into 
lamellipodia (Figure 4-8).  




Figure 4-8. Fluorescence immunocytochemistry demonstrating the localisation of WT and 
mutant PBF. MCF-7 cells were transfected with WT, EEN/AAA or Y174A PBF-HA for 48 
hours prior to fixing. HA-tagged PBF is identified in green using a mouse anti-HA antibody 
with the nuclei visualised in blue using Hoechst stain. White arrows indicate ruffles with 
pink arrows depicting lamellipodia. 100x magnification. n=3. 
 
4.3.8 EEN/AAA PBF does not alter NIS subcellular localisation 
Although EEN/AAA PBF has a similar subcellular localisation to WT PBF, it was important 
to assess its affect on the localisation of NIS within breast cancer cells. To investigate this, 
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alongside NIS-MYC and assessed using fluorescence immunocytochemistry. Cells 
transfected with WT PBF displayed intracellular colocalisation between NIS and PBF with 
limited NIS staining at the plasma membrane (Figure 4-9). In contrast, Y174A PBF was 
retained in the plasma membrane and there was a reduction in intracellular NIS levels. 
EEN/AAA PBF primarily localised within intracellular vesicles in a similar manner to PBF. 
However, there was an increase in the level of NIS staining at the plasma membrane, 
alongside a sharp reduction in the amount of co-localisation between NIS and PBF (Figure 
4-9). 
   




Figure 4-9. EEN/AAA PBF does not sequester NIS in intracellular vesicles. MCF-7 cells were 
transfected with WT, EEN/AAA or Y174A PBF-HA for 48 hours prior to fixing. MYC-tagged 
NIS is identified in green using a mouse anti-MYC antibody and HA-tagged PBF is 
identified in red using a mouse anti-HA antibody with the nuclei visualised in blue using 
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4.3.9 EEN/AAA PBF does not decrease radioiodide uptake 
Radioiodide uptake of EEN/AAA and Y174A PBF was assessed to determine if mutants 
lacking phosphorylation of PBF at Y174 could affect NIS function. WT PBF was previously 
demonstrated to be capable of decreasing radioiodide uptake in MCF-7 and MDA-MB-
231 cells exogenously expressing NIS (Figure 4-10 A&B) and MCF-7 cells treated with 
ATRA and dexamethasone (Figure 4-10 C). In contrast to WT PBF, both EEN/AAA PBF and 
Y174 PBF were not capable of reducing radioiodide uptake in either cell-line tested with 
exogenously expressed or ATRA/Dex-induced NIS. Both EEN/AAA and Y174A PBF had 
significantly increased radioiodide uptake compared with WT PBF and there was no 
significant difference from empty vector control transfected cells. 




Figure 4-10. EEN/AAA and Y174A PBF cannot reduce radioiodide uptake in the same 
manner as WT PBF. (A) MCF-7 and (B) MDA-MB-231 cells were transiently co-transfected 
with NIS-MYC and empty vector (VO), WT PBF, EEN/AAA PBF or Y174A PBF 48 hours prior 
to the addition of 125I. (C) MCF-7 cells stably transfected with empty vector (VO), WT, 
EEN/AAA or Y174A PBF were treated with ATRA and dexamethasone 48 hours prior to the 
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4.3.10 EEN/AAA PBF does not bind to NIS 
Co-immunoprecipitation (Co-IP) assays in COS-7 cells previously revealed binding 
between PBF and NIS. However when Y174A was transfected into these cells Y174A PBF 
was not capable of binding to NIS (Smith et al., 2013). A possible interaction between PBF 
and NIS was assessed here in breast cancer cells. In MCF-7 cells, it was clear that PBF-HA 
and NIS-MYC maintain a physical relationship with strong binding being observed 
between the two proteins (Figure 4-11). Again, Y174A PBF-HA demonstrated a significant 
reduction in the ability to bind NIS-MYC with the alanine substitution at the Y174 residue 
almost completely abrogating the binding between PBF and NIS. Mutation of PBF-HA to 
EEN/AAA PBF-HA also drastically reduced binding of NIS and PBF in MCF-7 cells, with 
binding being almost completely lost (Figure 4-11). 
 
Figure 4-11. Unphosphorylated forms of PBF do not bind NIS. MCF-7 cells were co-
transfected with NIS-MYC alongside empty vector (VO), WT, EEN/AAA or Y174A PBF-HA 
for 48 hours prior to harvesting. In the Co-IP, proteins were pulled down using the MYC 
antibody and probed with the HA antibody. Whole cell lysate was probed with HA, MYC 
and β-actin as a loading control. n=1. 
 
NIS-MYC - + + + +











4.4.1 EEN/AAA PBF is not phosphorylated 
The utilisation of phosphorylation prediction websites provided a vital tool in the 
identification of the pY174-null PBF. Although the tools were essential in the 
identification of potential mutants lacking phosphorylation, it was critical to confirm the 
phenotype in vitro. Similarly to Y174A PBF, EEN/AAA PBF was observed to be 
unphosphorylated in vitro by Western blotting allowing further investigation into the role 
of PBF phosphorylation.  
 One of the limitations observed with the PBF antibody is the epitope in which it 
binds to is located within the C-terminus of PBF, in the regions surrounding Y174. The 
presence of a phosphate group at Y174 of PBF can disrupt the binding efficacy of the PBF 
antibody. When phosphorylation is inhibited or not possible due to PBF mutation, 
increased levels of total PBF can be detected by Western blotting; as observed in Figure 
4-5 and Figure 4-6. This effect rendered quantification of Western blotting by 
densitometry inappropriate as total PBF levels could not be utilised as a control for 
phospho-PBF levels. 
 The creation of an alternative mutant of PBF with an additional YARF motif was 
intended to be created and characterised alongside EEN/AAA PBF, but unfortunately due 
to mutagenesis limitations this was not possible. The mutation involved the addition of 4 
amino acids to the Y174A PBF protein, with an intended amino acid sequence of 
KEENPAARFYARFENN. It was expected that the Y174A mutation would prevent PBF 
phosphorylation but the additional YARF would provide the tyrosine-based sorting signal. 
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This mutant alone would not have been ideal as there were questions as to whether the 
introduced tyrosine residue would become phosphorylated as well as whether the 
structure of PBF would be affected by the addition of 4 amino acids. Alongside the 
EEN/AAA mutant, it would have provided insight into a form of PBF that would hopefully 
not be phosphorylated but would localise correctly. However, the introduction of 12 
nucleic acids was not possible after multiple attempts to optimise the mutagenesis 
technique using several different mutagenesis kits and varying the PCR cycle lengths and 
temperatures. 
4.4.2 Characterisation of EEN/AAA PBF 
Modelling of EEN/AAA PBF revealed a similar structure between WT PBF and EEN/AAA 
PBF, particularly at the C-terminal end of PBF where the mutation is found. Although 
there were minor differences in this C-terminal section, both proteins had a small α-helix 
followed by a largely unstructured section in this region. With the structures of PBF and 
EEN/AAA PBF being similar, phenotypic differences between WT and EEN/AAA PBF are 
more likely to be attributable solely to the lack of phosphorylation at Y174. 
 To make further comparisons between the mutated and WT forms of the protein, 
several characteristics of PBF were assessed to identify the effect of phosphorylation. WT 
PBF has previously been described to be mildly pro-proliferative in thyroid cancer cells. In 
breast cancer cells, there was no difference in the proliferation between WT PBF and 
empty vector transfected cells. Both Y174A and EEN/AAA PBF did not alter proliferation 
significantly compared to both WT PBF and empty vector transfected cells suggesting that 
the phosphorylation of PBF does not affect the proliferation of breast cancer cells. 




Establishing the localisation of EEN/AAA PBF is fundamental to understanding the 
interaction between NIS and PBF in breast cancer. EEN/AAA PBF contains an intact 
tyrosine-based sorting signal (YARF) so was predicted to be capable of endocytosis similar 
to WT PBF. Immunofluorescence studies revealed that EEN/AAA PBF is localised 
throughout the cell, with a presence at both the plasma membrane and in intracellular 
vesicles. The localisation of EEN/AAA PBF was synonymous with that seen with WT PBF 
and in sharp contrast to the enhanced plasma membrane staining witnessed with Y174A 
PBF.  
 It has been previously hypothesised that phosphorylation of PBF regulates its 
localisation, with phosphorylation of Y174 impairing the interaction with clathrin-
associated adaptor complexes thereby inhibiting endocytosis (Smith et al., 2013). There is 
currently conflicting data as to whether phosphorylation enhances interaction with 
adaptor protein (AP) complexes that reco nise YXXφ si nals. Phosphor lation of the T cell 
co-stimulatory receptor CTLA-4 on the lead tyrosine of the receptor sorting signal (YVKM) 
blocks the protein's interaction with the µ2 subunit of the AP complex and inhibits 
receptor internalisation (Shiratori et al., 1997). This form of regulation can be easily 
explained by the impossibility of the binding pocket to sterically accommodate a large 
negatively charged phosphate group. However, in contrast to this negative regulation, 
phosphorylation of aquaporin 4 (AQP4) enhances the interaction between the protein 
and subunit µ3 of the AP complex increasing lysosomal targeting of the protein, although 
the structural basis for this regulation remain to be elucidated (Madrid et al., 2001). To 
determine whether phosphorylation does regulate the localisation of PBF, a constitutively 
phosphorylated form of PBF would need to be compared to both WT PBF and EEN/AAA 
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PBF. From these data, it is apparent that phosphorylation is not critical for the 
internalisation of PBF in breast cancer cells but does not establish how endocytosis of the 
protein is regulated. 
4.4.2.2 Interaction with NIS 
Within this chapter there is substantial evidence to suggest that unphosphorylated 
EEN/AAA PBF cannot interact with NIS in vitro. Immunofluorescence studies have 
previously revealed high levels of colocalisation between WT PBF and NIS in breast cancer 
cells, with staining of NIS primarily being in intracellular vesicles with some staining at the 
plasma membrane. Use of the unphosphorylated EEN/AAA mutant form of PBF reduced 
colocalisation between exogenous NIS and PBF and altered the localisation of NIS. These 
data agree with previous studies where Y174A PBF expression has been unable to 
internalise NIS, although there were questions as to whether this was due to plasma 
membrane retention of the Y174A form of PBF (Smith et al., 2013). The decreased 
colocalisation between EEN/AAA PBF and NIS observed using immunofluorescence is 
supported by the co-immunopreciptitation studies where little to no binding was 
detected between the two proteins. Both EEN/AAA and Y174A forms of PBF did not bind 
to NIS within breast cancer cells, with both forms having a lack of phosphorylation in 
common. In addition to this reduced binding, the presence of EEN/AAA PBF and Y174A 
PBF did not repress radioiodide uptake in the same manner as the expression of 
exogenous WT PBF in breast cancer cells.  
 These data suggest that phosphorylation of PBF at Y174 is critical for the 
interaction between NIS and PBF. The importance of the phosphorylation in protein 
binding has previously been witnessed with studies identifying that phosphosites have a 
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tendency to be located on the binding interfaces of protein complexes. Phosphorylation 
has been hypothesised to modulate the strength of interactions and bring about changes 
in binding energy that may trigger the transitions between conformational states, 
removing previous potential steric constraints (Nishi et al., 2011).  
 
Overall these data suggest that the phosphorylation of PBF at Y174 is essential for the 
interaction between PBF and NIS. Forms of PBF that cannot be phosphorylated are 
incapable of binding to NIS, altering its subcellular localisation and reducing radioiodide 
uptake, suggesting that therapeutically reducing pY174 PBF levels in breast cancer cells 
may increase radioiodide uptake. With phosphorylation of Y174 being observed to be 
critical, rather than the integrity of the endocytosis motif and PBF subcellular localisation, 
it is important to identify methods to abrogate Y174 phosphorylation to overcome PBF 
repression of NIS function. If PBF phosphorylation can be inhibited, the exact mechanics 
of the interaction between NIS and PBF can begin to be fully elucidated and exploited to 
boost NIS function and radioiodide uptake within breast cancer cells. 




CHAPTER 5 - SRC FAMILY KINASE INHIBITORS 
INCREASE RADIOIODIDE UPTAKE 
 
  




Previous work in thyroid cancer has identified that the use of a Src family kinase (SFK) 
inhibitor, PP1, can decrease phosphorylation of PBF (Smith et al., 2013). Use of PP1 in 
thyroid cancer cells also overcame the reduction in radioiodide uptake witnessed with 
PBF overexpression (Smith et al., 2013). With radioiodide uptake being proposed as a 
potential treatment for breast cancer, it is important to identify whether SFK inhibition 
can enhance radioiodide uptake in breast cancer cells and determine which inhibitors are 
the most specific and have the greatest effect. 
 
5.1.1 Src and Src Family Kinases 
Src, also referred to as c-Src, is a non-receptor tyrosine kinase that is the prototype 
member of the Src family of tyrosine kinases (SFKs), a family consisting of eight other 
members: Lck, Fyn, Lyn, Hck, Yes, Fgr, Blk and Yrk. All members of the family are closely 
related, having significant amino acid homology along with structural similarities such as 
SH2 (Src Homology 2), SH3 and kinase catalytic domains. SFKs modulate many signalling 
cascades involved in processes including cell proliferation, survival, differentiation, 
adhesion, migration and invasion (Thomas and Brugge, 1997). SFKs are aberrantly 
expressed or functionally dysregulated in many human cancers including breast, 
colorectal, pancreatic, prostatic and ovarian carcinomas (Summy and Gallick, 2003). In 
breast cancer, Src was found to be present in 95% of triple negative (TN) samples and 
84% of other breast cancer types. TN tumours exhibited increased membranous 
expression of Src with activated Src being localised within peripheral membrane-
associated focal adhesions (Tryfonopoulos et al., 2011). Src expression has also been 
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linked to aggressive disease and poor prognosis (Elsberger et al., 2009), and has been 
identified as a common signalling axis in trastuzumab resistance in breast cancer (Zhang 
et al., 2011). Due to SFK frequent dysregulation in multiple cancers, SFK inhibitors are 
being assessed in multiple cancers to inhibit cell proliferation, migration, tumour growth 
and invasion.  
 
5.1.2 SFK inhibitors 
5.1.2.1 PP1 
PP1 (1-(1,1-Dimethylethyl)-1-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine) is a 
potent small molecular inhibitor (Figure 5-1) of SFKs that was first identified in 1996 
(Hanke et al., 1996), with an IC50 of around 5nM, 6nM and 170nM for Lck, Fyn and Src 
respectively. PP1 was also identified as an inhibitor of other proteins such as ZAP-70 and 
JAK2 but at a much lower potency (IC50 >100µM and >50µM respectively). PP1 inhibits 
SFKs by interacting with the amino acid corresponding to Thr341 in c-Src, via interaction 
of a C3 phenyl ring, acting as an ATP competitive inhibitor (Liu et al., 1999). PP1 has since 
been extensively studied and identified as a moderate inhibitor of a plethora of proteins 
including p38, CSK (Bain et al., 2003), PDGF receptors, RET-derived oncogenes 
(Carlomagno et al., 2002), c-Kit and Bcr-Abl (Tatton et al., 2003). Due to its lack of 
specificity, PP1 is not used therapeutically but is a useful tool in identifying whether SFKs 
are involved in cellular processes in vitro. More potent and specific SFK inhibitors such as 
Dasatinib and Saracatinib are now being investigated. 









Dasatinib is a small molecular inhibitor (Figure 5-2) that targets Bcr-Abl, SFKs and c-Kit 
(IC50 <1nM, 0.8nM and 79nM respectively) and has been FDA approved for the treatment 
of Philadelphia chromosome-positive chronic myeloid leukaemia (CML) and acute 
lymphoblastic leukaemia (ALL) (FDA, 2010a). MDA-MB-231 cells have been observed to 
be sensitive to dasatinib with treatment decreasing cell proliferation, migration and 
invasion (Tryfonopoulos et al., 2011). Dasatinib has also been used in a number of phase 
II clinical trials in patients with advanced breast cancer, with partial responses and 
disease stabilisation being reported in some patients (Mayer et al., 2011). It has also been 
shown to significantly decrease growth, survival and colony formation in thyroid cancer 
cell-lines (Chan et al., 2012).  








Saracatinib (AZD0530) is another small molecular inhibitor (Figure 5-3) that 
targets Src and other SFKs (IC50 2.7nM and 4-10nM respectively); it is also capable of 
inhibiting Bcr-Abl and EGFR but at much lower potencies (IC50 30nM and 66nM 
respectively). Saracatinib has been observed to inhibit growth and invasion of four 
thyroid cancer cell-lines in both two- and three-dimensional culture (Schweppe et al., 
2009). Studies in MCF-7 cells have also shown saracatinib to have a synergistic effect with 
tamoxifen, decreasing growth and cell anchorage (Herynk et al., 2006). However phase II 
clinical trials of Saracatinib in patients with hormone receptor-negative metastatic breast 
cancer, no patients displayed evidence of stable disease or partial response when the 
drug was used in isolation over a 6 month period (Gucalp et al., 2011).  
 




Figure 5-3. The chemical structure of saracatinib. Taken from the SelleckChem website 
(http://www.selleckchem.com/products/AZD0530.html). 
 
5.1.3 Focal Adhesion Kinase (FAK) 
Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase that is a critical 
substrate of Src and the cellular functions of the two kinases are closely linked (Schweppe 
et al., 2009). FAK plays an important role in signal transduction pathways that are 
initiated at sites of integrin-mediated cell adhesions and by growth factor receptors. Like 
Src, FAK is a key regulator of survival, proliferation, migration and invasion and has been 
seen to have increased activity in many cancers including breast cancer (van Nimwegen 
and van de Water, 2007).  
5.1.3.1 PF573228 
PF573228 is a potent FAK inhibitor (IC50 4nM) (Figure 5-4) that is ~50 to 250-fold more 
selective for FAK than its other target kinases Pyk2, CDK1/7 and GSK-3β. PF573228 binds 
to FAK in its ATP-binding domain and prevents FAK autophosphorylation on Y397. 
Although PF573228 has not been reported to have any effect on the growth of MCF-7 
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cells, it has been found to decrease adhesion and migration of MCF-7 cells resistant to 
tamoxifen and fulvestrant (Hiscox et al., 2011). 
 




The aim of the work carried out in this chapter was to establish whether the inhibition of 
SFK could decrease levels of phosphorylated PBF and enhance radioiodide uptake in 
breast cancer in a similar manner to that witnessed in thyroid cancer (Smith et al., 2013). 
The inhibition of FAK was also investigated to determine whether SFK inhibition directly 
affects PBF or whether it may be through downstream kinases such as FAK. Specific SFK 
inhibitors that have been approved for clinical use were investigated with the intention of 
identifying a compound that has the potential to maximise radioiodine therapy in breast 
cancer patients. The effect of SFK inhibition on PBF phosphorylation and NIS function was 
determined in MCF-7 and MDA-MB-231 breast cancer cells. 
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5.2 Materials and Methods 
5.2.1 Cell Culture 
MCF-7 and MDA-MB-231 cells were maintained as described in 2.1.2 with stably 
transfected MCF-7 cells being cultured in medium containing G418 (1 mg/ml) and 
lentivirally-transduced MDA-MB-231 cells being cultured in medium containing blasticidin 
(15 µg/ml). All cell lines were seeded at 30,000 cells per well in a 24 well plate for 
radioiodide uptake and at 150,000 and 200,000 cells per well in a 6 well plate for 
fluorescence immunocytochemistry and protein extraction respectively. 
 
5.2.2 Drug Treatments 
MCF-7 cells were treated with ATRA and dexamethasone as described in section 3.2.3 at 
100nM and 1µM respectively. Cells were cultured with ATRA and dexamethasone for 48 
hours prior to harvesting or treatment with 125I. Src Family Kinase inhibitors PP1 (Tocris, 
Bristol, UK), Dasatinib (Selleck Chemicals, Houston, Texas, USA) and Saracatinib (Selleck 
Chemicals) and the FAK inhibitor, PF573228 (Tocris) were dissolved in DMSO to a stock 
concentration of 10mM. 
 
5.2.3  Transfection 
Transfection was performed as described in 2.2.3. WT PBF-HA and NIS-MYC (kindly gifted 
by Dr Vicki Smith) in pcDNA3.1 (+) vectors were transfected into MCF-7 and MDA-MB-231 
cells in 6 well plates for use in fluorescence immunocytochemistry and Western blotting. 
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For radioiodide uptake cells were seeded in 24 well plates and transfected with untagged 
PBF and NIS-MYC. 
 
5.2.4 Radioiodide uptake 
Radioiodide uptake was performed as described in 2.7. Transfection and drug treatments 
were performed 48 and 24 hours respectively before the addition of 125I to cells. 
 
5.2.5  Western Blotting 
Protein extraction and Western blotting were performed as described in 2.3.1 and 2.3.2 
respectively. Cells were treated with sodium pervanadate prior to harvesting to allow the 
detection of pY174 PBF. Antibodies used were anti-pY174 PBF antibody (Covalab) (Smith 
et al., 2013), anti-PBF (Eurogentec) (Smith et al., 2009), anti-phospho-Src (Y418) (Abcam), 
anti-Src (Cell Signalling) and β-actin (Sigma-Aldrich)(refer to section 2.8). Appropriate 
secondary antibodies were used. 
 
5.2.6 Fluorescence immunocytochemistry 
Fluorescence immunocytochemistry was performed as described in 2.4. Antibodies used 
include anti-HA tag (rabbit) (1:100) (Santa Cruz) and anti-Myc tag (1:750) (Cell Signalling). 
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5.2.7 BrdU Proliferation Assays 
The BrdU assays were performed as described in section 4.2.11. Cells were seeded at 
2,500 per well in a 96 well plate for 24 hours prior to the assay being performed.  
 
5.2.8 RNA extraction and qRT-PCR 
RNA extraction, reverse transcription and qRT-PCR were performed as described in 2.5 
and 2.6. Expression of PBF was assessed using the PBF TaqMan® Gene Expression Assay 
(Hs01036322_m1 )(Life Technologies). Expression of NIS was assessed using custom-
made primers and probe (Table 3-1). 
 
5.2.9 Statistics 
Data were analysed using Sigma Plot (SPSS Science Software UK Ltd). The student's t-test 
was utilised to compare data between two groups whereas the one-way ANOVA was 
used to compare more than two groups of parametric data with significance taken at 
p<0.05 for both.  




5.3.1 PP1 decreases levels of phosphorylated PBF in breast cancer cell 
lines 
PP1 has previously been demonstrated to inhibit the phosphorylation of PBF in thyroid 
cancer cells at a concentration of 2µM (Smith et al., 2013). To determine whether PP1 
was capable of inhibiting PBF phosphorylation in breast cells a dose response was 
performed for 24 hours in both MCF-7 and MDA-MB-231 cells. PP1 decreased pY174 PBF 
levels in a dose-dependent manner in both cell lines. In MCF-7 cells phosphorylation of 
PBF was completely abolished using 2µM of PP1 (Figure 5-5A), as previously 
demonstrated in thyroid cancer. Concentrations lower than 2µM were not capable of 
fully inhibiting the phosphorylation of PBF (Figure 5-5A). In MDA-MB-231 cells the 















Figure 5-5. PP1 inhibits the phosphorylation of PBF. (A) MCF-7 cells and (B) MDA-MB-231 
cells were treated with varying doses of PP1 (0nM-2000nM) for 24 hours before protein 
harvesting. Western blots were probed for pY174 PBF and total PBF with β-actin used a 






































































5.3.2 PP1 rescues radioiodide uptake in breast cancer cell lines 
PP1 has previously been demonstrated to restore radioiodide uptake in PBF expressing 
thyroid cancer cell-lines. PBF has already been demonstrated to reduce radioiodide 
uptake in breast cancer cell-lines including MCF-7 and MDA-MB-231 cells, so it was of 
interest to establish whether inhibition of SFK could restore radioiodide uptake in these 
cell-lines. Exogenous expression of PBF decreased radioiodide uptake by 25% (p=0.0008) 
in NIS-MYC co-transfected MCF-7 cells incubated with vehicle only (DMSO) for 24 hours 
(Figure 5-6A). However when PBF expressing cells were treated with 2µM PP1 for 24 
hours, radioiodide uptake was restored with a significant increase of 23.5% compared to 
vehicle only treated cells (p= 0.011) (Figure 5-6A). The uptake observed in the presence of 
PBF and PP1 was comparable to the uptake of MCF-7 cells lacking exogenous PBF (6.7% 
difference, p=0.69) (Figure 5-6A).  
 PP1 also had a similar effect on MDA-MB-231 cells. Exogenous expression of 
PBF reduced radioiodide uptake by 32% (p=0.008) in vehicle only treated cells (Figure 
5-6B). Treatment with PP1 lead to a significant increase in radioiodide uptake in these 
cells (41%, p=0.0005) (Figure 5-6B). PP1 treatment also displayed a trend of increasing 
radioiodide uptake in NIS-MYC expressing cells compared to vehicle only treatment 
however the effect was not significant (p=0.056). MCF-7 cells treated with ATRA and 
dexamethasone were also assessed to evaluate whether this effect was exclusive to cells 
exogenously expressing NIS. Expression of PBF decreased radioiodide uptake by 22% 
(p=0.03) compared to empty vector in vehicle only treated cells (Figure 5-6C). Treatment 
with PP1 significantly increased radioiodide uptake in PBF transfected cells by 56% 
(p=0.007) (Figure 5-6C).  




Figure 5-6. PP1 restores radioiodide uptake in breast cancer cells. (A) MCF-7 and (B) MDA-
MB-231 cells were transfected for 48 hours with empty vector (VO) + NIS-MYC or NIS-MYC 
+ PBF and treated with 2µM PP1 for 24 hours prior to the addition of 125I. (C) MCF-7 cells 
were stably transfected with empty vector (VO) or PBF and treated with ATRA and 
dexamethasone 48 hours prior to the addition of 125I. n=3 with 4 replicates in each n for all 
experiments. *=p<0.05.**=p<0.01. ***=p<0.001. 
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5.3.3 Dasatinib and Saracatanib decrease pY174 PBF levels in a dose-
dependent manner 
With PP1 being capable of inhibiting the phosphorylation of PBF and restoring 
radioiodide uptake in breast cancer cells, it was of interest to establish whether more 
specific and therapeutically relevant SFK inhibitors can act in the same way. To test this, 
MCF-7 and MDA-MB-231 cells were treated with dasatinib and saracatinib at 
concentrations ranging from 1nM - 2µM for 24 hours. A time response experiment was 
also performed varying the treatment time from 2 - 48 hours (data not shown) over the 
differential dose levels, with 24 hours identified as the most optimal for the inhibition for 
pY418 Src. 
 Dasatinib reduced the levels of pY418 Src at concentrations as low as 10nM in 
both cell-lines and fully abolished phosphorylation at 10nM in MCF-7 cells (Figure 5-7A). 
Dasatinib was the more effective inhibitor of PBF phosphorylation with pY174 PBF levels 
being almost completely abolished at 1nM in both MCF-7 and MDA-MB-231 cells (Figure 
5-7).  





Figure 5-7. Dasatinib inhibits the phosphorylation of PBF. (A) MCF-7 cells and (B) MDA-
MB-231 cells were treated with varying doses of dasatinib (0nM-2000nM) for 24 hours 
before protein harvesting. Western blots were probed for pY174 PBF, pY418 Src and total 
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Saracatinib completely inhibited pY418 Src at concentrations as low as 10nM in MDA-MB-
231 cells (Figure 5-8B). Saracatinib was not as potent at inhibiting PBF phosphorylation as 
dasatinib, with phosphorylation of Y174 not being completely eradicated below 
concentrations of 100nM (Figure 5-8).  
 
Figure 5-8. Saracatinib inhibits the phosphorylation of PBF. (A) MCF-7 cells and (B) MDA-
MB-231 cells were treated with varying doses of saracatinib (0nM-2000nM) for 24 hours 
before protein harvesting. Western blots were probed for pY174 PBF, pY418 Src and total 
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5.3.4 Inhibiting FAK has no effect on pY174 PBF levels 
To assess whether the inhibition of SFK has a direct effect on the phosphorylation of PBF 
or whether the effect is due to lack of activation of downstream targets such as FAK, 
inhibition of FAK was assessed. To investigate this MCF-7 and MDA-MB-231 cells were 
treated with a PF573228 at concentrations ranging from 1nM - 2µM for 24 hours.  
 Treatment with PF573228 did not reduce phosphorylated PBF levels until a 
concentration of 1µM was reached in MCF-7 cells. Even at concentrations as high as 2µM, 
phosphorylation of PBF could not be fully inhibited (Figure 5-9A). Although treatment 
with 1µM and 2µM did not fully abolish PBF phosphorylation in MCF-7 cells, treatment 
with these high concentrations caused a high level of cell death (data not shown). 
Treatment with PF573228 in MDA-MB-231 cells did not reduce pY174 PBF levels over the 
range of concentrations used (Figure 5-9B). For further experiments a concentration of 
100nM PF573228 was utilised as this was the highest concentration that did not 
compromise cell number in both cell-lines (data not shown).  






Figure 5-9. Inhibition of FAK does not significantly alter the phosphorylation status of PBF. 
(A) MCF-7 cells and (B) MDA-MB-231 cells were treated with varying doses of PF573228 
(0nM-2000nM) for 24 hours before protein harvesting. Western blots were probed for 
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5.3.5 Effect of drugs on PBF and NIS mRNA expression 
To assess whether inhibition of SFK affected PBF or NIS expression, qRT-PCR was 
performed and relative expression of NIS and PBF determined in both MCF-7 and MDA-
MB-231 cells. Treatment of MCF-7 and MDA-MB-231 cells with SFK or FAK inhibitors did 
not significantly alter PBF expression (Figure 5-10). Treatment with the SFK and FAK 
inhibitors did not alter NIS expression in a significant manner in either cell-line (Figure 
5-11).   




Figure 5-10. Inhibiting Src and FAK has no significant effect on PBF expression levels. (A) 
MCF-7 and (B) MDA-MB-231 cells were treated with DMSO, 1nM dasatinib, 10nM 
Saracatinib or 100nM PF573228 for 24hours prior to harvesting RNA. Expression levels of 
PBF mRNA were quantified using qRT-PCR. Expression levels normalised to DMSO. All 








DMSO 13.08 0.422 - -
Dasatinib 12.39 0.663 1.748 0.439
Saracatinib 12.73 0.494 1.356 0.627








DMSO 11.37 0.146 - -
Dasatinib 11.07 0.448 1.424 0.385
Saracatinib 12.18 0.459 0.664 0.299
PF573228 12.07 0.364 0.690 0.649
A 
B 




Figure 5-11. Inhibiting Src and FAK has no significant effect on NIS expression levels. (A) 
MCF-7 and (B) MDA-MB-231 cells were treated with DMSO, 1nM dasatinib, 10nM 
Saracatinib or 100nM PF573228 for 24 hours prior to harvesting RNA. Expression levels of 
NIS mRNA were quantified using qRT-PCR. Expression levels normalised to DMSO. All 








DMSO 18.65 0.197 - -
Dasatinib 18.78 0.278 0.916 0.735
Saracatinib 18.29 0.379 1.278 0.468








DMSO 17.18 0.819 - -
Dasatinib 16.17 0.828 1.389 0.716
Saracatinib 17.48 0.789 0.815 0.806
PF573228 17.91 0.533 0.604 0.533
A 
B 
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5.3.6 Cell proliferation is not affected by Src or FAK inhibition 
The effects of dasatinib, saracatinib and PF573228 on cell proliferation were assessed 
using BrdU assays. The use of dasatinib or saracatinib did not significantly alter the 
proliferation from control DMSO treatment in either cell-line across any of the 
transfections (Figure 5-12). Similarly PF573228 inhibition of FAK did not significantly alter 
cellular proliferation in any of the transfections and cell lines tested (Figure 5-12). For the 
BrdU experiments and all further experiments, 1nM dasatinib was utilised as this was the 
concentration of dasatinib that effectively inhibited PBF phosphorylation in both MCF-7 
and MDA-MB-231 cells. For Saracatinib a concentration of 10nM was utilised as this was 
the lowest concentration that displayed a marked reduction in PBF phosphorylation in 
both cell-lines. A concentration of 100nM PF573228 was MCF-7 and MDA-MB-231 cells 
(data not shown). 
  





Figure 5-12. Inhibition of Src and FAK does not significantly affect cell proliferation. MCF-7 
(A) and MDA-MB-231 (B) cells were transiently transfected with empty vector (VO), PBF 
and NIS-MYC for 48 hours and treated with DMSO, 1nM dasatinib, 10nM saracatinib or 
100nM PF573228 for 24 hours prior to addition of BrdU labelling solution. n=3 with 3 
replicates in each n. 
A 
B 
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5.3.7 Dasatinib and Saracatanib restore radioiodide uptake 
Both dasatinib and saracatinib can inhibit the phosphorylation of PBF at concentrations 
as low as 1nM and 10nM respectively in breast cancer cells. Neither drug was capable of 
significantly increasing NIS expression in both MCF-7 and MDA-MB-231 cells so it was of 
great interest to establish whether the drugs could increase radioiodide uptake through 
the post-translational regulation of NIS. In MCF-7 cells, treatment with 1nM dasatinib and 
10nM saracatinib restored radioiodide uptake in cells exogenously expressing PBF (Figure 
5-13A). In DMSO treated cells, PBF expression reduced radioiodide uptake by 33% 
(p=0.002). Treatment with 1nM dasatinib increased uptake in PBF transfected cells by 
65% (p= 0.038) (Figure 5-13A). This restoration of radioiodide uptake was also observed 
with treatment with 10nM saracatinib where there was an increase of 28% (p=0.021) 
compared to DMSO treatment) (Figure 5-13A). Treatment with neither dasatinib nor 
saracatinib could increase radioiodide uptake in MCF-7 cells not transfected with PBF 
(Figure 5-13A).  
 In MDA-MB-231 cells, exogenously expressed PBF significantly decreased 
radioiodide uptake by 33% (p=0.0016) (Figure 5-13B). Treatment with 1nM dasatinib 
rescued radioiodide uptake with an increase of 84% (p=0.0016) compared to DMSO 
treated PBF transfected cells and a difference of 23% (p=0.0355) compared to DMSO 
treated MDA-MB-231 cells lacking PBF transfection (Figure 5-13B). Again, saracatinib 
produced very similar results with an increase of 64% (p=0.049) compared to DMSO 
treated cells (Figure 5-13B). As observed in the MCF-7 cells, neither treatment could 
significantly influence radioiodide uptake in cells lacking exogenous PBF expression. 




Figure 5-13. Dasatinib and Saracatinib restore radioiodide uptake in breast cancer cells. 
(A) MCF-7 and (B) MDA-MB-231 cells were transfected for 48 hours with empty vector 
(VO) + NIS-MYC or NIS-MYC + PBF and treated with 1nM dasatinib or 10nM Saracatinib 
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5.3.8 Inhibiting FAK has differing effects on radioiodide uptake 
Although inhibition of FAK did not appear to decrease PBF phosphorylation in breast 
cancer cells, it was of interest to see if it had any effect on radioiodide uptake. In MCF-7 
cells, PBF reduced radioiodide uptake by 34% (p=0.0015) in DMSO treated cells (Figure 
5-14A). Treatment with 100nM PF573228 restored radioiodide uptake in PBF expressing 
MCF-7 cells, increasing radioiodide uptake by 70% (p=0.001) compared to DMSO treated 
cells with a 13% difference from DMSO treated MCF-7 cells lacking PBF transfection 
(Figure 5-14A). The effect of FAK inhibition on radioiodide uptake in MCF-7 cells was in 
stark contrast to that witnessed with MDA-MB-231 cells as treatment with 100nM 
PF573228 did not restore radioiodide uptake in MDA-MB-231 cells (Figure 5-14B). PBF 
transfection reduced radioiodide by 33% (p=0.00218) in DMSO treated cells and there 
was no significant difference compared to PF573228 treated cells (10% difference, 














Figure 5-14. Inhibition of FAK restores radioiodide uptake in MCF-7 breast cancer cells. (A) 
MCF-7 and (B) MDA-MB-231 cells were transfected for 48 hours with empty vector (VO) + 
NIS-MYC or NIS-MYC + PBF and treated with 100nM PF573228 for 24 hours prior to the 
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5.3.9 Saracatinib increase radioiodide uptake in cells with endogenous 
expression of PBF 
To assess whether tyrosine kinase inhibitors (TKIs) could increase radioiodide uptake in 
MCF-7 cells possessing only endogenous PBF expression, MCF-7 cells were treated with 
ATRA and dexamethasone and TKI/FAK inhibitors. Treatment with ATRA and 
dexamethasone significantly increased radioiodide uptake (p<0.05) across all treatments 
compared to vehicle only (VeO) MCF-7 cells (treated with ethanol and DMSO). In ATRA 
and dexamethasone treated cells, treatment with PP1 and PF573228 did not increase 
radioiodide uptake compared to DMSO treated cells. Treatment with dasatinib had a 
trend towards increased radioiodide uptake with a 1.57-fold increase in uptake but was 
not statistically significant. Treatment with saracatinib significantly increased radioiodide 
uptake compared to DMSO treated cells with a 2-fold increase in uptake. 
 
Figure 5-15. TKIs can increase radioiodide uptake in cells with endogenous PBF expression. 
MCF-7 cells were transfected for 48 hours with VeO (ethanol and DMSO) or ATRA and 
dexamethasone for 48 hours and treated with DMSO, 2µM PP1, 1nM dasatinib, 10nM 
saracatinib or 100nM PF573228 for 24 hours prior to the addition of 125I. n=3 with 4 










































































5.4.1 Inhibition of SFK inhibits PBF phosphorylation and restores 
radioiodide uptake in breast cancer cells 
The SFK kinase inhibitor PP1 has previously been demonstrated to inhibit the 
phosphorylation of PBF in thyroid cancer cell-lines (Smith et al., 2013). Both Src and Lyn 
are documented to be overexpressed in thyroid cancer, with limited expression of other 
members of the SFK family (Chan et al., 2012). Although Lyn is commonly overexpressed 
in thyroid cancers, evidence suggests that Src is the dominant SFK in thyroid carcinoma 
(Chan et al., 2012). With differential expression of SFK in breast cancer, it was important 
to assess the ability of PP1 and other SFK inhibitors to induce radioiodide uptake in breast 
cancer cells to establish whether targeting SFK prior to 131I delivery could be a potential 
therapy in this disease. 
5.4.1.1 PP1  
In thyroid cancer cells PP1 was capable of inhibiting the phosphorylation of PBF at a 
concentration of 2µM (Smith et al., 2013). The data generated using PP1 in breast cancer 
cells was comparable to that in thyroid cancer cells with PBF phosphorylation being 
inhibited at concentrations of 2µM in MCF-7 cells and 100nM in MDA-MB-231 cells. Use 
of PP1 in breast cancer cells not only inhibited phosphorylation in both cell-lines at 2µM 
but also decreased NIS staining in intracellular vesicles and rescued radioiodide uptake 
(Smith et al., 2013). Again, this is comparable to the data generated in primary thyroid 
cells where treatment with 2µM PP1 rescued the reduction in radioiodide uptake 
observed with exogenous PBF expression.  
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Although PP1 is a potent SFK inhibitor, it has limited specificity and can target multiple 
kinases, so it was important to assess more specific inhibitors to determine SFK role in 
PBF phosphorylation. 
5.4.1.2 Dasatinib and Saracatinib 
 Currently, there is no published evidence to suggest that the SFK inhibitors dasatinib or 
saracatinib can directly or indirectly influence NIS activity in any cell line or disease. In this 
chapter it was demonstrated that both dasatinib and saracatinib can inhibit PBF 
phosphorylation and ultimately rescue radioiodide uptake in cells overexpressing PBF. 
Dasatinib was observed to inhibit PBF phosphorylation at concentrations as low as 1nM in 
both MCF-7 and MDA-MB-231 cells, whilst a slightly increased concentration of 10nM 
was required for saracatinib to have the same effect. Not only did both inhibitors reduce 
PBF phosphorylation, they were also capable of reversing PBF's repression of radioiodide 
uptake. At the concentrations utilised in these experiments, neither compounds altered 
the proliferation of either MCF-7 or MDA-MB-231 cells across a range of different 
transfections, or significantly altered the expression of PBF or NIS in either cell-line. 
Saracatinib was also capable of significantly increasing radioiodide uptake in MCF-7 cells 
with only endogenous PBF expression and ATRA and dexamethasone boosted NIS 
expression. This effect could be to due to saracatinib increasing the levels of NIS 
expression within MCF-7 cells as seen by qRT-PCR.  
 Utilisation of these drugs to increase radioiodide uptake is potentially 
therapeutically important. Dasatinib already has FDA clearance for leukaemia treatments 
and saracatinib is currently being appraised in several clinical trials. Dasatinib was 
deemed to be tolerable for patients allowing a dose of 180 mg once daily over an 
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extended period (FDA, 2010b). In the proposed treatment regime for radioiodine therapy 
for breast cancer patients, dasatinib would be used as a pre-treatment for the therapy, 
only used in the days prior to radioiodine therapy to boost NIS activity and increase 
radioiodide uptake into breast cancer cells. The advantage of this short period of 
treatment with dasatinib is that patients are unlikely to experience the side-effects 
associated with prolonged treatment. 
 
5.4.2 FAK does not modulate PBF phosphorylation 
Previous mass spectrometry work identified FAK as a potential binding partner for PBF 
(unpublished data from the McCabe Group, Birmingham, UK), although the relationship 
between FAK and PBF has not been further investigated. From the data presented in this 
chapter it is evident that FAK does not modulate the phosphorylation status of PBF in 
breast cancer cells. Assessment of concentrations of PF573228 up to 2µM did not abolish 
pY174 PBF levels as determined by Western blotting and FAK inhibition was also 
incapable of restoring radioiodide uptake in MDA-MB-231 cells.  
 SFK and FAK are well-documented to have a complex relationship and one 
potential explanation for the discrepancies observed between the two cells lines may be 
due to the differential expression and different activation pathways of both SFKs and FAK 
in MCF-7 and MDA-MB-231 cells. The initiation of FAK activation involves FAK 
autophosphorylation at Y397, which creates a high-affinity SH2-dependent binding site 
for Src (Schaller et al., 1994). Src then further phosphorylates FAK at five tyrosine 
residues (Y407, Y576, Y577, Y861 and Y925) (Calalb et al., 1995; Calalb et al., 1996). In 
turn this leads to the activation of Src through the formation of a bipartite kinase 
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complex (Schaller et al., 1994). It could be hypothesised from the data in this chapter that 
inhibition of FAK may lead to indirect inhibition of Src in MCF-7 cells, whereas in MDA-
MB-231 cells activation of Src may be independent of FAK. This is potentially supported 
by the fact that FAK expression has also been positively associated with Her2 expression 
in breast cancer (Schmitz et al., 2005). MCF-7 cells are known to have a positive Her2 
status and so potentially have increased FAK levels compared with Her2 negative MDA-
MB-231 cells. Another potential hypothesis is that although FAK inhibition can indirectly 
inhibit Src in both cell lines, Src may not be the dominant SFK in MDA-MB-231 cells, with 
PBF phosphorylation being modulated by a different SFK. However this is largely 
speculation and substantial further work would be needed to establish the complex 
mechanisms involved in the interplay between Src and FAK and their roles in PBF 
phosphorylation and modulation of radioiodide uptake. 
 
Overall these data suggest that PBF is phosphorylated by members of the SFK family. 
Inhibition of the SFK family can reduce PBF phosphorylation which in turn reduces NIS 
mislocalisation and restores radioiodide uptake. Dasatinib and saracatinib appear to be of 
potential therapeutic value in breast cancer with both appearing to restore PBF's 
reduction in radioiodide uptake. Both Src (Smith et al., 2013) and Lyn (unpublished data) 
have the ability to bind to PBF in vitro, thus in order to further understand the 
mechanism of PBF phosphorylation in the hope of exploiting it, it is fundamental to 
establish which SFK is responsible for PBF phosphorylation.  
 





CHAPTER 6  - SRC REGULATES/POTENTIALLY 
PHOSPHORYLATES PBF 
  




The data presented so far in this thesis has provided strong evidence that the 
phosphorylation of PBF is critical for its interaction with NIS. PBF phosphorylation can be 
inhibited by SFK inhibitors. In thyroid cancer Src kinase is the dominant SFK with the only 
other family member expressed being Lyn (Chan et al., 2012). As SFKs are differentially 
expressed in breast cancer, it is important to understand which SFK is responsible for the 
phosphorylation of PBF within the disease. 
 
6.1.1 Expression of SFK in breast cancer 
In breast cancer, all 8 SFK family members have been shown to be expressed with Src and 
Lyn having the highest expression and being associated with poor prognosis and clinical 
outcome (Elsberger et al., 2010). Src was found to be primarily cytoplasmic with some 
nuclear and membranous expression in breast cancer whereas Lyn was localised mainly 
in the cytoplasm and nucleus with limited plasma membrane staining (Elsberger et al., 
2010). Lck is the only SFK member that has been associated with ER status, with ER 
negative tumours having the highest expression levels. However, Src expression was 
significantly associated with decreased disease-specific survival in ER-positive breast 
cancer patients compared to those with ER-negative tumours (Elsberger et al., 2010). Src 
has also been linked to high tumour grade and reduced recurrence-free survival in DCIS 
(Wilson et al., 2006). 
 
 




Src was the first characterised member of the SFK family, and is as such the most studied. 
The human Src protein is 536 amino acids in length and has a similar structure to all SFK, 
being comprised of a myristoylation site, a unique region, an SH3 and SH2 domain 
followed by a protein-tyrosine kinase SH1 domain (Waksman et al., 1993; Xu et al., 1999; 
Yu et al., 1992) (Figure 6-1). During biosynthesis, the N-terminal methionine is removed 
resulting in an N-terminal glycine that becomes myristoylated (Peseckis et al., 1993) 
(discussed further in Chapter 7) (Figure 6-1). Chicken and avian Rous sarcoma viral Src (v-
Src) have also been extensively investigated, sharing 99.6% and 95.8% homology with 
human c-Src respectively (Roskoski, 2015). Src contains two tyrosine residues whose 
phosphorylation is critical to regulation of the protein: Y418 and Y529. Tyrosine-Y529 
(Y527 in chicken Src) is an autoinhibitory phosphorylation site whereas Y418 is within the 
kinase (SH1) domain and phosphorylation of this residue results in a kinase with full 
catalytic activity (Nada et al., 1991; Smart et al., 1981). In vivo, Src kinases are 
phosphorylated on either Tyr 418 (in their active state) or Tyr 529 (in the inactive state) 
(Figure 6-1).  
 
Figure 6-1. A schematic diagram detailing the structure of Src. Src is comprised of unique 
region, Src homology 3 and 2 domains (SH3/2), a hinge region and a catalytic kinase 
domain. N-terminal myristoylation is illustrated along with important pY motifs that are 
phosphorylated in the inactive (pY529, red) and active (pY418, green) kinase.  
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 Src is a non-receptor tyrosine kinase that can be activated by cytoplasmic proteins 
including FAK and Crk-associated substrate (CAS). Interaction with proteins such as FAK 
disrupts the intermolecular interactions within Src, altering the conformation and leading 
to Src activation (Figure 6-2). Src is expressed ubiquitously throughout many human 
tissues and has been associated with many cellular processes including proliferation, 
differentiation, survival, adhesion and migration. Many cancers have been observed to 
have increased Src expression or activity due to overexpression or deregulation of 
upstream growth factor receptors such as EGFR or HER2 (Luttrell et al., 1994).  
 
Figure 6-2. The activation of Src. In the inactive conformation (the left panel), the 
phosphorylated Y529 interacts with the SH2 domain, positioning the SH3 domain to 
interact with the linker between the hinge region between the SH2 and SH1 domain. The 
middle panel illustrates the mechanisms by which Src can be activated with the right 
panel depicting activated Src. Adapted from Martin, 2001. 
 
 Src kinase activity is approximately 4-20 fold higher in breast tumours compared 
to normal breast tissue (Egan et al., 1999; Rosen et al., 1986), although overexpression of 
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found to be upregulated in 95% of triple negative (TN) samples and 84% of other breast 
cancer types, with TN tumours having increased membranous expression of Src, where 
active Src was localised within peripheral membrane-associated focal adhesions 
(Tryfonopoulos et al., 2011). Src has a fundamental role in signalling and cross-talk 
between growth-promoting pathways known to be active in breast cancer such as the ER 
and EGFR family signalling pathways. Expression of Src is required for EGF-induced 
mitogenesis (Wilson et al., 1989) and for the induction of mammary tumours using the 
polyomavirus middle T oncogene (Guy et al., 1994). In vitro, hypoxia has been found to 
activate Src resulting in upregulation of vascular endothelial growth factor (VEGF), a 
signalling molecule fundamental for malignant angiogenesis (Mukhopadhyay et al., 1995). 
Src has also been deemed a pivotal protein in cell migration with Src suppression 
resulting in significantly reduced cell migration, attachment and spread in MCF-7 cells 
(Gonzalez et al., 2006). Expression of phosphorylated Src and STAT3 have also been 
correlated with invasive carcinoma, with levels being significantly higher in invasive 
tumours compared to non-neoplastic tissue (Diaz et al., 2006). Src has also been 
identified as part of a common signalling axis in trastuzumab (Herceptin) resistance in 
breast cancer (Zhang et al., 2011). 
 As aforementioned in chapter 5, several Src and SFK inhibitors are being 
investigated in the treatment of breast cancer. Phase I and II clinical trials are on-going to 
assess dasatinib within the disease, along with a trial to specifically assess the potential of 
dasatinib as a treatment for in breast cancer bone metastasis (Finn, 2008; Mitri et al., 
2016). However, a gatekeeper mutation has been identified in Src that leads to a 
dasatinib-resistant, constituently active form of the kinase (Azam et al., 2008). 
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6.1.3 Src Gatekeeper residue (T341) 
Many small molecule inhibitors of kinases target the ATP binding pocket of the protein 
and dasatinib is no exception, functioning by competing for binding to this site with ATP. 
Threonine-341 (T341) in Src (T338 in chicken Src) is often referred to as the gatekeeper 
residue within the kinase due to the size of the residue's side chain governing the volume 
and shape of the ATP-binding pocket and thereby determining the size of the ATP-
competitive ligands that can bind.  
 The Src protein kinase domain is comprised of a small amino-terminal lobe and 
large carboxy-terminal lobe that form a cleft that serves as a docking site for ATP. The 
larger lobe can exist in two forms; an extended open conformation when Src is activated 
and a closed conformation when inactive. Within the activation segment of the kinase 
domain there are three key amino acids DFG (Asp-Phe-Gly). When the kinase is dormant, 
the aspartate side chain of the conserved DFG-sequence faces away from the active site 
(termed the DFG-Asp out conformation). When Src is activated the aspartate side faces 
into the ATP-binding pocket (DFG-Asp in conformation) and coordinates a Mg2+ ion 
(Hubbard, 1997; Hubbard et al., 1994). There are two major classes of reversible ATP-
competitive protein kinase inhibitors: type I and type II. Dasatinib is a type I inhibitor 
binding to the DFG-Asp in kinase conformation (Getlik et al., 2009)(Figure 6-3). Dasatinib 
interacts with A296 and L396 and forms hydrophobic contacts with Y343, T341, M339 
and V284 (Figure 6-3). T341 has been deemed the gatekeeper molecule, with mutation of 
the residue to isoleucine or a bulkier amino acid stabilising a 'hydrophobic spine' which 
further stabilises Src in an active conformation (Figure 6-4). Mutation to T341I Src not 
only results in a constituently active form of Src but also causes significant steric 
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hindrance from the presence of a bulkier side chain that is unable to form hydrophobic 
bonds with small-molecule inhibitors creating a dasatinib resistant form of the kinase 
(Azam et al., 2008).  
 
 
Figure 6-3. Crystal structure of the c-Src-dasatinib complex. Electron density map of 
dasatinib bound to the ATP-pocket of the active DFG-Asp in Src. Src is shown in grey with 
dasatinib in red with chicken Src nomenclature for amino acid numbering. Taken from 
Getlik et al., 2009. 




Figure 6-4. The hydrophobic spine in active and inactive Src kinases. (A) Crystal structure 
T341I Src bound to ATP. The residues Leu328, Met317, Phe408 and His387, which 
constitute the hydrophobic spine, are shown in blue. The gatekeeper isoleucine residue is 
shown in orange. The activation loop is shown in red. (B) The inactive conformation of WT 
Src, coloured as in (A). Adapted from Azam et al., 2008. 
 
 In vitro studies have shown that mutation of T341 in lung cancer cells rescued cell 
viability from dasatinib over a range of concentrations (Li et al., 2010). This effect has also 
been observed in thyroid cancer cells where expression of the gatekeeper mutant 
blocked the growth inhibitory effects of dasatinib, shifting the IC50 value from ~40 nmol/L 
to 1,200 nmol/L (Chan et al., 2012). Up to now, two mutations to T341 have been 
identified in the COSMIC database, a lung cancer sample with a T341R mutation (COSMIC 
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The aim of the work described in this chapter was to establish whether Src has a 
fundamental role in the phosphorylation of PBF in vitro. Thus far inhibition of SFK has 
been observed to decrease PBF phosphorylation and restore radioiodide uptake in PBF 
expressing cells. Both Src (Smith et al., 2013) and Lyn (unpublished data) can bind to PBF 
in thyroid cancer cells with the expression of other SFKs being limited in this disease 
(Chan et al., 2012). In breast cancer, all family members of the SFK are expressed 
(Elsberger et al., 2010) increasing the number of possible kinases that could be 
responsible for PBF phosphorylation. To maximise radioiodide uptake it is fundamental to 
establish which kinase is responsible for PBF phosphorylation in breast cancer with the 
hope of identifying a specific and potent inhibitor.  
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6.2 Materials and Methods 
6.2.1 Cell Culture 
MCF-7 and MDA-MB-231 cells were maintained as described in 2.1.2 with stably-
transfected MCF-7 cells cultured in medium containing G418 (1 mg/ml) and lentivirally-
transduced MDA-MB-231 cells cultured in medium containing blasticidin (15 µg/ml). All 
cell lines were seeded at 30,000 cells per well in a 24 well plate for radioiodide uptake 
and at 150,000 and 200,000 cells per well in a 6 well plate for fluorescence 
immunocytochemistry and protein extraction respectively. 
 
6.2.2 Drug Treatments 
MCF-7 cells were treated with 100nM ATRA and 1µM dexamethasone as described in 
section 3.2.3. In all combination treatments, an equal volume of ethanol and DMSO in cell 
media was used as a control. Cells were treated with dasatinib as described in 5.2.2 at a 
concentration of 10nM.  
 
6.2.3 Mutagenesis 
Mutagenesis was performed as described in 4.2.4. A pcDNA3.1 (+) vector containing WT 
Src (kindly gifted by Neil Sharma, University of Birmingham) was utilised to create a T341I 
mutant form of Src. The sequence for the forward and reverse mutagenesis primers for 
T341I Src (Sigma-Aldrich) (Table 6-1) were designed and manufactured as recommended 
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by the QuikChange II XL Site-directed mutagenesis kit. Mutated plasmid DNA was then 




5' GAG CCC ATT TAC ATC GTC ATC GAG TAC ATG AGC AAG GGG 3' 
T341I Src 
Reverse 
5' CCC CTT GCT CAT GTA CTC GAT GAC GAT GTA AAT GGG CTC 3' 
 
Table 6-1. Mutagenesis primers for T341I Src. The red letter signifies changes to the Src 
sequence intended for the creation of a mutant Src. 
 
6.2.4  Transfection 
Transfection was performed as described in 2.2.3. WT PBF-HA, Y174 PBF-HA (kindly gifted 
by Dr Vicki Smith), EEN/AAA PBF-HA, WT Src, Src T341I and EEN170-172AAA PBF-HA in 
pcDNA3.1 (+) vectors were transfected into MCF-7 cells in 6 well plates for use in 
fluorescence immunocytochemistry and Western blotting. For radioiodide uptake cells 
were seeded in 24 well plates and transfected with untagged forms of WT, EEN170-
172AAA and Y174A PBF. 
 
6.2.5 Fluorescence immunocytochemistry 
Fluorescence immunocytochemistry was performed as described in 2.4. Cells were 
treated with 100µM sodium pervanadate for 20 minutes prior to fixing to allow the 
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detection of pY418 Src. Antibodies used included anti-HA tag (mouse) (1:200) (Covance), 
anti-pY418 Src (rabbit) (1:50) (Abcam) and anti-Src (mouse) (1:100) (Abcam).  
 
6.2.6 Co-immunoprecipitation Assay (Co-IP) 
Co-IP was performed as described in 4.2.12. Cells were cultured in T75 flasks and 
transfected with Src and empty pcDNA3.1(+) vector, PBF-HA, EEN/AAA PBF-HA or Y174A 
PBF-HA. Protein was IP-ed with mouse anti-HA tag antibody (Covance) (7.5µl) overnight 
at 4°C with end-over-end rotation.  
 
6.2.7  Western Blotting 
Protein extraction and Western blotting were performed as described in sections 2.3.1 
and 2.3.2 respectively. Cells were treated with 100µM sodium pervanadate for 20 
minutes prior to harvesting to allow the detection of pY174 PBF. Antibodies used were 
anti-pY174 PBF antibody (Covalab) (Smith et al., 2013), anti-PBF (Eurogentec) (Smith et 
al., 2009), anti-phospho-Src (Y418) (Abcam), anti-Src (Cell Signalling) and β-actin (Sigma-
Aldrich)(refer to section 2.8). Appropriate secondary antibodies were used.  
 
6.2.8 Radioiodide uptake 
Radioiodide uptake was performed as described in 2.7. Transfection and drug treatments 
were performed 48 and 24 hours respectively before the addition of 125I to cells. 
 




Data were analysed using Sigma Plot (SPSS Science Software UK Ltd). The one-way 
ANOVA was used to compare groups of parametric data with significance taken at 
p<0.05.  




6.3.1 PBF colocalises with Src and pY418 Src 
Transient transfection of Src into MCF-7 cells resulted in Src expression within the 
cytoplasm and at the plasma membrane (Figure 6-5A) with activated pY418 Src locating 
primarily at the plasma membrane (Figure 6-5B). Co-transfection with PBF revealed 
colocalisation between Src and PBF primarily in cytoplasmic vesicles (depicted by 
localised yellow spots) with limited plasma membrane yellow (Figure 6-5A). pY418 Src 
that also appeared to colocalise with PBF in intracellular vesicles (Figure 6-5B). Co-
transfection of PBF and Src appeared to alter the subcellular localisation of Src increasing 
levels of cytoplasmic Src (Figure 6-5A). 
  
 





Figure 6-5. PBF colocalises with Src and pY418 Src. MCF-7 cells were co-transfected with 
empty pcDNA3.1(+) vector (VO) + Src or PBF-HA + Src. In A, Src is visualised using a rabbit 
anti-Src antibody in red and PBF-HA with a mouse anti-HA antibody in green. In B, pY418 
Src is visualised using a rabbit anti-pY418 Src antibody in red and PBF-HA visualised using 
a mouse anti-HA tag antibody in green. In all images nuclei are visualised in blue using 


























































































































































6.3.2 Src and PBF bind in breast cancer cells 
To assess whether Src and PBF bind in vitro, co-immunoprecipitation studies were 
performed by pulling down HA-tagged PBF and assessing the levels of bound Src. In MCF-
7 cells, binding was observed between WT PBF-HA and Src (Figure 6-6). Although the 
antibody staining was not particularly strong, there was evidence to suggest that WT, 
EEN/AAA and Y174A PBF were all capable of binding Src with little difference in the 
binding affinity (Figure 6-6).  
 
 
Figure 6-6. All forms of PBF bind to Src. MCF-7 cells were co-transfected with Src alongside 
empty pcDNA3.1(+) vector (VO), WT, EEN/AAA or Y174A PBF-HA for 48 hours prior to 
harvesting. In the Co-IP, proteins were pulled down using the HA antibody and probed 
with the Src antibody. Whole cell lysate was probed with HA, Src and β-actin as a loading 
control. n=2. 
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6.3.3 Exogenous Src increases levels of pY174 PBF 
To assess the effect of Src on the phosphorylation status of PBF, Src was transfected into 
MCF-7 and MDA-MB-231 cells and protein was extracted. Western blotting confirmed Src 
transfection to be successful in both cell lines through increased levels of both total Src 
and pY418 active Src (Figure 6-7). Exogenous Src expression also led to increased levels of 
pY174 PBF while levels of total PBF remained unchanged (Figure 6-7). 
 
Figure 6-7. Exogenous Src expression increases levels of pY174 PBF. MCF-7 and MDA-MB-
231 cells were transfected with empty pcDNA3.1(+) vector (VO) or Src for 48 hours prior to 
protein harvesting. pY174 PBF, total PBF, pY418 Src and total Src were detected with β-
actin used a loading control. n=3. 
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6.3.4 Exogenous Src decreases radioiodide uptake 
To assess whether exogenous Src affects the radioiodide uptake of breast cancer cells, 
ATRA and dexamethasone-treated MCF-7 cells stably transfected with empty pCI-neo 
vector, WT, EEN/AAA and Y174A PBF were then transiently transfected with Src or empty 
pcDNA3.1(+) vector. Exogenous Src was capable of significantly reducing radioiodide 
uptake across each of the stable cell lines compared to empty pcDNA3.1(+) vector 
transfected cells except for EEN/AAA PBF (Figure 6-8). Stable transfection of PBF reduced 
radioiodide uptake by 43% (p= 0.02) compared to control pCI-neo vector transfected cells 
and this was even further reduced in the presence of Src (33% decreased compared to 
PBF + empty pcDNA3.1(+) vector, p=0.045) (Figure 6-8). PBF stable transfection also 
reduced radioiodide uptake significantly compared to stable transfection with EEN/AAA 
and Y174A PBF (42% and 37% reduction, p=0.01 and p=0.02 respectively). Stable 
transfection of EEN/AAA PBF was unable to significantly reduce radioiodide uptake 
compared to empty pCI-neo vector stable transfection (3% reduction, p=0.8), with 
transfection of Src again not significantly reducing radioiodide uptake (21% reduction, 
p=0.15) (Figure 6-8). Y174A PBF stable transfection did not reduce significantly 
radioiodide uptake compared to stable transfection with empty pCI-neo vector (11% 
reduction, p=0.4) however transient transfection with Src did significantly decrease 
radioiodide uptake in Y174A PBF stable cells compared to Y174A PBF co-transfected with 
empty vector (29% reduction, p=0.0098) (Figure 6-8). 
 Transfection of PBF and Src was also capable of reducing radioiodide uptake 
compared to empty vector and Src (42% reduction, p=0.006). EEN/AAA PBF + Src and 




Y174A PBF + Src were not significantly different to empty vector + Src (15% increase and 
2% reduction, p=0.34 and p=0.84 respectively). 
 
Figure 6-8. Src reduces radioiodide uptake in MCF-7 cells. ATRA and dexamethasone 
treated MCF-7 cells stably transfected with empty pCI-neo vector (VO), PBF, EEN/AAA or 
Y174A PBF were transiently transfected with empty vector (VO) or Src and radioiodide 
uptake assessed. Cells were transiently transfected for 48 hours prior to the addition of 
radioiodide. n=3 with 4 replicates in each n. * = p<0.05. ** = p<0.01. 
 
6.3.5 Successful production of the mutant T341I Src 
Wild-type Src was successfully mutated to T341I via mutagenesis. The new plasmid was 
sequenced and BLAST used to compare the sequences. BLAST confirmed the correct 
mutation of the Src plasmid, with both the nucleotide sequence (Figure 6-9) and 
translated amino acid sequence displaying the correct mutation.  





Figure 6-9. Successful mutation of Src at residue 341. Sequencing of the pcDNA 3.1 
plasmid containing human Src confirmed successful mutagenesis with the presence of 
ATC instead of ACG. 
 
6.3.6 T341I Src increases pY174 PBF levels in the presence of dasatinib 
Exogenous WT Src is capable of increasing levels of phosphorylated Y174 PBF as observed 
in Figure 6-7. However this increase in pY174 PBF was abrogated in the presence of 10nM 
dasatinib (Figure 6-10). Treatment with dasatinib decreased levels of active pY418 Src in 









did not display a decrease in pY418 Src, confirming this mutant Src is constitutively active 
(Figure 6-10). Expression of mutant T341I Src was still capable of increasing levels of 
pY174 PBF compared to empty vector control in DMSO treated cells (Figure 6-10). 
However, unlike WT Src, T341I Src was resistant to dasatinib and could still increase 
pY174 PBF levels in the presence of this inhibitor. Dasatinib had no effect on the levels of 
total PBF or Src (Figure 6-10). 
 
Figure 6-10. T341I Src increases pY174 PBF levels irrespective of dasatinib treatment. 
MCF-7 cells were transfected with empty vector (VO), WT Src or T341I Src for 48 hours and 
treated with 10nM dasatinib 24 hours prior to protein harvesting. pY174 PBF, total PBF, 
pY418 Src and total Src were detected with β-actin used a loading control. n=3. 
 
6.3.7 T341I Src reduces radioiodide uptake in the presence of dasatinib 
To assess whether exogenous Src affects the radioiodide uptake of breast cancer cells, 
ATRA and dexamethasone-treated MCF-7 cells stably transfected with empty pCI-neo 
vector, WT, EEN/AAA and Y174A PBF were then transiently transfected with empty 
pcDNA3.1(+) vector, or Src and treated with either DMSO or 10nM dasatinib. In DMSO 
treated, control empty vector transiently transfected cells stable transfection of PBF 
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reduced radioiodide uptake (37% decrease, p=0.02) whereas stable transfection with 
EEN/AAA and Y174A PBF could not significantly reduce radioiodide uptake (1% and 3% 
reduction, p=0.83 and p=0.80 respectively) (Figure 6-11). This reduction in radioiodide 
uptake with WT PBF was restored after treatment with 10nM dasatinib (49% increase, 
p=0.04) replicating earlier data in this thesis (Figure 6-11). 
 In DMSO treated cells, transient transfection with Src reduced radioiodide uptake 
in cells stably transfected with empty vector, WT and Y174A PBF (31%, 36% and 35% 
reduction, p=0.03 p=0.02 and p=0.01 respectively compared to the respective stable 
transfection with transient empty vector transfection)(Figure 6-11). Transfection with PBF 
+ Src significantly reduced radioiodide uptake compared to empty vector + Src with a 42% 
reduction (p=0.048) replicating data from 6.3.4. EEN/AAA PBF + Src and Y174A PBF + Src 
did not reduce radioiodide significantly compared to empty vector + Src (13% increase 
and 9% decrease, p=0.46 and p=0.64 respectively). In PBF + Src expressing cells dasatinib 
was capable of rescuing Src's reduction in radioiodide uptake with a 126% increase 
(p=0.01) restoring radioiodide uptake to near empty vector levels (7% difference, 
p=0.40)(Figure 6-11). Dasatinib also rescued radioiodide uptake in empty vector + Src 
(43% increase, p=0.045) expressing cells (Figure 6-11). 
 To establish whether dasatinib was acting on Src or another kinase, the T341I 
dasatinib-resistant form of Src was utilised. Across stable transfection with empty pCI-neo 
vector, WT, EEN/AAA and Y174A PBF, T341I Src reduced radioiodide uptake in the same 
manner as wild-type Src. T341I Src significantly reduced radioiodide uptake in PBF stably 
transfected cells by 30% (p=0.039). However unlike with WT Src transfection, dasatinib 
was not capable of rescuing radioiodide uptake with T341I Src in any of the stable 




transfections (Figure 6-11), suggesting Src is the kinase responsible for PBF 
phosphorylation and repression of NIS function.  
 
Figure 6-11. Dasatinib cannot restore radioiodide uptake with T341I Src. ATRA and 
dexamethasone treated MCF-7 cells stably transfected with empty pCI-neo vector (VO), 
PBF, EEN/AAA or Y174A PBF were transiently transfected with empty pcDNA3.1(+) vector 
(VO), Src or T341I Src and treated with DMSO or 10nM dasatinib before radioiodide 
uptake was assessed. Cells were transiently transfected for 48 hours and treated for 24 
hours prior to the addition of radioiodide. n=2 with 4 replicates in each n. * = p<0.05. 
  





6.4.1 Src binds to PBF and increases PBF phosphorylation 
The evidence presented in this thesis chapter suggests that Src and PBF interact within 
breast cancer cells and that Src can phosphorylate PBF. Investigations revealed that Src 
kinase can colocalise with and bind to PBF in vitro and that overexpression of Src results 
in increased levels of pY174 PBF. These data reflect studies carried out in thyroid cancer 
cells where Src was identified as a binding partner for PBF by mass spectrometry and Co-
IP with Src overexpression increasing PBF phosphorylation (Smith et al., 2013). Further to 
the work in thyroid cancer cells, it was observed here that overexpression of Src could 
decrease radioiodide uptake in breast cancer cells. Not only did Src decrease radioiodide 
uptake in MCF-7 cells stably transfected with empty pCI-neo vector, radioiodide uptake 
was further reduced in cells overexpressing both Src and PBF. However co-transfection of 
Src alongside EEN/AAA PBF could not significantly reduce radioiodide uptake further. The 
EEN/AAA form of PBF was generated to have a mutation upstream from Y174 to reduce 
Src's recognition of Y174 as a potential phosphorylation site. Although EEN/AAA PBF 
could not be phosphorylated by Src, as evidenced via Co-IP, it appeared that it was still 
able to interact with Src. There are three potential hypotheses as to why: (i) it may be 
that Src cannot phosphorylate EEN/AAA PBF due to the mutant having a slightly altered 
conformation, (ii) Src may bind to and phosphorylate PBF at an different site such as 
Y165, or (iii) alternatively that Src is unable to recognise Y174 as a potential 
phosphorylation site as the consensus sequence for the SH1 kinase domain is no longer 
intact. Although Src was capable of further reducing radioiodide uptake in vitro, use of 
the potent SFK inhibitor dasatinib restored radioiodide uptake. These results support the 




data presented in chapter 5, where use of SFK kinase inhibitors prevented PBF 
phosphorylation and rescued radioiodide uptake.  
 
6.4.2 Src regulates and can phosphorylate PBF 
Although there is much evidence to suggest that Src can phosphorylate PBF, it is 
important to fully assess Src's role as it may not be the only kinase involved in the 
phosphorylation of PBF in breast cancer. Mass spectrometry in thyroid cancer cells also 
revealed that Lyn was a binding partner of PBF suggesting that it can also phosphorylate 
PBF (unpublished data). Here, a mutant form of Src was created that was constitutively 
active and could not be inhibited by dasatinib, as confirmed by Western blotting. The use 
of this mutant in radioiodide uptake experiments showed that it was capable of reducing 
radioiodide uptake with a similar potency to that of WT Src, although dasatinib could not 
restore radioiodide uptake in cells expressing T341I Src. Western blotting and radioiodide 
uptake studies suggest that dasatinib is inhibiting WT Src directly and this has a direct 
effect on PBF phosphorylation and radioiodide uptake. If another SFK was 
phosphorylating PBF and is inhibited by dasatinib, it could be hypothesised that dasatinib 
could restore radioiodide uptake even in the presence of T34I Src. 
 While these results do not prove that Lyn or another SFK have no role, the data 
produced with the T341 Src mutant provides evidence that Src has an important role in 
PBF phosphorylation. This is further supported by the similarity in the data produced in 
breast cancer cells and thyroid cancer (Smith et al., 2013), a disease where Src has been 
reported to be the dominant SFK (Chan et al., 2012). 




 Overall these data suggest that PBF interacts with and can be phosphorylated by 
Src. Overexpression of Src led to increased PBF phosphorylation and reduced radioiodide 
uptake in breast cancer cells, with the potent SFK inhibitor dasatinib restoring radioiodide 
uptake in cells with Src overexpression. This rescue is therapeutically important as many 
breast cancers have upregulated Src activity compared to normal tissue (Egan et al., 
1999; Rosen et al., 1986). Thus, for radioiodide to be an effective treatment in breast 
cancer dasatinib would be required to overcome the reduction in radioiodide uptake 
even in tumours with the highest levels of Src expression. Use of the T341I Src mutant 
revealed that the effect of dasatinib was Src-specific as the inhibitor was not able to 
restore radioiodide uptake in the presence of this resistant mutant. Although these data 
do not rule out PBF involvement with other SFK, they present evidence suggesting that 
PBF can be regulated and phosphorylated by Src in breast cancer cells.  





CHAPTER 7 - INHIBITION OF N-









Protein N-myristoylation is a form of irreversible post-translational modification to a 
subset of eukaryotic and viral proteins (Sefton and Buss, 1987). The term refers to the 
covalent attachment of a 14-carbon saturated fatty acid, myristate, to the N-terminal 
glycine of proteins. Although the process is referred to as a post-translational 
modification, it usually occurs co-translationally (Wilcox et al., 1987), when fewer than 
100 residues of the target protein have been polymerised by the ribosome (Deichaite et 
al., 1988). The modification usually occurs imminently following removal of the initiator 
methionine residue by methionylaminopeptidases (Wilcox et al., 1987) (Figure 7-1). More 
rarely, myristoylation can occur after the exposure of internal glycine following protein 
cleavage as found in the apoptosis pathway where pro-apoptotic proteins such as BID are 
myristoylated after cleavage by caspases (Zha et al., 2000) (Figure 7-1). Not all proteins 
with a N-terminal glycine are myristoylated; the consensus sequence for protein 
substrates is Gly-X-X-X-Ser/Thr (Johnson et al., 1994). 




Figure 7-1. Mechanisms of N-myristoylation. A schematic diagram illustrating the two 
mechanisms of N-myristoylation. (A) Co-translationally, N-terminal methionines are 
cleaved from proteins by methionylaminopeptidases (MetAP). Following cleavage, NMT 
catalyses the addition of a myristrate to the exposed newly N-terminal glycine. (B) 
Proteins are cleaved by proteases revealing a new N-terminal glycine that can be 
myristoylated by NMT. Taken from Wright et al., 2010. 
 
 N-terminal myristoylation of proteins is catalysed by myristoyl-CoA:proteinN-
myristoyltransferase (NMT), a member of the Gcn5-related N-acetyltransferases (GNAT) 
superfamily of proteins (Weston et al., 1998). Nineteen different NMT have thus far been 
identified from fifteen species with human, mouse and cow each possessing two NMT 
termed NMT type I and type II (Giang and Cravatt, 1998). Both types show a high level of 
homology across species with the two forms being 76% homologous to each other. The 
greatest divergence is situated within the N-terminal region of the protein (Giang and 
Cravatt, 1998). The N-terminal divergence is hypothesised to allow the two isoforms of 
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NMT to localise differentially in the cell to influence co-translational ribosome-based or 
post-translational cytosol-based protein myristoylation (Glover et al., 1997) (Farazi et al., 
2001).  
 It is estimated that 0.5-3% of all proteins are myristoylated (Martinez et al., 2008; 
Maurer-Stroh et al., 2002). Myristoylation of target proteins has multiple effects including 
influencing protein-protein interaction, protein stability and enhancing interaction of 
protein with cellular organelles or membranes (Wright et al., 2010). X-ray crystallography 
studies have revealed that myristoylation is required to stabilise the three-dimensional 
protein conformation of several N-myristoylated proteins, including protein kinase A 
(PKA) where the myristate is positioned in the hydrophobic pocket of the kinase and is 
necessary for both structural and thermal stability of the protein (Zheng et al., 1993). 
Many proteins require N-terminal myristoylation to associate with the plasma membrane 
or other intracellular membranes.  
 
7.1.2 N-myristoylation of Src 
One of the best studied families of myristoylated proteins are the SFK, particularly Src. All 
members of the SFK family are known to be myristoylated (Resh, 1994). Myristoylation of 
SFK is necessary for the kinases to anchor to the membrane but is not sufficient for 
anchorage with a second signal being required. For Src, this second signal for anchorage 
is a cluster of polybasic amino acids that can interact with the acidic phospholipids on the 
inner leaflet of the membrane bilayer (Cross et al., 1984; Murray et al., 1998). 
Myristoylation-null mutant forms of Src have been observed to lose the ability to bind to 
membranes, and cannot mediate cellular transformation (Cross et al., 1984; Kamps et al., 
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1985). This is a defining feature of Src with the other SFK family members relying on the 
attachment of a 16-carbon saturated fatty acid palmitate to Cys3 and Cys5/6 alongside 
myristoylation to anchor to the membrane (Resh, 1999). Src is yet to be crystallised, but it 
is hypothesised that the myristate is situated within a myristate binding pocket in a 
similar manner to that observed in c-Abl (Cowan-Jacob et al., 2005). 
 Membrane binding is critical for many of the cellular functions of Src. Non-
myristoylated Src has been observed to be cytoplasmic, with membrane localisation of 
Src being essential for mitotic Src activation (Bagrodia et al., 1993). Myristoylation has 
also been hypothesised to play a role in the regulation of nuclear translocation of Src 
(David-Pfeuty et al., 1993). The expression of non-myristoylated Src in vitro was found to 
be higher than expression of the myristoylated form, with non-myristoylated Src being 
degraded at a slower rate than the myristoylated form (Patwardhan and Resh, 2010). 
However myristoylated Src has been observed to have a higher rate of kinase activity 
than non-myristoylated Src (Patwardhan and Resh, 2010). With myristoylation-null 
mutants being less active than WT Src and being unable to mediate cellular 
transformation, NMT inhibitors have been investigated as anti-cancer reagents. 
 
7.1.3 Clinical uses of NMT inhibitors 
NMT has been investigated as a therapeutic target in multiple disease states but also for 
use as a fungicide or antiprotozoan. Although NMT enzymes are relatively well conserved 
amongst species, it has been possible to differentiate between viral, parasitic and 
mammalian NMT allowing for the creation of drugs to target species-specific NMT 
(Wright et al., 2010). The identification of species-specific inhibitors has focused on the 
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peptide binding pocket as this is the least conserved region of NMT enzymes (Wright et 
al., 2010). The NMT enzyme is essential for the human pathogen C. albicans to grow and 
be virulent, and inhibitors have been identified that are approximately 250-fold more 
selective for C. albicans NMT than human NMT (Devadas et al., 1995). NMT has also been 
identified to be a critical enzyme for L. major, T. brucei and P. falciparum which have 
been associated with diseases including leishmaniasis, African sleeping sickness and 
malaria, for which selective inhibitors are being investigated to aid in the treatment of 
these diseases (Bowyer et al., 2007; Gunaratne et al., 2000; Panethymitaki et al., 2006; 
Price et al., 2003). NMT inhibitors have also been suggested for use in the treatment of 
HIV-1 infection, however there have been concerns about toxicity in targeting human 
NMT to combat disease and the effects on uninfected cells (Furuishi et al., 1997; Seaton 
and Smith, 2008; Takamune et al., 2008). 
 NMT enzymes were first proposed as chemotherapuetic targets in 1995 due to 
their interaction with proteins involved in the regulation of cell proliferation and growth 
(Felsted et al., 1995). Overexpression of NMT has been associated with several neoplasms 
including colorectal, gallbladder, brain and oral squamous cell carcinomas (Lu et al., 2005; 
Magnuson et al., 1995; Rajala et al., 2000; Raju et al., 1997; Shrivastav et al., 2007). NMT 
expression has also been correlated with proliferative capacity in mammary epithelial 
cells (Clegg et al., 1999). Inhibition and knockdown of NMT in vitro has been observed to 
reduce cell proliferation by approximately 27%, to reduce Src phosphorylation on Y418 
and to inhibit signalling through the c-Raf/MEK/ERK/Elk pathway (Ducker et al., 2005). 
However, inhibition of myristoylation in carcinogenesis may also have negative effects on 
tumour suppressor genes. One tumour suppressor gene known to be myristoylated is 
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Fus1, a protein implicated in lung cancers that can promote apoptosis (Ji and Roth, 2008). 
Non-myristoylated forms of Fus1 lose tumour suppressor activity and cannot induce 
cellular apoptosis (Uno et al., 2004). Although potential use of NMT inhibitors for 
treatment of cancer appears to have merit, the findings are very preliminary and there 
are multiple factors to consider. Currently there are no NMT inhibitors in clinical trials but 
as interest grows in the enzymes and effective inhibitors are identified then it is expected 
that these inhibitors may prove a potent strategy in the fight against cancer. 
 
The aim of this chapter is to assess the ability of three NMT inhibitors, kindly donated by 
the Drug Discovery Group at the University of Dundee, to reduce Src myristoylation, 
inhibit the phosphorylation of PBF and increase radioiodide uptake in breast cancer cells. 
The Drug Discovery Group was working to inhibit parasitic NMT with the aim to combat 
parasites commonly affecting third world countries. Two of the three compounds they 
donated to this project were found to inhibit human NMT as well as parasitic NMT 
rendering them unsuitable for treatment of parasitic disease. The group decided to 
redeploy the compounds and establish whether the compounds had anti-cancer 
properties or could be used in the treatment of cancer. In this collaboration, the three 
compounds were individually assessed to establish their effect on radioiodide uptake. 
With NMT inhibition being known to affect Src activity it is hypothesised that inhibition of 
NMT will increase radioiodide uptake in a similar manner to that observed with SFK 
inhibitors. Of the three drugs the most potent was taken forward to establish the effect 
that NMT inhibition has on PBF phosphorylation and radioiodide uptake both on its own 
and in combination with dasatinib with the aim of maximising radioiodide uptake. 
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7.2 Materials and Methods 
7.2.1 Cell Culture 
MCF-7 and MDA-MB-231 cells were maintained as described in 2.1.2 with stably-
transfected MCF-7 cells being cultured in media containing G418 (1 mg/ml) and 
lentivirally transduced MDA-MB-231 cells being cultured in media containing blasticidin 
(15 µg/ml). All cell lines were seeded at 30,000 cells per well in a 24 well plate for 
radioiodide uptake and at 150,000 and 200,000 cells per well in a 6 well plate for 
fluorescence immunocytochemistry and protein extraction respectively. 
 
7.2.2 Drug Treatments 
MCF-7 cells were treated with ATRA and dexamethasone as described in section 3.2.3 at 
100nM and 1µM respectively. Cells were cultured with ATRA and dexamethasone for 48 
hours prior to harvesting or treatment with 125I. Cells were treated with dasatinib as 
described in 5.2.2 at a concentration of 1nM.  
 NMT Inhibitor compounds 1 (MW= 463), 2 (MW=523) and 3 (MW=610) (kindly 
donated from the Drug Discovery Group, University of Dundee) were dissolved in DMSO 
to give a stock concentration of 10mM. Cells were treated with dilutions of NMT inhibitor 
1, 2 and 3 ranging from 1nM - 1µM in RPMI media. DMSO was used as a vehicle-only 
control in all experiments.  
Chapter 7  NMT Inhibition 
212 
 
7.2.3 Radioiodide uptake, retention and efflux 
Radioiodide uptake was performed as described in section 2.7. NMT inhibitor dose curves 
were generated following treatment with NMT for 2 hours prior to the addition of 125I 
upon recommendation from the University of Dundee. 
 Radioiodide retention and efflux were performed simultaneously. MCF-7 cells 
were treated with ATRA and dexamethasone for 48 hours and with DMSO/dasatinib/NMT 
inhibitor 3 for 24 hours prior to the addition of 125I. Cells were incubated at 37°C for 1 
hour with 1µM NaI containing 0.05µCi 125I (Hartmann Analytic) before cell media was 
removed and replaced with fresh RPMI media. The cells were then incubated at 37°C for 
a further 1, 2 or 4 hours. After the appropriate amount of time, media was removed and 
assessed using a gamma counter (1260 Multigamma II, Wallac) for 60 seconds to 
determine iodide efflux. The cells then were lysed with 100µl 2% SDS and the 
radioactivity of the lysate assessed for one minute using the gamma counter. A BCA assay 
was undertaken to calculate the protein concentration of the lysates, which was then 
used to standardise the counts observed. 
 
7.2.4 Western Blotting 
Protein extraction and Western blotting were performed as described in sections 2.3.1 
and 2.3.2 respectively. Cells were treated with 100µM sodium pervanadate for 20 
minutes prior to harvesting to allow the detection of pY174 PBF. Antibodies used were 
anti-pY174 PBF antibody (Covalab) (Smith et al., 2013), anti-PBF (Eurogentec) (Smith et 
al., 2009), anti-phospho-Src (Y418) (Abcam), anti-Src (Cell Signalling) and β-actin (Sigma-
Aldrich) (refer to section 2.8). Appropriate secondary antibodies were used. 




Data were analysed using Sigma Plot (SPSS Science Software UK Ltd). One-way ANOVA 
was used to compare groups of parametric data with significance taken at p < 0.05. 




7.3.1 Both NIS and PBF are not predicted to be targeted by NMT 
Online prediction software (http://mendel.imp.ac.at/myristate/SUPLpredictor.htm) 
(Eisenhaber et al., 2003) did not detect any potential sites in either PBF or NIS that could 
be targeted by NMT. The NMT enzymes are well documented to target N-terminal 
glycines after cleavage of methionines, but neither PBF nor NIS have a glycine in the 
second position of their amino acid sequences. NMT is also capable of acting on N-
terminal glycines after proteolytic processing of pro-proteins, and although PBF is 
predicted to be cleaved following the signal peptide, any potential cleavage to the 
protein does not create an N-terminal glycine.  
 Src has previously been described to be myristoylated, having an N-terminal 
glycine following methionine cleavage. For this reason Src was used as a positive control, 
with the prediction software correctly identifying Src as a target for myristoylation.  
 
7.3.2 Inhibition of NMT increases radioiodide uptake 
Radioiodide uptake experiments were performed using the three NMT inhibitor 
compounds donated from The Drug Discovery Group at the University of Dundee. Prior to 
experiments, it was disclosed that one of the compounds was inactive whereas the other 
two readily inhibited NMT at varying efficacies. To ensure an unbiased experiment the 
identity of the compounds were blinded and labelled NMTi 1, NMTi 2 and NMTi 3. In NIS 
lentivirally transduced MDA-MB-231 cells, NMTi 3 appeared to be the most active 
compound increasing radioiodide uptake by the cells by 51% at 50nM when compared to 
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the DMSO control (Figure 7-2). NMTi 3 maximally increased radioiodide uptake at a 
concentration of 200nM where a 68% increase in uptake was observed (p = 0.004) (Figure 
7-2). NMTi 1 appeared to be the inactive compound with radioiodide uptake being 
unaffected by the presence of the inhibitor at any dose (Figure 7-2). NMTi 2 marginally 
increased radioiodide uptake in a dose-dependent manner up to 100nM; however this 
uptake was not significant (Figure 7-2). Subsequently, the Drug Discovery group in 
Dundee confirmed that inhibitor 3 was the most active NMTi in their biological tests, 
followed by 2, and that 1 was an inactive compound. 




Figure 7-2. Treatment with NMT inhibitor 3 increases radioiodide uptake. NIS lentivirally 
transduced MDA-MB-231 cells were treated with varying doses of NMT inhibitor 
compounds 1, 2 and 3 for 2 hours prior to the addition of 125I. n=3 with 4 replicates in each 
n. ** = p < 0.01. *** = p <0.001 compared to cells treated with vehicle control (0nM). 
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7.3.3 NMT Inhibitor 3 reduces pY418 Src plasma membrane localisation 
To determine the effect of NMT inhibitor 3 on the localisation of pY418 Src MCF-7 cells 
were transfected with NIS-MYC and treated with 100nM NMT inhibitor 3. In control 
DMSO treated cells, pY418 Src was located ubiquitously throughout the cells with strong 
staining at the plasma membrane (Figure 7-3). The use of NMT inhibitor 3 decreased 
plasma membrane staining for pY418 Src suggesting the NMT inhibitor 3 inhibits the 
myristoylation of Src effectively (Figure 7-3).  
 In DMSO treated cells, NIS-MYC appeared to be expressed in defined intracellular 
vesicles, with little plasma membrane staining (Figure 7-3). However in NMT inhibitor 3 
treated cells there was a marked increase in plasma membrane NIS and increased 
visualisation of lamellipodia-like structures in the NIS stained cells. NIS was also present 
in a similar number of defined intracellular vesicles in DMSO treated cells, suggesting a 
potential increase in total NIS levels (Figure 7-3). 
  




Figure 7-3. NMT inhibitor 3 decreases pY418 Src plasma membrane localisation and 
increases NIS plasma membrane localisation. MCF-7 cells were transfected with empty 
pcDNA3.1 (+) vector and NIS-MYC for 48 hours and treated with DMSO or 100nM NMT 
inhibitor 3 for 24 hours prior to fixing. MYC-tagged NIS is identified in green using a 
mouse anti-MYC antibody,pY418 Src is visualised using a rabbit anti-pY418 Src antibody in 
red and PBF-HA visualised using a mouse anti-HA tag antibody in green. In all images 
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7.3.4 Phosphorylation of PBF is not affected by NMT inhibitor 3 
To determine the effect of NMT inhibitor 3 on the phosphorylation of PBF and Src, NIS 
lentivirally transduced MDA-MB-231 cells were treated with NMT inhibitor 3 at varying 
doses before protein was extracted and Western blotted. NMTi 3 did not alter the levels 
of phosphorylated PBF at any concentration compared to the DMSO control (Figure 7-4). 
Levels of total PBF were also unchanged. Expression levels of pY418 Src and total Src 
were also unaltered within the 2 hour treatment (Figure 7-4). 
 
Figure 7-4. Treatment with increasing NMT inhibitor 3 doses. NIS lentivirally transduced 
MDA-MB-231 cells were treated with varying concentrations of NMT inhibitor 3 for 2 
hours prior to harvesting. pY174 PBF, total PBF, pY418 Src and total Src were detected, 































Concentration of NMT inhibitor 3
Figure  7-2 - NMT inhibitor 3 dose curve - NIS lentivirally transduced MDA-MB-231 cells were treated with varying concentrations of NMT 
inhibitor 3 for 2 hours prior to harvesting. pY174 PBF, total PBF, pY418 Src and total Src were detected, with β-actin used a loading control.
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7.3.5 NMT inhibitor 3 cannot restore radioiodide in the presence of 
exogenous PBF 
To assess whether NMT inhibitor 3 was capable of rescuing radioiodide uptake in cells 
overexpressing PBF, ATRA and dexamethasone-treated MCF-7 and NIS lentivirally 
transduced MDA-MB-231 cells were employed. In both DMSO-treated cell lines, PBF 
transfection significantly reduced radioiodide uptake compared to empty vector 
transfected cells (29% reduction, p= 0.0015 and 29% reduction, p=0.0297 in MCF-7 and 
MDA-MB-231 cells respectively) (Figure 7-5). This reduction was rescued after treatment 
with 1nM dasatinib for 24 hours (100% increase compared to DMSO + PBF, p=0.0283 and 
78% increase, p=0.0344 in MCF-7 and MDA-MB-231 cells respectively) (Figure 7-5). NMT 
inhibitor 3 could not significantly rescue PBF's reduction in radioiodide uptake at either 
time-point in either cell line (Figure 7-5). Treatment with NMT inhibitor 3 for 2 hours 
significantly increased radioiodide uptake in MDA-MB-231 cells transfected with empty 
vector (32% increase, p=0.0474) (Figure 7-5B). MCF-7 and MDA-MB-231 cells transfected 
with empty vector displayed increased uptake with NMTi 3 at 24 hours but the increase 








Figure 7-5. NMT inhibitor 3 cannot restore radioiodide uptake in the same manner as 
dasatinib. (A) ATRA and dexamethasone-treated MCF-7 cells stably transfected with 
empty vector (VO) or PBF and (B) NIS lentivirally transduced MDA-MB-231 cells transiently 
transfected with empty vector (VO) or PBF were treated with DMSO, 1nM dasatinib or 
100nM NMT inhibitor 3 for either 24 or 2 hours before the addition of 125I. Radioiodide 
counts were normalised to protein concentration. n=3 with 4 replicates in each n. *= 
p<0.05. ** = p<0.01. 
A 
B 
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7.3.6 NMT inhibition combined with dasatinib affects MCF-7 and MDA-
MB-231 cells differently 
When ATRA and dexamethasone-treated MCF-7s were treated with a combination of 
dasatinib and NMT inhibitor 3, an increased uptake was observed in comparison to single 
drug treatments (Figure 7-6A). A pre-treatment with NMT inhibitor 3 for 2 hours prior to 
the addition of dasatinib gave the highest levels of radioiodide uptake, with a 96% 
increase in radioiodide uptake compared to control DMSO treated cells (p=0.003) (Figure 
7-6A). Simultaneous treatment with both drugs also provided a 71% increase in MCF-7 
radioiodide uptake (p=0.015), and 24 hour dasatinib treatment with NMTi 3 in the final 2 
hours gave an increase of 63% compared to control treated cells (p=0.0008) (Figure 7-6A).  
 Treatment of NIS lentivirally transduced MDA-MB-231 cells with dasatinib and 
NMT inhibitor 3 in combination did not significantly alter radioiodide uptake from 
control-treated cells (Figure 7-6B). NMT inhibitor 3 treatment alone for 2 hours was the 
only treatment that significantly altered radioiodide uptake from the control DMSO-
treated cells (p=0.0474) (Figure 7-6B). 
 It was evident in both cell lines that the phosphorylation status of PBF was not 
reduced by the presence of NMT inhibitor 3 (Figure 7-7). These preliminary data 
suggested that in both cell lines dasatinib alone was the best modulator of PBF 
phosphorylation, with combination treatments appearing to have higher levels of pY174 
PBF than dasatinib alone (Figure 7-7). MDA-MB-231 cells treated with 100nM NMT 
inhibitor 3 for both 2 and 24 hours appeared to have increased levels of pY174 PBF 
compared to DMSO (Figure 7-7B); however this effect was not observed in the MCF-7 
cells (Figure 7-7A). 




Figure 7-6. Combination treatments affect MCF-7 and MDA-MB-231 cells differently. (A) 
ATRA and dexamethasone-treated MCF-7 and (B) NIS-lentivirally transduced MDA-MB-
231 cells transiently transfected were treated with DMSO, 1nM dasatinib and 100nM 
NMT inhibitor 3.Timepoints indicate treatment time prior to the addition of 125I. n=3 with 
4 replicates in each n. *= p<0.05. ** = p<0.01. *** = p<0.01.  
A 
B 






Figure 7-7. Dasatinib alone reduces pY174 PBF levels the most effectively. (A) MCF-7 cells 
and (B) NIS lentivirally transduced MDA-MB-231 cells treated with DMSO, dasatinib or 
NMT inhibitor 3 or a combination of the two drugs. pY174 and total PBF were detected 
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7.3.7 NMT inhibition does not have an additive effect on the rescue of 
PBF-repressed radioiodide uptake by dasatanib 
As observed throughout this thesis, PBF was capable of significantly reducing radioiodide 
uptake in MCF-7 and MDA-MB-231 cells (31% and 42% decrease, p=0.048 and p=0.026 
respectively) (Figure 7-8). Treatment with NMT inhibitor 3 did not have an additive 
effective when paired with dasatinib on rescuing exogenous PBF's reduction of 
radioiodide uptake. Three different time combinations were investigated but none of the 
tested combinations produced results significantly above dasatinib treatment alone in 
both cell lines (Figure 7-8). Conversely, treatment with dasatinib for 24 hours and NMT 
inhibitor 3 for the final two hours in MDA-MB-231 cells appeared to reverse the rescue 
effect dasatinib treatment alone has on radioiodide uptake (Figure 7-8B).  
 




Figure 7-8. Dasatinib and NMT inhibitor 3 do not have an additive effective when rescuing 
radioiodide uptake in the presence of PBF. (A) ATRA and dexamethasone-treated MCF-7 
cells stably transfected with PBF and (B) NIS-lentivirally transduced MDA-MB-231 cells 
transiently transfected with PBF were treated with DMSO, 1nM dasatinib and 100nM 
NMT inhibitor 3. n=3 with 4 replicates in each n. *= p<0.05 compared to PBF + DMSO.  
A 
B 
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7.3.8 NMT Inhibitor 3 does not reduce co-localisation between PBF and 
NIS 
In MCF-7 cells there has been significant evidence to suggest PBF and NIS co-localise in 
intracellular vesicles. Here, it was demonstrated that dasatinib can disrupt the 
relationship between NIS and PBF. In MCF-7 cells treated with DMSO, there were clear 
signs of colocalisation (depicted in yellow and indicated by white arrows in Figure 7-9) 
with minimal plasma membrane staining for NIS. Treatment with dasatinib for 24 hours 
decreased intracellular colocalisation between NIS and PBF and increased the plasma 
membrane staining of NIS, increasing the visualisation of apparent lamellipodia in NIS 
stained cells (Figure 7-9). MCF-7 cells treated with NMT inhibitor 3 for 24 hours appeared 
to have similar levels of PBF and NIS colocalisation as those cells treated with vehicle only 
DMSO. However in the NMT inhibitor treated cells there was also increased visualisation 
of lamellipodia-like structures in NIS stained cells, potentially suggesting an increase in 
total NIS levels (Figure 7-9).  






Figure 7-9. NMT inhibition cannot reduce colocalisation between NIS and PBF. MCF-7 cells 
were transfected with WT PBF-HA and NIS-MYC for 48 hours and treated with DMSO, 
1nM dasatinib or 100nM NMT inhibitor 3 for 24 hours prior to fixing. MYC-tagged NIS is 
identified in green using a mouse anti-MYC antibody and HA-tagged PBF is identified in 
red using a mouse anti-HA antibody with the nuclei visualised in blue using Hoechst stain. 
White arrows indicate high levels of colocalisation as depicted by yellow staining. 100x 





























































































7.3.9 NMTi 3 and dasatinib affect radioiodide retention and efflux 
To assess whether dasatinib and NMT inhibitor 3 were capable of extending the time that 
breast cancer cells were able to retain radioiodide, retention and efflux experiments were 
performed. The preliminary data suggested that 24 hour treatment with NMT inhibitor 3 
was capable of extending iodide retention in empty vector transfected MCF-7 cells as 
they appeared to retain 88% more radioiodide after 1 hour and 36% more after 2 hours 
than DMSO control-treated cells (Figure 7-10). Dasatinib-treated empty vector 
transfected MCF-7 cells were also capable of retaining 88% more radioiodide than DMSO-
treated cells after 2 hours (Figure 7-10). A combination of the two drugs also enhanced 
radioiodide retention but not above the levels of single drug treatments (Figure 7-10). 
 Cells overexpressing PBF displayed decreased radioiodide uptake at 0 hours 
compared to empty vector transfected cells, which was partially restored in the presence 
of dasatinib (Figure 7-10). Dasatinib-treated PBF stable cells retained 33% more 
radioiodide after 1 hr and 15% after 2 hours compared to their DMSO treated 
counterparts (Figure 7-10). NMT inhibitor 3 had very little effect on the retention of 
radioiodide even in combination with dasatinib (Figure 7-10). 
 Apart from dasatinib-treated cells, all of the PBF transfected cells appeared to 
efflux less radioiodide than their empty vector transfected counterparts across all 
timepoints (Figure 7-11) but this may be due to not taking up as much radioiodide 
initially. DMSO-treated MCF-7 cells with PBF overexpression effluxed the least amount of 
radioiodide after 4 hours (Figure 7-11).   





Figure 7-10. Radioiodide retention. ATRA and dexamethasone-treated MCF-7 cells stably 
transfected with empty pCI-neo vector (VO) or PBF were treated with DMSO, 1nM 
dasatinib, 100nM NMT inhibitor 3 or a combination of the two drugs for 24 hours before 
the addition of 125I. After 1 hour media was replaced and cells were harvested after 0, 1, 2 






















































































































Figure 7-11. Radioiodide efflux. ATRA and dexamethasone-treated MCF-7 cells stably 
transfected with empty pCI-neo vector (VO) or PBF were treated with DMSO, 1nM 
dasatinib, 100nM NMT inhibitor 3 or a combination of the two drugs for 24 hours before 
the addition of 125I. After 1 hour medium was replaced and then the medium was 
harvested and counted after 0, 1, 2 or 4 hours. n=1. 





7.4.1 Inhibition of NMT increases radioiodide uptake 
The University of Dundee Drug Discovery Group identified two potent inhibitors of NMT 
and a structurally related negative control compound. The initial assessment of these 
compounds using radioiodide uptake studies over a range of doses correctly identified 
the two active compounds as observed by increased radioiodide. NMT inhibitor 3 was 
observed to be the most effective compound, significantly increasing radioiodide uptake. 
This compound had previously been identified as the most potent NMT inhibitor by the 
Drug Discovery Group. Thus far, the data in this thesis have suggested that Src is 
responsible for the phosphorylation of PBF and a reduction in radioiodide uptake in 
breast cancer cells. With the N-myristoylation of Src by NMT being critical for Src 
association with the plasma and intracellular membrane where Src is known to be 
activated, it is logical that inhibition of NMT would increase radioiodide uptake in breast 
cancer cells. This increase in radioiodide uptake is a key finding as the treatment time 
utilised in these dose curves is two hours prior to the addition of 125I. This short treatment 
time would negate any of the side effects of NMT inhibition such as deactivation of Fus1 
as exposure time would be minimal.  
 
7.4.2 Inhibition of NMT does not affect PBF phosphorylation 
To assess whether the increase in radioiodide uptake witnessed with the use of NMT 
inhibitor 3 was PBF dependent, the effect of the inhibitor on PBF phosphorylation was 
assessed. Inhibition of NMT was identified not to affect PBF phosphorylation with levels 




of pY174 PBF remaining unaltered over a range of doses. However the levels of activated 
pY418 Src also remained consistent over the range of doses. The protein utilised for 
Western blotting was harvested two hours after treatment with NMT. Since N-
myristoylation of Src occurs co-translationally, this two hour treatment may have not 
allowed for sufficient time to alter the cellular phosphorylation of Src and therefore PBF. 
These data suggest that the increase in radioiodide uptake observed with NMT inhibitor 3 
treatment may be through a PBF independent mechanism. 
 To test this hypothesis that NMT inhibition is acting independently of PBF to 
increase radioiodide uptake, it was assessed whether NMT inhibition could rescue the 
reduction in radioiodide uptake with PBF in a similar manner to dasatinib. The use of 
NMT inhibitor 3 for 2 hours did not rescue radioiodide uptake in either MCF-7 or MDA-
MB-231 cells. Although there was a small trend towards increased radioiodide uptake 
after 24 hours treatment with NMT inhibitor 3, the compound again could not rescue 
radioiodide uptake. These data suggest again that the increase in radioiodide uptake 
identified when using NMT inhibitor 3 is PBF independent. This was further supported by 
immunofluorescence studies where treatment with NMT inhibitor 3 for 24 hours did not 
decrease the colocalisation between PBF and NIS in breast cancer cells. 
 
7.4.3 Src and NMT inhibition may have synergistic effects 
Both NMT inhibition and Src inhibition have been observed to increase radioiodide 
uptake when used separately, and it was therefore of interest to assess the effect the two 
drugs had in combination. In untransfected MCF-7 cells, treatment with 100nM NMT 
inhibitor 3 for 24 hours and dasatinib for 22 hours provided the highest level of 




radioiodide uptake across all the treatment combinations tested. However this synergistic 
effect was not observed in MDA-MB-231 cells suggesting the effect may be cell type 
specific. The combination of the two drugs was also ineffective at combating the effect of 
PBF transfection on radioiodide uptake with dual treatment being no more effective than 
dasatinib alone in both MCF-7 and MDA-MB-231 cells. 
 In radioiodide retention experiments, the combination of treatment with 
dasatinib and NMT inhibitor 3 did not initially show increased radioiodide activity after 
one or 2 hours but empty vector transfected MCF-7 cells treated with both dasatinib and 
NMT inhibitor 3 retained the most 125I after 4 hours. However, with initial treatment after 
1 hour cells treated with a combination treatment effluxed the most radioiodide. In cells 
transfected with PBF, the addition of NMT inhibitor 3 in combination did not affect the 
retention of radioiodide when compared with dasatinib treatment alone.  
 Although initial radioiodide uptake studies in MCF-7 cells suggested that 
treatment with dasatinib and NMT inhibitor 3 may be synergistic increasing radioiodide 
uptake beyond solo treatment, it appears this effect may be cell type specific as it was 
not observed in MDA-MB-231 cells. The results presented in this chapter are preliminary 
and further experiments are required before a definitive conclusion can be made on the 
combined effects of the drugs.  
 
7.4.4 Hypotheses and further work 
Although the mechanism by which NMT inhibition increases radioiodide uptake is 
unknown, there are several hypotheses that can be formed from this study. Firstly, the 




increased radioiodide uptake observed with NMTi 3 treatment could be as a result of 
NMT inhibition increasing NIS expression or stability. NIS expression after treatment with 
NMTi 3 could easily be assessed by qRT-PCR and Western blotting, and protein stability 
could be assessed by using the protein synthesis inhibitor anisomycin and monitoring the 
expression of NIS protein by Western blotting over a period of several hours. If NMT 
inhibition is observed to promote NIS stability or increase NIS expression, the additional 
radioiodide uptake observed can be accounted for. However, should this not be the case 
then further work is required to elucidate the mechanism by which NMT inhibitor 3 is 
increasing radioiodide uptake.  
 Another hypothesis may be that although neither NIS nor PBF are predicted to be 
N-myristoylated, there may be another putitative binding partner of NIS capable of 
influencing its activity. NIS activity has been observed to increase when its binding 
partner hsp90 is inhibited (Marsee et al., 2004) and with hsp90 containing a N-
myristoylation site (Chen et al., 2005) it is possible that NMT inhibition is indirectly 
increasing NIS function via hsp90 inhibition. With 0.5-3% of all proteins predicted to be N-
myristoylated, there are a plethora of reasons that NMT inhibition could be increasing 
radioiodide uptake. 
  It was also observed that MCF-7 and MDA-MB-231 cells behaved differently in 
the presence of PBF and NMT inhibition. An explanation for this may lie within intrinsic 
differences in expression of NMT isoforms between the two cell lines. The two cell-lines 
may express differing levels of both NMT 1 and NMT 2, with NMTi 3 having different 
affinities for the two isoforms of the enzyme effecting the level to which NMT is 
inhibition on a whole. 




Overall these data suggest that the inhibition of NMT with a potent inhibitor can increase 
radioiodide uptake in breast cancer cells. This increased radioiodide uptake appears to be 
independent of PBF suggesting another mechanism to increase plasma membrane NIS 
expression in breast cancer cells. Further work is required to elucidate whether inhibition 
of NMT is increasing total NIS levels or is solely increasing plasma membrane expression, 
with an aim to exploit the mechanism for therapeutic purposes. Once this mechanism is 
identified it would be advantageous to further assess whether inhibition of NMT could be 
used synergistically with Src inhibition to further increase radioiodide uptake in breast 
cancer cells. 




CHAPTER 8 – FINAL CONCLUSIONS AND 
FUTURE STUDIES  
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The work described in this thesis investigated the relationship between PBF and NIS in 
breast cancer cells with the primary focus of increasing the ability of breast cancer cells to 
uptake radioactive iodide. This was based on previous work detailing the important role 
of PBF in thyroid cancer and the protein's ability to decrease radioiodide uptake in these 
cells. In thyroid cancer, PBF is capable of binding to and altering the subcellular 
localisation of NIS, rendering the transporter inactive due to its aberrant localisation 
(Smith et al., 2009). The phosphorylation of PBF at Y174 is critical for this interaction 
between NIS and PBF with abrogation of phosphorylation restoring radioiodide uptake in 
thyroid cancer cells (Smith et al., 2013). PBF and NIS have been individually described to 
be upregulated in the majority of breast cancers (Tazebay et al., 2000; Watkins et al., 
2010), however prior to this thesis the relationship between the two proteins had never 
been investigated in breast cancer.  
 
8.1 PBF and NIS interact in breast cancer 
Previous studies have demonstrated that in thyroid cancer PBF binds directly to NIS and 
can alter its subcellular localisation, translocating it away from the plasma membrane 
into intracellular vesicles resulting in decreased radioiodide uptake. In this thesis, it has 
been demonstrated over a small number of samples that both NIS and PBF are 
overexpressed within breast cancer tumours compared to matched normal tissue. 
However, in future studies, more matched tissue samples would be necessary to 
correlate the expression between the two proteins. In a similar manner to thyroid cancer, 
PBF was observed to bind to NIS in breast cancer cells. Overexpression of PBF increased 
intracellular staining of NIS in vitro and decreased radioiodide uptake as hypothesised.  
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 Although the posttranslational effects of PBF and NIS are similar in thyroid and 
breast cancer, the relationship between the two appears to differ between the diseases 
in terms of gene regulation. In thyroid cancer, NIS expression has been reported to be 
repressed by PBF expression. This is through PBF's interaction with the NUE (Boelaert et 
al., 2007), a thyroid-specific enhancer of NIS (Schmitt et al., 2002; Taki et al., 2002). As 
hypothesised, PBF overexpression did not repress NIS expression in the absence of an 
active NUE. However, and more unexpectedly, PBF overexpression was actually capable 
of upregulating NIS mRNA. Although NIS expression is increased in the presence of PBF, 
there is no increase in activity due to the aberrant subcellular localisation of NIS within 
breast cancer cells. Further work is required to identify the mechanism by which PBF can 
increase NIS expression within breast cancer cells. One hypothesised mechanism is 
through PBF's induction of Akt, a protein that has been associated with NIS regulation in 
breast cancer (Kogai et al., 2008). This hypothesis could be tested by treating PBF 
transfected cells with an Akt inhibitor prior to harvesting RNA. If Akt is involved with 
upregulating NIS expression, then the Akt inhibitor should counteract this effect and the 
increase in NIS mRNA would not be observed.  
 From the data presented in this thesis it is clear that PBF and NIS have a functional 
relationship in breast cancer similar to that observed in thyroid cancer. Overexpression of 
PBF in breast cancer cells consistently reduced radioiodide uptake by at least 25%. This 
loss of activity in NIS functionality can be attributed to increased intracellular NIS 
observed in the presence of PBF overexpression. In 80% of breast tumours that express 
NIS, the majority of them are observed to have primarily intracellular NIS, rendering 
radioiodide uptake ineffective in these patients. It would be of great interest to obtain 
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more breast cancer tumour samples, correlate the levels of PBF and NIS within the 
samples and identify whether there is an association between PBF levels and the 
intracellular localisation of NIS. However it is already clear from the data presented that 
PBF and NIS have a functional relationship in breast cancer, and minimising their 
interaction can increase the radioiodide uptake of breast cancer cells. 
 
8.2 PBF phosphorylation is critical for protein 
interaction with NIS 
In this thesis, a new mutant form of PBF lacking Y174 phosphorylation was identified and 
characterised. Though this form is unlikely to be witnessed within breast cancer tumours, 
it served as an ideal tool to study the effect PBF phosphorylation has on PBF's interaction 
with NIS. The EEN/AAA PBF mutant was observed to lack phosphorylation at Y174 in vitro 
similar to the previously characterised Y174A PBF mutant. However the major difference 
between the two mutant forms was EEN/AAA PBF's ability to localise within cells in the 
same manner as WT PBF. The Y174A PBF mutant is known to have an interrupted 
endocytosis motif and be retained in the plasma membrane. The ability for EEN/AAA PBF 
to localise like WT PBF allowed the study of the effects of phosphorylation alone. Neither 
phospho-mutant forms of PBF appeared to be capable of interacting with NIS, with 
EEN/AAA PBF exhibiting reduced colocalisation with NIS compared with WT PBF. This lack 
of interaction was confirmed with Co-IP data in which NIS and EEN/AAA PBF or Y174A PBF 
did not bind whereas strong binding was witnessed with WT PBF. In cells expressing 
EEN/AAA PBF, there appeared to be reduced intracellular NIS compared to cells 
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containing WT PBF and neither EEN/AAA PBF nor Y174A PBF were able to reduce 
radioiodide uptake in vitro as WT PBF had. Taken together the data suggest that PBF 
phosphorylation at Y174 is critical for PBF's interaction with NIS. 
 To further assess the role that PBF phosphorylation plays in the relationship 
between PBF and NIS, SFK inhibitors were assessed. PP1, a potent SFK inhibitor had 
previously been identified to inhibit the phosphorylation of PBF in thyroid cells. Here, it 
was identified that the more specific and effective SFK inhibitors dasatinib and saracatinib 
can also inhibit the phosphorylation of PBF in vitro. Both inhibitors were capable of 
inhibiting PBF phosphorylation at concentrations much lower than previously 
demonstrated with PP1. All Src inhibitors tested were capable of restoring PBF's 
reduction in radioiodide uptake in breast cancer cells, again suggesting a link between 
unphosphorylated PBF being unable to interact with NIS and alter its subcellular 
localisation.  
 Together the data presented suggest that the phosphorylation of PBF at Y174 is 
critical for the interaction between NIS and PBF. Utilisation of FDA cleared dasatinib to 
inhibit PBF phosphorylation and increase radioiodide uptake is potentially therapeutically 
important. In the proposed treatment regime, dasatinib could be used as a pre-
treatment, only used a few days prior to radioiodide therapy to boost plasma membrane 
localisation of NIS and increase radioiodide uptake into breast cancer cells, thereby 
avoiding any potential side effects caused by long term dasatinib exposure. 
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8.3 Src regulates/potentially phosphorylates PBF 
Previous work has demonstrated that inhibition of SFK can inhibit PBF phosphorylation, 
with both Src (Smith et al., 2013) and Lyn (unpublished work) observed to bind to PBF. 
Here, it was demonstrated that Src can bind to PBF in breast cancer cell lines. 
Overexpression of Src increased PBF phosphorylation and decreased radioiodide in the 
presence of exogenous PBF further than PBF expression alone, suggesting that Src can 
regulate PBF phosphorylation. Dasatinib was capable of restoring radioiodide uptake in 
the presence of both Src and PBF. Phosphorylation mutants of PBF were observed to still 
be capable of binding to Src, but were unable to become phosphorylated or reduce 
radioiodide uptake in the presence of exogenous Src. 
 A constitutively active mutant form of Src was utilised to ascertain whether Src 
was the primary SFK responsible for phosphorylating PBF. The T341I Src mutant contains 
an activating mutation at Src's gatekeeper residue and is resistant to dasatinib inhibition. 
The data presented here suggest that Src can regulate PBF phosphorylation. Use of the 
T341I Src mutant increased PBF phosphorylation levels even in the presence of dasatinib, 
which was also unable to rescue T341I Src's reduction in radioiodide uptake. While these 
results do not prove that Lyn or another SFK do not have additional roles in PBF 
phosphorylation, they provide evidence that Src has a key role PBF phosphorylation and 
is thereby an indirect inhibitor of radioiodide uptake.  
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8.4 Inhibition of NMT does not affect PBF but can 
increase radioiodide uptake 
The effect of NMT inhibition on the cellular ability to uptake radioiodide had previously 
never been investigated. Of the three compounds gifted to the study by The Drug 
Discovery Group at the University of Dundee, one compound referred to as NMT inhibitor 
3 was capable of increasing radioiodide uptake in MCF-7 cells after 2hours at 
concentrations as low as 100nM. However, investigations into the inhibitor's effect on 
PBF showed that inhibition of NMT did not affect PBF's phosphorylation status at Y174. 
Further studies revealed that inhibition of NMT could not overcome PBF's repression of 
radioiodide uptake in vitro suggesting that the initial increase in radioiodide uptake 
observed with NMT inhibitor 3 is independent of PBF. 
 Although the effects of NMT inhibition on radioiodide uptake appear to be 
independent of PBF, it is of interest to establish whether NMT inhibitors can be 
administered alongside dasatinib to produce a positive synergistic effect on radioiodide 
uptake. In MCF-7 cells, treatment with both drugs increased radioiodide uptake above 
the levels witnessed with either drug in isolation. This effect was not observed in MDA-
MB-231 cells, although both drugs in combination presented no adverse effects on 
radioiodide uptake. However even in MCF-7 cells there was no additive effect of dasatinib 
and NMT inhibition on restoring the radioiodide uptake observed in the presence of PBF. 
The combination of the two drugs did increase the radioiodide retention of MCF-7 cells 
after treatment with 125I. 
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8.5 Critical Evaluation and Future Directions 
Although this thesis constitutes a comprehensive study, there are notable limitations to 
several aspects of the study. Throughout the thesis, multiple differential in vitro models 
were utilised including endogenous cells, transient and stable transfection, lentiviral and 
chemically induced cells. The use of two or three models throughout the study may have 
provided a better overview and greater consistency. However, the use of multiple models 
can highlight the effectiveness of the work with the same effect being witnessed across 
the models. In this study, PBF expression whether transient or stable consistently 
decreased radioiodide uptake in cells expressing transfected, lentiviral and chemically 
induced NIS. As many of the experiments described in this thesis were protein expression 
and functional studies the use of multiple models demonstrates that the effects observed 
are not attributed solely to the method by which protein overexpression was achieved.  
 Transient transfection provided a quick method with which to assess the effect of 
single and combinatorial protein overexpression for short term experiments. It also 
provides a polyclonal mix of cells with differential levels of protein expression, simulating 
the heterogeneity of malignant tumours. Long term stable transfection and lentiviral 
expression of proteins provided a robust method for observing specific effects caused by 
overexpression of specific proteins.. As all cells were derived from a single cell clone, copy 
number and genomic transgene insertion points were consistent throughout experiments 
whereby lentiviral transduction was applied. Additionally, transient transfection can 
induce cellular stress with transfection reagents often being cytotoxic. With many 
transient transfection experiments typically spanning 48-72 hours, the cells may not have 
recovered sufficiently from the transfection process and thus behaved abberantly, 
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invalidating results. Stable transfection allows for ample time to recover from the 
procedure, thus avoiding this potential pitfall. The use of both models often alongside 
each other, has the advantage of assessing the overexpression of the protein in question, 
allowing for more confidence that any observable effects were due to protein 
overexpression rather than artefacts of the transfection process.  
 Western blotting was a powerful tool that provided a qualitative assessment of 
protein expression levels within a cell population. For quantitative analysis of protein 
expression, densitometry could have been employed. Densitometry was not utilised in 
this study due to the complexity of quantifying the loading controls. Many of the Western 
blots in this study were performed to assess the differences in the expression of 
phosphorylated proteins, such as PBF, and to accurately quantify the differences in 
phosphorylated protein both the loading control and and total target protein expression 
is required to normalise the data. With the limitations of the PBF antibody discussed in 
3.4.2 and 4.4.1, accurate quantification of Western blotting was difficult to achieve and 
was therefore not included in the study. 
 To determine protein localisation within breast cancer cells, immunofluroscence 
microscopy was utilised, for which the use of the Zeiss Axioplan fluroescent microscope 
provided a reliable platform. However use of confocal microscopy could have allowed z-
stacking and provided even greater accuracy of protein localisation within the cells. In 
future studies, counting an arbitrary number of cells and assessing the percentage of co-
localisation would have also been a suitable method to quantify protein co-localisation 
over a population of cells. Proximity ligation assay (PLA) could also be utilised in future 
studies as a sensitive technique for identifying protein interactions in situ. 
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 Additionally, the use of Src kinase inhibitors was heavily relied on during this 
study. There are many caveats to using inhibitors experimentally, such as their sensitivity 
and specificity. Dasatinib was utilised mainly as an inhibitor of Src, but is also known to 
inhibit all SFK along with Bcr-Abl and c-Kit. Although the use of T341I Src aided in the 
dissection of Src specific effects there are still flaws to the methodology. Use of Src siRNA 
and Src kinase assays should be utilised alongside inhibitors in future experiments to 
further aid in identifying the true effect of Src on PBF phosphorylation. 
  During the final weeks of this project, plasma membrane fractionation was 
undergoing optimisation. This technique would have been very useful for the study 
presented in this thesis as it would have provided a more quantifiable method to assess 
PBF's effect on the subcellular localisation of NIS within breast cancer cells. The technique 
allows the separation of the plasma membrane from all other membranes within the cell 
and thus would have provided a means of assessing the reduction of plasma membrane 
NIS in the presence of PBF.  
 In terms of NMT inhibition, future studies should involve elucidating the 
mechanism by which inhibition of NMT can increase radioiodide uptake. From the 
information presented in this study, it could be hypothesised that inhibition of NMT may 
influence the expression of NIS. Work could be done to assess NIS mRNA levels and 
protein levels after treatment with NMT inhibitors to test this hypothesis. With the short 
treatment times, it could be speculated that NMT inhibition may increase the stability of 
the NIS protein or the activity of the transporter.  
 Due to time and financial restraints, in vivo work was unable to be performed 
within the remit of this project. Had the study been without barriers, nude mice would 
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have been subjected to orthotopic MCF-7 tumours with either empty vector, WT PBF and 
EEN/AAA PBF stably expressing cells being injected into the mammary fat pad. Once the 
tumours were established, to boost endogenous NIS levels the mice would have been 
treated with ATRA and dexamethasone and then the three different transfection groups 
further divided into different experimental treatment groups. The first group would have 
been the control group, treated with saline containing vehicle only and DMSO. The 
second treatment group would have been treated with dasatinib and the third with a 
combination of dasatinib and NMT inhibitor 3. 24 hours after the treatment the mice 
would have been given 125I and harvested the same day. Tumours would have been 
removed and radioiodide accumulation assessed. The study would have sought to 
validate all the work done in vitro and demonstrate that dasatinib can boost NIS activity 
within breast cancer cells overexpressing PBF making radioiodide therapy a potentially 
viable treatment for breast cancer.  
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8.6 Conclusions  
This thesis has generated data that can improve the current understanding of the 
relationship between NIS and PBF within breast cancer cells. It has been demonstrated 
that PBF can bind to NIS and repress the ability of breast cancer cells to take up 
radioiodide. The interaction between PBF and NIS is regulated by PBF phosphorylation at 
Y174, with unphosphorylated forms of PBF being unable to interact with NIS. The 
phosphorylation of PBF in breast cancer cells can be inhibited using SFK inhibitors 
including the potent SFK inhibitor dasatinib, which not only abrogates pY174 PBF but also 
overcomes PBF's reduction in radioiodide uptake. Although further studies are required 
to establish the role NMT inhibition plays within radioiodide uptake and to validate the 
treatments in vivo, the data presented here have potentially important therapeutic 
implications. If the in vitro data prove to be translational, then there is potential for a 
novel treatment strategy for breast cancer patients that are unresponsive to current 
conventional treatments.  
 This work not only impacts breast cancer research but also has wider implications 
for thyroid and other cancer types. Methods to increase the efficacy of radioiodide 
therapy are of great value to the treatment of thyroid disease, particularly for patients 
with radioactive iodine-refractory differentiated thyroid cancer. Additionally, the work of 
Professor Christine Spitzweg (Muenchen) and other research groups could benefit greatly 
from these findings with their investigations into non-thyroidal NIS gene delivery, further 
widening the applicability of this research into cancers that do not express endogenous 
NIS. As PBF is overexpressed in many cancers, the conclusions of this thesis may help to 
overcome the major pitfall of NIS gene delivery in that PBF is identified as an orchestrator 
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of aberrant NIS localisation, thus reducing the effectiveness of NIS alone on radioiodide 
uptake. PBF is over-expressed within a plethora of cancers so delivery of NIS to tumours 
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